

89 Rec'd PCT/PTC

1996

89 Rec'd PCT/PTO 30 AUG 1996

FORM PCT-1100 (REV 10-95)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER BWI-120CPUS
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371			U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 08/702525
INTERNATIONAL APPLICATION NO. PCT/US95/02576	INTERNATIONAL FILING DATE 02 March 1995 (02.03.95)	PRIORITY DATE CLAIMED 02 March 1994 (02.03.94)	
TITLE OF INVENTION NOVEL FORMS OF T CELL COSTIMULATORY MOLECULES AND USES THEREFOR			
APPLICANT(S) FOR DO/EO/US Arlene H. SHARPE; Francescopaolo BORRIELLO; Gordon J. FREEMAN; & Lee M. NADLER			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
<ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). 4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> has been transmitted by the International Bureau. c. <input checked="" type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendemnts has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). (unexecuted) 10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 			
Items 11. to 16. below concern document(s) or information included:			
<ol style="list-style-type: none"> 11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 14. <input type="checkbox"/> A substitute specification. 15. <input type="checkbox"/> A change of power of attorney and/or address letter. 16. <input checked="" type="checkbox"/> Other items or information: <ol style="list-style-type: none"> 1) Published International Application (WO 95/23859); 2) International Search Report; 3) PCT Communication Form PCT/RO/132; 4) Response (dated 14 March 1996) to Communication Form PCT/RO/132 with attached Certificate of Corporate Authority; 5) Written Opinion (NO RESPONSE WAS FILED); 6) International Preliminary Examination Report; 7) Certificate of Express Mailing (EM558575965US); and 8) Postcard Receipt. 			

960280 52520480

107 08/702,525 07 FEB 1997

08/702,525
154-1130

H
3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Arlene H. Sharpe et al.

Serial No.: 08/702,525

Filed: August 30, 1996

For: *Novel Forms of T Cell Costimulatory Molecules
and Uses Therefor*

Attorney Docket No.: BWI-120CPUS

Group Art Unit:

Examiner:

Assistant Commissioner for Patents

Box PCT

Washington, D.C. 20231


Certificate of Express Mailing

Express Mail Label No. EM 128 844 588 US

I hereby certify that this correspondence is deposited with the U.S. Postal Service as Express Mail in an envelope addressed to: Assistant Commissioner for Patents, Box PCT, Washington, DC 20231, on the date indicated below:

February 7, 1997

By:



Date of Signature and Mail Deposit

Ariel I. Collazo

RESPONSE TO NOTIFICATION OF MISSING REQUIREMENTS
UNDER 35 U.S.C. 371

Dear Sir:

Responsive to the Notification of Missing Requirements Under 35 U.S.C. 371 dated October 7, 1996, Applicants' attorney submits herewith two executed Declaration, Petition and Power of Attorneys for the above-identified patent application. A check in the amount of \$130 for the surcharge under 37 CFR 1.492(e). A copy of Form PCT/DO/EO/905 is also enclosed. A separate request for an extension of time in which to respond is being filed concurrently herewith.

520 RD 03/17/97 08702525
1 154 130.00 CK

107 Rec'd PCT/PTO 07 FEB 1997

08/702, 525
217-465

IN THE UNITED STATES RECEIVING OFFICE

In re: the application of: Arlene H. Sharpe, et al.

Serial No.: 08/702,525

Filed: August 30, 1996

For: *Novel Forms of T Cell Costimulatory
Molecules and Uses Therefor*

Attorney Docket No: BWI-120CPUS

4

Assistant Commissioner for Patents
Box PCT
Washington, DC 20231

Certificate of Express Mailing
Express Mail Label No. EM 128 844 588 US

I hereby certify that this correspondence is deposited with the U.S. Postal Service as Express Mail in an envelope addressed to: Assistant Commissioner for Patents, Box PCT, Washington, DC 20231, on the date indicated below:

February 7, 1997
Date of Signature and Mail Deposit

By:

Ariel I. Collazo

REQUEST FOR THREE-MONTH EXTENSION OF TIME


Dear Sir:

Applicants request a three-month extension of time pursuant to 37 CFR 1.136(a) in which to respond to the Notification of Missing Requirements dated October 7, 1996.

Enclosed is a check which covers the appropriate fee of \$465.00 based on small entity status. Please charge any underpayments or credit any overpayments to our Deposit Account No. 12-0080. A duplicate of this sheet is enclosed.

Respectfully submitted,

LAHIVE & COCKFIELD, LLP


Amy E. Mandragouras
Reg. No. 36,207

60 State Street
Boston, MA 02109
(617) 227-7400

Dated: February 7, 1997

924 48 02137107 08748555
1-227 1-11 00-00

IN THE UNITED STATES RECEIVING OFFICE

In re: the application of: Arlene H. Sharpe, et al.

Serial No.: 08/702,525

Filed: August 30, 1996

For: *Novel Forms of T Cell Costimulatory
Molecules and Uses Therefor*

Attorney Docket No: BWI-120CPUS

12 0080

117 H65

30 Rec'd 10/7/96

FEB 07 1997

Assistant Commissioner for Patents
Box PCT
Washington, DC 20231

Certificate of Express Mailing
Express Mail Label No. EM 128 844 588 US

I hereby certify that this correspondence is deposited with the U.S. Postal Service as Express Mail in an envelope addressed to: Assistant Commissioner for Patents, Box PCT, Washington, DC 20231, on the date indicated below:

February 7, 1997
Date of Signature and Mail Deposit

By:

Ariel I. Collazo
Ariel I. Collazo

REQUEST FOR THREE-MONTH EXTENSION OF TIME

Dear Sir:

Applicants request a three-month extension of time pursuant to 37 CFR 1.136(a) in which to respond to the Notification of Missing Requirements dated October 7, 1996.

Enclosed is a check which covers the appropriate fee of \$465.00 based on small entity status. Please charge any underpayments or credit any overpayments to our Deposit Account No. 12-0080. A duplicate of this sheet is enclosed.


Respectfully submitted,

LAHIVE & COCKFIELD, LLP

Amy E. Mandragouras
Amy E. Mandragouras
Reg. No. 36,207

60 State Street
Boston, MA 02109
(617) 227-7400

Dated: February 7, 1997

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)		INTERNATIONAL APPLICATION NO. PCT/US95/02576		ATTORNEYS DOCKET NUMBER BWI-120CPUS	
17. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)): Search Report has been prepared by the EPO or JPO \$880.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) \$680.00 No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$750.00 Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$1010.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) \$94.00 ENTER APPROPRIATE BASIC FEE AMOUNT =				CALCULATIONS PTO USE ONLY	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	76 - 20 =	56	X \$22.00	\$ 1232	
Independent claims	21 - 3 =	18	X \$78.00	\$ 1404	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$250.00	\$ 0	
TOTAL OF ABOVE CALCULATIONS =				\$ 3516	
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).				\$	
SUBTOTAL =				\$ 3516	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	
TOTAL NATIONAL FEE =				\$ 3516	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				\$	
TOTAL FEES ENCLOSED =				\$ 3516	
				Amount to be: refunded	\$
				charged	\$
a. <input checked="" type="checkbox"/> A check in the amount of \$ <u>3516</u> to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>12-0080</u> . A duplicate copy of this sheet is enclosed.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO: MANDRAGOURAS, Amy E. Lahive & Cockfield 60 State Street Boston, Massachusetts 02109 phone: (617) 227-7400 fax: (617) 227-5941					
				SIGNATURE:  Amy E. Mandragouras NAME 36,207 REGISTRATION NUMBER	

NOVEL FORMS OF T CELL COSTIMULATORY MOLECULES
AND USES THEREFOR

Background of the Invention

5 For CD4+ T lymphocyte activation to occur, two distinct signals must be delivered by antigen presenting cells to resting T lymphocytes (Schwartz, R.H. (1990) *Science* 248:1349-1356; Williams, I.R. and Unanue, E.R. (1991) *J. Immunol.* 147:3752-3760; Mueller, D.L. et al., (1989) *J. Immunol.* 142:2617-2628). The first, or primary, activation signal is mediated physiologically by the interaction of the T cell receptor/CD3 complex
10 (TcR/CD3) with MHC class II-associated antigenic peptide and gives specificity to the immune response. The second signal, the costimulatory signal, regulates the T cell proliferative response and induction of effector functions. Costimulatory signals appear pivotal in determining the functional outcome of T cell activation since delivery of an antigen-specific signal to a T cell in the absence of a costimulatory signal results in functional
15 inactivation of mature T cells, leading to a state of tolerance (Schwartz, R.H. (1990) *Science* 248:1349-1356).

Molecules present on the surface of antigen presenting cells which are involved in T cell costimulation have been identified. These T cell costimulatory molecules include murine B7-1 (mB7-1; Freeman, G.J. et al., (1991) *J. Exp. Med.* 174:625-631), and the more recently
20 identified murine B7-2 (mB7-2; Freeman, G.J. et al., (1993) *J. Exp. Med.* 178:2185-2192). Human counterparts to the murine B7-1 and B7-2 molecules have also been described (human B7-1 (hB7-1) Freedman, A.S. et al., (1987) *J. Immunol.* 137:3260-3267; Freeman, G.J. et al., (1989) *J. Immunol.* 143:2714-2722; and human B7-2 (hB7-2); Freeman, G.J. et al., (1993) *Science* 262:909-911; Azuma, M. et al. (1993) *Nature* 366:76-79). The B7-1 and B7-
25 2 genes are members of the immunoglobulin gene superfamily.

B7-1 and B7-2 display a restricted pattern of cellular expression, which correlates with accessory cell potency in providing costimulation (Reiser, H. et al. (1992; *Proc. Natl. Acad. Sci. USA* 89:271-275; Razi-Wolf Z. et al., (1992) *Proc. Natl. Acad. Sci. USA* 89:4210-4214; Galvin, F. et al. (1992) *J. Immunol.* 149:3802-3808; Freeman, G.J. et al., (1993) *J. Exp. Med.* 178:2185-2192). For example, B7-1 has been observed to be expressed on activated B cells, T cells and monocytes but not on resting B cells, T cells or monocytes, and its
30 expression can be regulated by different extracellular stimuli (Linsley, P.S. et al., (1990) *Proc. Natl. Acad. Sci. USA* 87:5031-5035; Linsley, P.S. et al., (1991) *J. Exp. Med.* 174:561-569; Reiser, H. et al. (1992); *Proc. Natl. Acad. Sci. USA* 89:271-275; Gimmi, C.D. et al. (1991) *Proc. Natl. Acad. Sci. USA* 88:6575-6579; Koulouva, L. et al. (1991) *J. Exp. Med.* 173:759-762; Azuma, M. et al. (1993) *J. Exp. Med.* 177:845-850; Sansom, D.M. et al. (1993) *Eur. J. Immunol.* 23:295-298)

Both B7-1 and B7-2 are counter-receptors for two ligands, CD28 and CTLA4, expressed on T lymphocytes (Linsley, P.S. et al., (1990) *Proc. Natl. Acad. Sci. USA* 87:5031-

5035; Linsley, P.S. et al., (1991) *J. Exp. Med.* 174:561-569). CD28 is constitutively expressed on T cells and, after ligation by a costimulatory molecule, induces IL-2 secretion and T cell proliferation (June, C.H. et al. (1990) *Immunol. Today* 11:211-216). CTLA4 is homologous to CD28 and appears on T cells after activation (Freeman, G.J. et al. (1992) *J. Immunol.* 149:3795-3801). Although CTLA4 has a significantly higher affinity for B7-1 than does CD28, its role in T cell activation remains to be determined. It has been shown that antigen presentation to T cells in the absence of the B7-1/CD28 costimulatory signal results in T cell anergy (Gimmi, C.D. et al. (1993) *Proc. Natl. Acad. Sci. USA* 90:6586-6590; Boussiotis, V.A. et al. (1993) *J. Exp. Med.* 178:1753). The ability of T cell costimulatory molecules such as B7-1 and B7-2 to bind to CD28 and/or CTLA4 on T cells and trigger a costimulatory signal in the T cells provides a functional role for these molecules in T cell activation.

Summary of the Invention

15 This invention pertains to novel forms of T cell costimulatory molecules. In particular, the invention pertains to isolated proteins encoded by T cell costimulatory molecule genes which contain amino acid sequences encoded by novel exons of these genes. The isolated proteins of the invention correspond to alternative forms of T cell costimulatory molecules. Preferably, these alternative forms correspond to naturally-occurring,
20 alternatively spliced forms of T cell costimulatory molecules or are variants of alternatively spliced forms which are produced by recombinant DNA techniques. The novel forms of T cell costimulatory molecules of the invention contain an alternative structural domain (i.e., a structural domain having an amino acid sequence which differs from a known amino acid sequence) or have a structural domain deleted or added. The occurrence in nature of
25 alternative structural forms of T cell costimulatory molecules supports additional functional roles for T cell costimulatory molecules.

The invention also provides isolated nucleic acid molecules encoding alternative forms of proteins which bind to CD28 and/or CTLA4 and isolated proteins encoded therein. Isolated nucleic acid molecules encoding polypeptides corresponding to novel structural
30 domains of T cell costimulatory molecules, and isolated polypeptide encoded therein are also within the scope of the invention. The novel structural domains of the invention are encoded by exons of T cell costimulatory molecule genes. In one embodiment of the invention, the T cell costimulatory molecule gene encodes B7-1. In another embodiment, the T cell costimulatory molecule gene encodes B7-2.

35 Another aspect of the invention provides proteins which bind CD28 and/or CTLA4 and contain a novel cytoplasmic domain. T cell costimulatory molecule genes which contain exons encoding different cytoplasmic domains which are used in an alternate manner have been discovered. Alternative splicing of mRNA transcripts of a T cell costimulatory molecule gene has been found to generate native T cell costimulatory molecules with

different cytoplasmic domains. The existence of alternative cytoplasmic domain forms of T cell costimulatory molecules supports a functional role for the cytoplasmic domain in transmitting an intracellular signal within a cell which expresses the costimulatory molecule on its surface. This indicates that costimulatory molecules not only trigger an intracellular signal in T cells, but may also deliver a signal to the cell which expresses the costimulatory molecule. This is the first evidence that the interaction between a costimulatory molecule on one cell and its receptor on a T cell may involve bidirectional signal transduction between the cells (rather than only unidirectional signal transduction to the T cell).

In yet another aspect of the invention, proteins that bind CD28 and/or CTLA4 and contain a novel signal peptide domain are provided. T cell costimulatory molecule genes which contain exons encoding different signal peptide domains which are used in an alternate manner have been discovered. Alternative splicing of mRNA transcripts of the gene can generate native T cell costimulatory molecules with different signal peptide domains. The existence of alternative signal peptide domain forms of T cell costimulatory molecules also suggests a functional role for the signal peptide of T cell costimulatory molecules.

Still another aspect of the invention pertains to isolated proteins that bind CD28 and/or CTLA4 in which a structural domain has been deleted or added, and isolated nucleic acids encoding such proteins. In a preferred embodiment, the protein (e.g., B7-1) has an immunoglobulin constant-like domain deleted (i.e., an immunoglobulin variable-like domain is linked directly to a transmembrane domain). In another embodiment, the protein has an immunoglobulin variable-like domain deleted (i.e., a signal peptide domain is linked directly to an immunoglobulin constant-like domain).

An isolated nucleic acid molecule of the invention can be incorporated into a recombinant expression vector and transfected into a host cell to express a novel structural form of a T cell costimulatory molecule. The isolated nucleic acids of the invention can further be used to create transgenic and homologous recombinant non-human animals. The novel T cell costimulatory molecules provided by the invention can be used to trigger a costimulatory signal in a T lymphocyte. These molecules can further be used to raise antibodies against novel structural domains of costimulatory molecules. The novel T cell costimulatory molecules of the invention can also be used to identify agents which stimulate the expression of alternative forms of costimulatory molecules and to identify components of the signal transduction pathway induced in a cell expressing a costimulatory molecule in response to an interaction between the costimulatory molecule and its receptor on a T lymphocyte.

Brief Description of the Drawings

Figure 1 is a photograph of an agarose gel depicting the presence of mB7-1 cytoplasmic domain II-encoding exon 6 in mB7-1 cDNA, determined by nested Reverse Transcriptase Polymerase Chain Reaction (RT-PCR).

Figure 2 is a schematic representation depicting three mB7-1 transcripts (A, B and C) detected by nested RT-PCR.

Figure 3 is a graphic representation of interleukin-2 production by T cells stimulated with either untransfected CHO cells (CHO), CHO cells transfected to express full-length mouse B7-1 (CHO-B7-1) or CHO cells transfected to express the IgV-like isoform of mouse B7-1 (CHO-SV).

Detailed Description of the Invention

This invention pertains to novel structural forms of T cell costimulatory molecule which contain a structural domain encoded by a novel exon of a T cell costimulatory molecule gene, or have a structural domain deleted or added. Preferably, the isolated T cell costimulatory molecule corresponds to a naturally-occurring alternatively spliced form of a T cell costimulatory molecule, such as B7-1 or B7-2. Alternatively, the isolated protein can be a variant of a naturally-occurring alternatively spliced form of a T cell costimulatory molecule which is produced by standard recombinant DNA techniques.

Typically, a domain structure of a T cell costimulatory molecule of the invention includes a signal peptide domain (e.g., exon 1), an immunoglobulin variable region-like domain (IgV-like) (e.g., exon 2), an immunoglobulin constant region-like domain (IgC-like) (e.g. exon 3), a transmembrane domain (e.g., exon 4) and a cytoplasmic domain (e.g., exon 5). T cell costimulatory molecule genes are members of the immunoglobulin gene superfamily. The terms "immunoglobulin variable region-like domain" and "immunoglobulin constant region-like domain" are art-recognized and refer to protein domains which are homologous in sequence to an immunoglobulin variable region or an immunoglobulin constant region, respectively. For a discussion of the immunoglobulin gene superfamily and a description of IgV-like and IgC-like domains see Hunkapiller, T. and Hood, L. (1989) *Advances in Immunology* 44:1-63.

Each structural domain of a protein is usually encoded in genomic DNA by at least one exon. The invention is based, at least in part, on the discovery of novel exons in T cell costimulatory molecule genes which encode different forms of structural domains.

Moreover, it has been discovered that exons encoding different forms of a structural domain of a T cell costimulatory molecule can be used in an alternative manner by alternative splicing of primary mRNA transcripts of a gene. Alternative splicing is an art-recognized term referring to the mechanism by which primary mRNA transcripts of a gene are processed to produce different mature mRNA transcripts encoding different proteins. In this mechanism different exonic sequences are excised from different primary transcripts. This results in mature mRNA transcripts from the same gene that contain different exonic sequences and thus encode proteins having different amino acid sequences. The terms "alternative forms" or "novel forms" of T cell costimulatory molecules refer to gene products of the same gene which differ in nucleotide or amino acid sequence from previously

disclosed forms of T cell costimulatory molecules, e.g., forms which result from alternative splicing of a primary mRNA transcript of a gene encoding a T cell costimulatory molecule.

Accordingly, one aspect of the invention relates to isolated nucleic acids encoding T cell costimulatory molecules corresponding to naturally-occurring alternatively spliced forms or variants thereof, and uses therefor. Another aspect of the invention pertains to novel structural forms of T cell costimulatory molecules which are produced by transcription and translation of the nucleic acid molecules of the invention, and uses therefor. This invention further pertains to isolated nucleic acids encoding novel structural domains of T cell costimulatory molecules, isolated polypeptides encoded therein, and uses therefor.

The various aspects of this invention are described in detail in the following subsections. Forming part of the present disclosure is the appended Sequence Listing. The numerous nucleotide and amino acid sequences presented in the Sequence Listing are summarized below.

- 15 SEQ ID NO: 1 - nucleotide sequence of mouse B7-1 exons 1-2-3-4-6
- SEQ ID NO: 2 - amino acid sequence of mouse B7-1 protein encoded by exons 1-2-3-4-6
- SEQ ID NO: 3 - nucleotide sequence of mouse B7-1 exons 1-2-3-4-5-6
- SEQ ID NO: 4 - nucleotide sequence of mouse B7-1 exon 6 (CytII)
- SEQ ID NO: 5 - amino acid sequence of mouse B7-1 peptide encoded by exon 6 (CytII)
- 20 SEQ ID NO: 6 - nucleotide sequence of mouse B7-1 full-length exon 1
- SEQ ID NO: 7 - nucleotide sequence of mouse B7-1 promoter
- SEQ ID NO: 8 - nucleotide sequence of B7-1 exons 1-3-4-5
- SEQ ID NO: 9 - amino acid sequence of mB7-1 protein encoded by exons 1-3-4-5
- SEQ ID NO: 10 - nucleotide sequence of mouse B7-1 exons 1-3-4-6
- 25 SEQ ID NO: 11 - amino acid sequence of mouse B7-1 protein encoded by exons 1-3-4-6
- SEQ ID NO: 12 - nucleotide sequence of mouse B7-2 exons m1B-2-3-4-5
- SEQ ID NO: 13 - amino acid sequence of mouse B7-2 protein encoded by exons m1B-2-3-4-5
- SEQ ID NO: 14 - nucleotide sequence of mouse B7-2 exon m1B
- SEQ ID NO: 15 - amino acid sequence of mouse B7-2 peptide encoded by exon m1B
- 30 SEQ ID NO: 16 - nucleotide sequence of mouse B7-1 exons 1-2-3-4-5 (as disclosed in Freeman, G. J. et al. (1991) *J. Exp. Med.* 174:625-631)
- SEQ ID NO: 17 - amino acid sequence of mouse B7-1 protein encoded by exons 1-2-3-4-5
- SEQ ID NO: 18 - nucleotide sequence of human B7-1 exons 1-2-3-4-5 (as disclosed in Freeman, G.J. et al. (1989) *J. Immunol.* 143:2714-2722)
- 35 SEQ ID NO: 19 - amino acid sequence of human B7-1 protein encoded by exons 1-2-3-4-5
- SEQ ID NO: 20 - nucleotide sequence of mouse B7-2 exons m1A-2-3-4-5 (as disclosed in Freeman, G.J. et al. (1993) *J. Exp. Med.* 178:2185-2192)
- SEQ ID NO: 21 - amino acid sequence of mouse B7-2 protein encoded by exons m1A-2-3-4-5

960E80 52520280

SEQ ID NO: 22 - nucleotide sequence of human B7-2 exons h1A-2-3-4-5 (as disclosed in Freeman, G.J. et al. (1993) *Science* 262:909-911)

SEQ ID NO: 23 - amino acid sequence of human B7-2 protein encoded by exons h1A-2-3-4-5

SEQ ID NO: 24 - nucleotide sequence of human B7-2 exons h1B-2-3-4-5 (as disclosed in

5 Azuma, M. et al. (1993) *Nature* 366:76-79)

SEQ ID NO: 25 - nucleotide sequence of mouse B7-1 exon 5 (Cyt I)

SEQ ID NO: 26 - amino acid sequence of mouse B7-1 peptide encoded by exon 5 (Cyt I)

SEQ ID NO: 27 - nucleotide sequence of human B7-1 exon 5 (Cyt I)

SEQ ID NO: 28 - amino acid sequence of human B7-1 peptide encoded by exon 5 (Cyt I)

10 SEQ ID NO: 29 - nucleotide sequence of mouse B7-2 exon 5 (Cyt I)

SEQ ID NO: 30 - amino acid sequence of mouse B7-2 peptide encoded by exon 5 (Cyt I)

SEQ ID NO: 31 - nucleotide sequence of human B7-2 exon 5 (Cyt I)

SEQ ID NO: 32 - amino acid sequence of human B7-2 peptide encoded by exon 5 (Cyt I)

SEQ ID NO: 33 - nucleotide sequence of mouse B7-1 truncated exon 1 (signal)

15 SEQ ID NO: 34 - amino acid sequence of mouse B7-1 peptide encoded by exon 1 (signal)

SEQ ID NO: 35 - nucleotide sequence of human B7-1 exon 1 (signal)

SEQ ID NO: 36 - amino acid sequence of human B7-1 peptide encoded by exon 1 (signal)

SEQ ID NO: 37 - nucleotide sequence of mouse B7-2 exon m1A (signal)

SEQ ID NO: 38 - amino acid sequence of mouse B7-2 peptide encoded by exon m1A (signal)

20 SEQ ID NO: 39 - nucleotide sequence of human B7-2 exon h1A (signal)

SEQ ID NO: 40 - amino acid sequence of human B7-2 peptide encoded by exon h1A (signal)

SEQ ID NO: 41 - nucleotide sequence of human B7-2 exon h1B (signal)

SEQ ID NO: 42 - amino acid sequence of human B7-2 peptide encoded by exon h1B (signal)

SEQ ID NOs: 43-61: oligonucleotide primers for PCR

25 SEQ ID NO: 62: nucleotide sequence of mouse B7-1 exons 1-2-4-5

SEQ ID NO: 63: nucleotide sequence of mouse B7-1 protein encoded by exons 1-2-4-5

SEQ ID NO: 64: nucleotide sequence of mouse B7-1 exons 1-2-4-6

SEQ ID NO: 65: nucleotide sequence of mouse B7-1 protein encoded by exons 1-2-4-6

30 I. Isolated Nucleic Acid Molecules Encoding T Cell Costimulatory Molecules

The invention provides an isolated nucleic acid molecule encoding a novel structural form of a T cell costimulatory molecule. As used herein, the term "T cell costimulatory molecule" is intended to include proteins which bind to CD28 and/or CTLA4. Preferred T cell costimulatory molecules are B7-1 and B7-2. The term "isolated" as used herein refers to

35 nucleic acid substantially free of cellular material or culture medium when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized. An "isolated" nucleic acid is also free of sequences which naturally flank the nucleic acid (i.e., sequences located at the 5' and 3' ends of the nucleic acid) in the organism from which the nucleic acid is derived. The term "nucleic acid" is intended to include DNA

and RNA and can be either double stranded or single stranded. Preferably, the isolated nucleic acid molecule is a cDNA.

A. Nucleic Acids Encoding Novel Cytoplasmic Domains

One aspect of the invention pertains to isolated nucleic acids that encode T cell costimulatory molecules, each containing a novel cytoplasmic domain. It has been discovered that a gene encoding a costimulatory molecule can contain multiple exons encoding different cytoplasmic domains. In addition, naturally-occurring mRNA transcripts have been discovered which encode different cytoplasmic domain forms of T cell costimulatory molecules. Thus, one embodiment of the invention provides an isolated nucleic acid encoding a protein which binds CD28 or CTLA4 and comprises a contiguous nucleotide sequence derived from at least one T cell costimulatory molecule gene. In this embodiment, the nucleotide sequence can be represented by a formula A-B-C-D-E, wherein

A comprises a nucleotide sequence of at least one first exon encoding a signal peptide domain,

B comprises a nucleotide sequence of at least one second exon of a T cell costimulatory molecule gene, wherein the at least one second exon encodes an immunoglobulin variable region-like domain,

C comprises a nucleotide sequence of at least one third exon of a T cell costimulatory molecule gene, wherein the at least one third exon encodes an immunoglobulin constant region-like domain,

D comprises a nucleotide sequence of at least one fourth exon of a T cell costimulatory molecule gene, wherein the at least one fourth exon encodes a transmembrane domain, and

E comprises a nucleotide sequence of at least one fifth exon of a T cell costimulatory molecule gene, wherein the at least one fifth exon encodes a cytoplasmic domain,

with the proviso that E does not comprise a nucleotide sequence encoding a cytoplasmic domain selected from the group consisting of SEQ ID NO:25 (mB7-1), SEQ ID NO:27 (hB7-1), SEQ ID NO:29 (mB7-2) and SEQ ID NO:31 (hB7-2).

In the formula, A, B, C, D, and E are contiguous nucleotide sequences linked by phosphodiester bonds in a 5' to 3' orientation from A to E. According to the formula, A can be a nucleotide sequence of an exon which encodes a signal peptide domain of a heterologous protein which efficiently expresses transmembrane or secreted proteins, such as the oncostatin M signal peptide. Preferably, A comprises a nucleotide sequence of at least one exon which encodes a signal peptide domain of a T cell costimulatory molecule gene. It is

also preferred that A, B, C, D and E comprise nucleotide sequences of exons of the B7-1 gene, such as the human or murine B7-1 gene.

As described in detail in Examples 1 and 2, naturally-occurring murine B7-1 mRNA transcripts which contain a nucleotide sequence encoding one of at least two different cytoplasmic domains have been discovered. The alternative cytoplasmic domains are encoded in genomic DNA by different exons (i.e., either exon 5 or exon 6) and the different mB7-1 mRNA transcripts are produced by alternative splicing of the mRNA transcripts. The genomic structure of mB7-1 has been reported to contain only a single exon encoding cytoplasmic domain (i.e., exon 5; see Selvakumar, A. et al. (1993) *Immunogenetics* 38:292-295). The nucleotide sequence for the mB7-1 cDNA expressed in B cells has been reported to correspond to usage of five exons, 1-2-3-4-5 (the nucleotide sequence of which is shown in SEQ ID NO: 16) corresponding to signal, Ig-variable, Ig-constant, transmembrane and cytoplasmic domains (see Freeman, G.J. et al., (1991) *J. Exp. Med.* 174:625-631). This transcript includes a single exon encoding cytoplasmic domain, exon 5. As described herein, the nucleotide sequence of a sixth exon for the mB7-1 gene which encodes a cytoplasmic domain having a different amino acid sequence than the cytoplasmic domain encoded by exon 5 has been discovered. The nucleotide sequence encoding the first cytoplasmic domain of mB7-1 (i.e., exon 5) is shown in SEQ ID NO: 25 and the amino acid sequence of this cytoplasmic domain (referred to herein as Cyt I) is shown in SEQ ID NO: 26. A nucleotide sequence encoding a second, alternative cytoplasmic domain for mB7-1 (i.e., exon 6) is shown in SEQ ID NO: 4. This alternative cytoplasmic domain encoded by exon 6 (also referred to herein as Cyt II) has an amino acid sequence shown in SEQ ID NO: 5.

The Cyt II domain of mB7-1 has several characteristic properties. Of interest is the preferential expression of mRNA containing the exon encoding Cyt II (i.e., exon 6) in thymus. In contrast, mRNA containing exon 6 of mB7-1 is not detectable in spleen. Accordingly, this invention encompasses alternative cytoplasmic domain forms of T cell costimulatory molecules which are expressed preferentially in thymus. As defined herein, the term "expressed preferentially in the thymus" is intended to mean that the mRNA is detectable by standard methods in greater abundance in the thymus than in other tissues which express the T cell costimulatory molecule, particularly the spleen. The Cyt II domain of mB7-1 has also been found to contain several consensus phosphorylation sites and, thus, alternative cytoplasmic domain forms of T cell costimulatory molecules which contain at least one consensus phosphorylation site are also within the scope of this invention. As used herein, the term "consensus phosphorylation site" describes an amino acid sequence motif which is recognized by and phosphorylated by a protein kinase, for example protein kinase C, casein kinase II etc. It has also been discovered that exon 6 is encoded in genomic DNA approximately 7.5 kilobases downstream of exon 5. This invention therefore includes alternative cytoplasmic domain forms of T cell costimulatory molecules which are located in genomic DNA less than approximately 10 kb downstream (i.e., 3') of an exon encoding a first

cytoplasmic domain of the T cell costimulatory molecule. Additionally, a second, alternative cytoplasmic domain of another T cell costimulatory molecule is likely to be homologous to the Cyt II domain of mB7-1. For example, the first cytoplasmic domains of mB7-1, hB7-1, mB7-2 and hB7-2 display between 4 % and 26 % amino acid identity (see Freeman, G.J. et al. (1993) *J. Exp. Med.* 178:2185-2192). Accordingly, in one embodiment, an alternative cytoplasmic domain of a T cell costimulatory molecule has an amino acid sequence that is at least about 5 % to 25 % identical in sequence with the amino acid sequence of mB7-1 Cyt II (shown in SEQ ID NO: 5).

Another embodiment of the invention provides an isolated nucleic acid encoding a protein which binds CD28 or CTLA4 and is encoded by a T cell costimulatory molecule gene having at least one first exon encoding a first cytoplasmic domain and at least one second exon encoding a second cytoplasmic domain. The at least one first cytoplasmic domain exon of the gene comprises a nucleotide sequence selected from the group consisting of a nucleotide sequence of SEQ ID NO:25 (mB7-1), SEQ ID NO:27 (hB7-1), SEQ ID NO:29 (mB7-2) and SEQ ID NO:31 (hB7-2). In this embodiment, the isolated nucleic acid includes a nucleotide sequence encoding at least one second cytoplasmic domain. Preferably, the isolated nucleic acid does not comprise a nucleotide sequence encoding a first cytoplasmic domain (i.e., the nucleic acid comprises an alternative splice form of a transcript of the gene in which the exon encoding the first cytoplasmic domain, e.g., exon 5, has been excised from the transcript). Preferred T cell costimulatory molecule genes from which nucleotide sequences can be derived include B7-1 and B7-2.

In yet another embodiment, the isolated nucleic acid of the invention encodes a protein which binds CD28 or CTLA4 and comprises a nucleotide sequence shown in SEQ ID NO: 1. This nucleotide sequence corresponds to a naturally-occurring alternatively spliced form of mB7-1 which includes the nucleotide sequences of exons 1-2-3-4-6. Alternatively, the isolated nucleic acid comprises a nucleotide sequence shown in SEQ ID NO: 3, which corresponds to a naturally-occurring alternatively spliced form of mB7-1 comprising the nucleotide sequences of exons 1-2-3-4-5-6.

B. Nucleic Acids Encoding Novel Signal Peptide Domains

Other aspects of this invention pertain to isolated nucleic acids which encode T cell costimulatory molecules containing novel signal peptide domains. It has been discovered that a gene encoding a costimulatory molecule can contain multiple exons encoding different signal peptide domains and that mRNA transcripts occur in nature which encode different signal peptide domain forms of T cell costimulatory molecules. Thus, isolated nucleic acids which encode proteins which bind CD28 or CTLA4 and comprise contiguous nucleotide sequences derived from at least one T cell costimulatory molecule gene are within the scope of this invention. The nucleotide sequence can be represented by a formula A-B-C-D-E, wherein

A comprises a nucleotide sequence of at least one first exon of a T cell costimulatory molecule gene, wherein the at least one first exon encodes a signal peptide domain,

5 B comprises a nucleotide sequence of at least one second exon of a T cell costimulatory molecule gene, wherein the at least one second exon encodes an immunoglobulin variable region-like domain,

10 C comprises a nucleotide sequence of at least one third exon of a T cell costimulatory molecule gene, wherein the at least one third exon encodes an immunoglobulin constant region-like domain,

D, which may or may not be present, comprises a nucleotide sequence of at least one fourth exon of a T cell costimulatory molecule gene, wherein the at least one fourth exon encodes a transmembrane domain, and

15 E, which may or may not be present, comprises a nucleotide sequence of at least one fifth exon of a T cell costimulatory molecule gene, wherein the at least one fifth exon encodes a cytoplasmic domain,

20 with the proviso that A does not comprise a nucleotide sequence encoding a signal peptide domain selected from the group consisting of SEQ ID NO:33 (mB7-1), SEQ ID NO:35 (hB7-1), SEQ ID NO:37 (mB7-2), SEQ ID NO:39 (hB7-2) and SEQ ID NO:41 (hB7-2).

25 In the formula, A, B, C, D, and E are contiguous nucleotide sequences linked by phosphodiester bonds in a 5' to 3' orientation from A to E. To produce a soluble form of the T cell costimulatory molecule D, which comprises nucleotide sequence of a transmembrane domain and E, which comprises a nucleotide sequence of a cytoplasmic domain may not be present in the molecule. In a preferred embodiment, A, B, C, D and E comprise nucleotide sequences of exons of the B7-2 gene, such as the human or murine B7-2 gene.

30 As described in detail in Example 6, naturally-occurring murine B7-2 mRNA transcripts which contain a nucleotide sequence encoding one of at least two different signal peptide domains have been discovered. One of these signal domains corresponds to the signal domain of murine B7-2 disclosed in Freeman et al. (1993) *J. Exp. Med.* 178:2185-2192 (this signal domain is referred to herein as exon m1A). However, the second signal domain corresponds to a novel nucleotide sequence (referred to herein as m1B). Accordingly, an mRNA transcript containing a nucleotide sequence encoding the novel signal peptide domain (m1B) represents an alternatively spliced form of murine B7-2. A naturally-occurring mB7-2 mRNA transcript comprising the alternative signal peptide domain (i.e., comprising exons m1B-2-3-4-5) preferably comprises the nucleotide sequence shown in SEQ ID NO: 12, and encodes a protein comprising the amino acid sequence shown in SEQ ID NO: 13. The nucleotide and amino acid sequences of the novel signal peptide domain (i.e., exon m1B) are shown in SEQ ID NOs: 14 and 15, respectively.

In yet another embodiment of the invention, the isolated nucleic acid encodes a protein which binds CD28 or CTLA4 and is encoded by a T cell costimulatory molecule gene having at least one first exon encoding a first signal peptide domain and at least one second exon encoding a second signal peptide domain. The at least one first exon comprises a nucleotide sequence selected from the group consisting of a nucleotide sequence of SEQ ID NO:33 (mB7-1), SEQ ID NO:35 (hB7-1), SEQ ID NO:37 (mB7-2) and SEQ ID NO:39 (hB7-2) and SEQ ID NO:41 (hB7-2). In this embodiment, the isolated nucleic acid includes a nucleotide sequence encoding at least one second signal peptide domain. Preferably, the isolated nucleic acid does not comprise a nucleotide sequence encoding the first signal peptide domain (i.e., the nucleic acid comprises an alternative splice form of a transcript of the gene in which the exon encoding a first signal domain has been excised from the transcript). Preferred T cell costimulatory molecule gene from which nucleotide sequences can be derived include B7-1 and B7-2.

C. Nucleic Acids Encoding Proteins With Domains Deleted or Added

Another aspect of the invention pertains to isolated nucleic acids encoding T cell costimulatory molecules having structural domains which have been deleted or added. This aspect of the invention is based, at least in part, on the discovery that alternative splicing of mRNA transcripts encoding T cell costimulatory molecules generates transcripts in which an exon encoding a structural domain has been excised or in which at least two exons encoding two forms of a structural domain are linked in tandem. In one embodiment, the nucleic acid is one in which an exon encoding an IgV-like domain has been deleted (i.e., the signal peptide domain exon is linked directly to the IgC-like domain exon). Accordingly, in one embodiment, the isolated nucleic acid encodes a protein comprising a contiguous nucleotide sequence derived from at least one T cell costimulatory molecule gene, the nucleotide sequence represented by a formula A-B-C-D, wherein

A comprises a nucleotide sequence of at least one first exon of a T cell costimulatory molecule gene, wherein the at least one first exon encodes a signal peptide domain,

B comprises a nucleotide sequence of at least one second exon of a T cell costimulatory molecule gene, wherein the at least one second exon encodes an immunoglobulin constant region-like domain,

C comprises a nucleotide sequence of at least one third exon of a T cell costimulatory molecule gene, wherein the at least one third exon encodes a transmembrane domain, and

D comprises a nucleotide sequence of at least one fourth exon of a T cell costimulatory molecule gene, wherein the at least one fourth exon encodes a cytoplasmic domain.

In the formula, A, B, C and D are contiguous nucleotide sequences linked by phosphodiester bonds in a 5' to 3' orientation from A to D.

Naturally-occurring mRNA transcripts encoding murine B7-1 have been detected in which the exon encoding the IgV-like domain (i.e., exon 2) has been excised and the exon encoding the signal peptide domain (i.e., exon 1) is spliced to the exon encoding the IgC-like domain (i.e., exon 3) (see Example 7). In one embodiment, an isolated nucleic acid encoding an alternatively spliced form of murine B7-1 in which an IgV-like domain exon has been deleted comprises a nucleotide sequence corresponding to usage of exons 1-3-4-5 (SEQ ID NO: 8). Alternatively, an alternatively spliced form of murine B7-1 comprises a nucleotide sequence corresponding to usage of exons 1-3-4-6 (SEQ ID NO: 10), which contains the second, alternative cytoplasmic domain of mB7-1.

In another embodiment, nucleic acid is one in which an exon encoding an IgC-like domain has been deleted (i.e., the IgV-like domain exon is linked directly to the transmembrane domain exon). Accordingly, in one embodiment, the isolated nucleic acid encodes a protein comprising a contiguous nucleotide sequence derived from at least one T cell costimulatory molecule gene, the nucleotide sequence represented by a formula A-B-C-D, wherein

A comprises a nucleotide sequence of at least one first exon of a T cell costimulatory molecule gene, wherein the at least one first exon encodes a signal peptide domain,

B comprises a nucleotide sequence of at least one second exon of a T cell costimulatory molecule gene, wherein the at least one second exon encodes an immunoglobulin variable region-like domain,

C comprises a nucleotide sequence of at least one third exon of a T cell costimulatory molecule gene, wherein the at least one third exon encodes a transmembrane domain, and

D comprises a nucleotide sequence of at least one fourth exon of a T cell costimulatory molecule gene, wherein the at least one fourth exon encodes a cytoplasmic domain.

In the formula, A, B, C and D are contiguous nucleotide sequences linked by phosphodiester bonds in a 5' to 3' orientation from A to D.

In one embodiment, an isolated nucleic acid encoding an alternatively spliced form of murine B7-1 in which an IgC-like domain exon has been deleted comprises a nucleotide sequence corresponding to usage of exons 1-2-4-5 (shown in SEQ ID NO: 62). The amino acid sequence of the protein encoded by this nucleic acid is shown in SEQ ID NO: 63.

Moreover, in another embodiment, an alternatively spliced form of murine B7-1 in which an IgC-like domain exon has been deleted can comprise a nucleotide sequence corresponding to usage of exons 1-2-4-6 (shown in SEQ ID NO: 64), which contains the second, alternative

cytoplasmic domain of mB7-1. The amino acid sequence of the protein encoded by this nucleic acid is shown in SEQ ID NO: 65. Naturally-occurring mRNA transcripts encoding murine B7-1 have been detected in which the exon encoding the IgC-like domain (i.e., exon 3) has been excised and the exon encoding the IgV-like domain (i.e., exon 2) is spliced to the exon encoding the transmembrane domain (i.e., exon 4) (see Example 7). When expressed in a host cell, the IgV-like isoform of mB7-1 is capable of binding to both mouse CTLA4 and mouse CD28 and can trigger a costimulatory signal in a T cell such that the T cell proliferates and produces interleukin-2 (see Example 7).

Yet another aspect of this invention features an isolated nucleic acid encoding a T cell costimulatory molecule which contains exons in addition to a known or previously identified form of the T cell costimulatory molecule. For example, a naturally-occurring murine B7-1 mRNA transcript has been identified which contains two cytoplasmic domain-encoding exons in tandem, i.e., the transcript contains exons 1-2-3-4-5-6 (the nucleotide sequence of which is shown in SEQ ID NO: 3). Since there is an in-frame termination codon within exon 5, translation of this transcript produces a protein which contains only the Cyt I cytoplasmic domain. However, if desired, this termination codon can be mutated by standard site-directed mutagenesis techniques to create a nucleotide sequence which encodes an mB7-1 protein containing both a Cyt I and a Cyt II domain in tandem.

II. Isolation of Nucleic Acids of the Invention

An isolated nucleic acid having a nucleotide sequence disclosed herein can be obtained by standard molecular biology techniques. For example, oligonucleotide primers suitable for use in the polymerase chain reaction (PCR) can be prepared based upon the nucleotide sequences disclosed herein and the nucleic acid molecule can be amplified from cDNA and isolated. At least one oligonucleotide primer should be complimentary to a nucleotide sequence encoding an alternative structural domain. It is even more preferable that at least one oligonucleotide primer span a novel exon junction created by alternative splicing. For example, an oligonucleotide primer which spans the junction of exon 4 and exon 6 can be used to preferentially amplify a murine B7-1 cDNA that contains the second, alternative cytoplasmic domain (e.g., a cDNA which contains exons 1-2-3-4-6; SEQ ID NO: 1). Alternatively, an oligonucleotide primer complimentary to a nucleotide sequence encoding a novel alternative structural domain can be used to screen a cDNA library to isolate a nucleic acid of the invention.

Isolated nucleic acid molecules having nucleotide sequences other than those specifically disclosed herein are also encompassed by the invention. For example, novel structural forms of B7-1 from species other than mouse are within the scope of the invention (e.g., alternatively spliced forms of human B7-1). Likewise, novel structural forms of B7-2 from species other than mouse are also within the scope of the invention (e.g., alternatively spliced forms of human B7-2). Furthermore, additional alternatively spliced forms for

murine B7-1 and murine B7-2 can be identified using techniques described herein. These alternatively spliced forms of murine B7-1 and B7-2 are within the scope of the invention. Isolated nucleic acid molecules encoding novel structural forms of T cell costimulatory molecules can be obtained by conventional techniques, such as by methods described below and in the Examples.

An isolated nucleic acid encoding a novel structural form of a T cell costimulatory molecule can be obtained by isolating and analyzing cDNA clones encoding the T cell costimulatory molecule (e.g., mB7-1; hB7-1; mB7-2; hB7-2 etc.) by standard techniques (see for example Sambrook *et al.* *Molecular Cloning: A Laboratory Manual*, 2nd Edition, Cold Spring Harbor Laboratory press (1989) or other laboratory handbook). For example, cDNAs encoding the costimulatory molecule can be amplified by reverse transcriptase-polymerase chain reaction (RT-PCR) using oligonucleotide primers specific for the costimulatory molecule gene. The amplified cDNAs can then be subcloned into a plasmid vector and sequenced by standard methods. Oligonucleotide primers for RT-PCR can be designed based upon previously disclosed nucleotide sequences of costimulatory molecules (see Freeman, G.J. et al., (1991) *J. Exp. Med.* 174:625-631 for mB7-1; Freeman, G.J. et al., (1989) *J. Immunol.* 143:2714-2722 for hB7-1; Freeman, G.J. et al., (1993) *J. Exp. Med.* 178:2185-2192 for mB7-2; and Freeman, G.J. et al., (1993) *Science* 262:909-911 for hB7-2; nucleotide sequences are shown in SEQ ID NOS: 16, 18, 20, 22 and 24). For analyzing the 5' or 3' ends of mRNA transcripts, cDNA can be prepared using a 5' or 3' "RACE" procedure ("rapid amplification of cDNA ends) as described in the Examples. Alternative to amplifying specific cDNAs, a cDNA library can be prepared from a cell line which expresses the costimulatory molecule and screened with a probe containing all or a portion of the nucleotide sequence encoding the costimulatory molecule.

Individual isolated cDNA clones encoding a T cell costimulatory molecule can then be sequenced by standard techniques, such as dideoxy sequencing or Maxam-Gilbert sequencing, to identify a cDNA clone encoding a T cell costimulatory molecule having a novel structural domain. A novel structural domain can be identified by comparing the sequence of the cDNA clone to the previously disclosed nucleotide sequences encoding T cell costimulatory molecules (e.g., sequences shown in SEQ ID NO: 16, 18, 20, 22 and 24). Once a putative alternative structural domain has been identified, the nucleotide sequence encoding the domain can be mapped in genomic DNA to determine whether the domain is encoded by a novel exon. This type of approach provides the most extensive information about alternatively spliced forms of mRNAs encoding the costimulatory molecule.

Alternatively, a novel structural domain for T cell costimulatory molecules can be identified in genomic DNA by identifying a novel exon in the gene encoding the T cell costimulatory molecule. A novel exon can be identified as an open reading frame flanked by splice acceptor and splice donor sequences. Genomic clones encoding a T cell costimulatory molecule can be isolated by screening a genomic DNA library with a probe encompassing all

or a portion of a nucleotide sequence encoding the costimulatory molecule (e.g., having all or a portion of a nucleotide sequence shown in SEQ ID NO: 16, 18, 20, 22 and 24). For costimulatory molecules whose genes have been mapped to a particular chromosome, a chromosome-specific library rather than a total genomic DNA library can be used. For example, hB7-1 has been mapped to human chromosome 3 (see Freeman, G.J. et al. (1992) *Blood* 79:489-494; and Selvakumar, A. et al. (1992) *Immunogenetics* 36:175-181. Genomic clones can be sequenced by conventional techniques and novel exons identified. A probe corresponding to a novel exon can then be used to detect the nucleotide sequence of this exon in mRNA transcripts encoding the costimulatory molecule (e.g., by screening a cDNA library or by PCR).

A more preferred approach for identifying and isolating nucleic acid encoding a novel structural domain of a T cell costimulatory molecule is by "exon trapping". Exon trapping is a technique that has been used successfully to identify and isolate novel exons (see e.g. Duyk, G.M. et al. (1990) *Proc. Natl. Acad. Sci. USA* 87:8995-8999; Auch, D. and Reth, M. (1990) *Nucleic Acids Res.* 18:6743-6744; Hamaguchi, M. et al. (1992) *Proc. Natl. Acad. Sci. USA* 89:9779-9783; and Krizman, D.B and Berget, S.M. (1993) *Nucleic Acids Res.* 21:5198-5202). The approach of exon trapping can be applied to the isolation of exons encoding novel structural domains of T cell costimulatory molecules, such as a novel alternative cytoplasmic domain of human B7-1, as described in Example 5.

In addition to the isolated nucleic acids encoding naturally-occurring alternatively spliced forms of T cell costimulatory molecules provided by the invention, it will be appreciated by those skilled in the art that nucleic acids encoding variant alternative forms, which may or may not occur naturally, can be obtained using standard recombinant DNA techniques. The term "variant alternative forms" is intended to include novel combinations of exon sequences which can be created using recombinant DNA techniques. That is, novel exons encoding structural domains of T cell costimulatory molecules, either provided by the invention or identified according to the teachings of the invention, can be "spliced", using standard recombinant DNA techniques, to other exons encoding other structural domains of the costimulatory molecule, regardless of whether the particular combination of exons has been observed in nature. Thus, novel combinations of exons can be linked *in vitro* to create variant alternative forms of T cell costimulatory molecules. For example, the structural form of murine B7-1 which has the signal peptide domain directly joined to the IgC-like domain (ie., which has the IgV-like domain deleted) has been observed in nature in combination with the cytoplasmic domain encoded by exon 5. However, using conventional techniques, an alternative structural form can be created in which the IgV-like domain is deleted and the alternative cytoplasmic domain is encoded by exon 6. In another example, a murine B7-1 cDNA containing exons 1-2-3-4-5-6 can be mutated by site-directed mutagenesis to change a stop codon in exon 5 to an amino acid encoding-codon such that an mB7-1 protein can be produced which contains both a Cyt I domain and a Cyt II domain in tandem. Additionally,

an exon encoding a structural domain of one costimulatory molecule can be transferred to another costimulatory molecule by standard techniques. For example, the cytoplasmic domain of mB7-2 can be replaced with the novel cytoplasmic domain of mB7-1 provided by the invention (i.e., exon 6 of mB7-1 can be "swapped" for the cytoplasmic domain exon of mB7-2).

For the purposes of this invention, the amino acid residues encompassing the different "domains" or "exons" (i.e., signal (S), IgV-like (V), IgC-like (C), transmembrane (TM) and cytoplasmic (Cyt)) of mouse and human B7-1 and B7-2 proteins are defined as follows: mouse B7-1 (as shown in SEQ ID NO: 17): ~1-37 (S), ~38-142 (V), ~143-247 (C), ~248-274 (TM) and ~275-306 (Cyt); human B7-1 (as shown in SEQ ID NO: 19): ~1-33 (S), ~34-138 (V), ~139-242 (C), ~243-265 (TM) and ~266-288 (Cyt); mouse B7-2 (as shown in SEQ ID NO: 21): ~1-5 (S), ~6-133 (V), ~134-233 (C), ~234-264 (TM) and ~265-309 (Cyt); and human B7-2 (as shown in SEQ ID NO: 23): ~1-6-22 (S), ~23-132 (V), ~133-245 (C), ~246-268 (TM) and ~269-329 (Cyt). It will be appreciated by the skilled artisan that regions slightly longer or shorter than these amino acid domains (i.e., a few amino acid residues more or less at either the amino-terminal or carboxy-terminal end) may be equally suitable for use as signal, IgV-like, IgC-like, transmembrane and/or cytoplasmic domains in the proteins of the invention (i.e., there is some flexibility in the junctions between different domains within the proteins of the invention as compared to the domain junctions delineated above for B7-1 and B7-2 proteins). Accordingly, proteins comprising signal, IgV-like, IgC-like, transmembrane and/or cytoplasmic domains having essentially the same amino acid sequences as those regions delineated above but which differ from the above-delineated junctions merely be a few amino acid residues, either longer or shorter, at either the amino- or carboxy-terminal end of the domain are intended to be encompassed by the invention. Nucleic acid segments encoding any of the domains delineated above can be obtained by standard techniques, e.g., by PCR amplification using oligonucleotide primers based on the nucleotide sequences disclosed herein, and can be ligated together to create nucleic acid molecules encoding recombinant forms of the proteins of the invention.

It will also be appreciated by those skilled in the art that changes can be made in the nucleotide sequences provided by the invention without changing the encoded protein due to the degeneracy of the genetic code. Additionally, nucleic acids which have a nucleotide sequence different from those disclosed herein due to degeneracy of the genetic code may be isolated from biological sources. Such nucleic acids encode functionally equivalent proteins (e.g., a protein having T cell costimulatory activity) to those described herein. For example, a number of amino acids are designated by more than one triplet codon. Codons that specify the same amino acid, or synonyms (for example, CAU and CAC are synonyms for histidine) may occur in isolated nucleic acids from different biological sources or can be introduced into an isolated nucleic acid by standard recombinant DNA techniques without changing the protein encoded by the nucleic acid. Isolated nucleic acids encoding alternatively spliced

forms of T cell costimulatory molecules having a nucleotide sequence which differs from those provided herein due to degeneracy of the genetic code are considered to be within the scope of the invention.

5 III. Additional Isolated Nucleic Acid Molecules of the Invention

10 In addition to isolated nucleic acids encoding alternative forms of T cell costimulatory molecules, the invention also discloses previously undescribed nucleotide sequences of the murine B7-1 gene and mRNA transcripts. As described in detail in Example 3, it has now been discovered that murine B7-1 mRNA transcripts contain additional 5' untranslated (UT) sequences which were not previously reported. A 5' UT region of approximately 250 base pairs has been reported for mB7-1 mRNA transcripts, determined by primer extension analysis (see Selvakumar et al. (1993) *Immunogenetics* 38:292-295). As described herein, an additional ~1500 nucleotides of 5' UT sequences have been discovered in mB7-1. These 5' UT sequences are contiguous with known exon 1 sequences, thereby extending the size of exon 1 by approximately 1500 base pairs. Thus the novel 5' UT sequence of the invention corresponds to the 5' region of mB7-1 exon 1 (i.e., exon 1 extends an additional ~1500 nucleotides at its 5' end than previously reported) rather than corresponding to a new exon upstream of exon 1. Computer analysis of the potential secondary structure of the 5' UT region reveals that the most stable structure is comprised of multiply folded palindromic sequences. This high degree of secondary structure may explain the results of Selvakumar et al. ((1993) *Immunogenetics* 38:292-295) in that the secondary structure could account for premature termination of the primer extension reaction. The potential for excessive secondary structure in the 5' UT region suggests that post-transcriptional mechanisms are involved in controlling mB7-1 expression. Thus, inclusion of the long 5' UT sequence in recombinant expression vectors encoding mB7-1 may provide post-transcriptional regulation that is similar to that of the endogenous gene. Accordingly, the 5' UT region of mB7-1 provided by the invention can be incorporated by standard recombinant DNA techniques at the 5' end of a cDNA encoding a mB7-1 protein. The nucleotide sequence of the 5' UT region of mB7-1 (i.e., the full nucleotide sequence of exon 1) is shown in SEQ ID NO: 6.

30 The discovery of additional 5' UT sequences in mB7-1 cDNA demonstrates that transcription of the mB7-1 gene initiates further upstream (i.e., 5') in genomic DNA than previously reported in Selvakumar et al. (*Immunogenetics* (1993) 38:292-295). Transcription of a gene is typically regulated by sequences in genomic DNA located immediately upstream of sequences corresponding to the 5' UT region of the transcribed mRNA. Nucleotides located within approximately 200 base pairs of the start site of transcription are generally considered to encompass the promoter of the gene and often include canonical CCAAT or TATA elements indicative of a typical eukaryotic promoter. For a gene having a promoter which contains a TATA box, transcription usually starts approximately 30 base pairs downstream of the TATA box. In addition to CCAAT and TATA-containing promoters, it is

now appreciated that many genes have promoters which do not contain these elements. Examples of such genes include many members of the immunoglobulin gene superfamily (see for example Breathnach, R. and Chambon, P. (1981) *Ann. Rev. Biochem.* 50:349-383; Fisher, R.C. and Thorley-Lawson, D.A. (1991) *Mol. Cell. Biol.* 11:1614-1623; Hogarth, P.M. et al. (1991) *J. Immunol.* 146:369-376; Schanberg, L.E. (1991) *Proc. Natl. Acad. Sci. USA* 88:603-607; Zhou, L.J. et al. (1991) *J. Immunol.* 147:1424-1432). In such TATA-less promoters, transcriptional regulation is thought to be provided by other DNA elements which bind transcription factors. Sequence analysis of ~180 base pairs of mB7-1 genomic DNA immediately upstream of the newly identified 5' UT region revealed the presence of numerous consensus sites for transcription factor binding, including AP-2, PU.1 and NFκB. The nucleotide sequence of this region is shown in SEQ ID NO: 7. The structure of this region (i.e., the DNA elements contained therein) is consistent with it functioning as a promoter for transcription of the mB7-1 gene. The ability of this region of DNA to function as a promoter can be determined by standard techniques routinely used in the art to identify transcriptional regulatory elements. For example, this DNA region can be cloned upstream of a reporter gene (e.g., encoding chloramphenicol acetyl transferase, β-galactosidase, luciferase etc.) in a recombinant vector, the recombinant vector transfected into an appropriate cell line and expression of the reporter gene detected as an indication that the DNA region can function as a transcriptional regulatory element. If it is determined that this DNA region can function as a B7-1 promoter, it may be advantageous to use this DNA region to regulate expression of a B7-1 cDNA in a recombinant expression vector to mimic the endogenous expression of B7-1.

IV. Uses for the Isolated Nucleic Acid Molecules of the Invention

A. Probes

The isolated nucleic acids of the invention are useful for constructing nucleotide probes for use in detecting nucleotide sequences in biological materials, such as cell extracts, or directly in cells (e.g., by *in situ* hybridization). A nucleotide probe can be labeled with a radioactive element which provides for an adequate signal as a means for detection and has sufficient half-life to be useful for detection, such as ³²P, ³H, ¹⁴C or the like. Other materials which can be used to label the probe include antigens that are recognized by a specific labeled antibody, fluorescent compounds, enzymes and chemiluminescent compounds. An appropriate label can be selected with regard to the rate of hybridization and binding of the probe to the nucleotide sequence to be detected and the amount of nucleotide available for hybridization. The isolated nucleic acids of the invention, or oligonucleotide fragments thereof, can be used as suitable probes for a variety of hybridization procedures well known to those skilled in the art. The isolated nucleic acids of the invention enable one to determine whether a cell expresses an alternatively spliced form of a T cell costimulatory

molecule. For example, mRNA can be prepared from a sample of cells to be examined and the mRNA can be hybridized to an isolated nucleic acid encompassing a nucleotide sequence encoding all or a portion of an alternative cytoplasmic domain of a T cell costimulatory molecule (e.g., SEQ ID NO: 1) to detect the expression of the alternative cytoplasmic domain form of the costimulatory molecule in the cells. Furthermore, the isolated nucleic acids of the invention can be used to design oligonucleotide primers, e.g. PCR primers, which allow one to detect the expression of an alternatively spliced form of a T cell costimulatory molecule. Preferably, this oligonucleotide primer spans a novel exon junction created by alternative splicing and thus can only amplify cDNAs encoding this alternatively spliced form. For example, an oligonucleotide primer which spans exon 4 and exon 6 of murine B7-1 can be used to distinguish between the expression of a first cytoplasmic domain form of mB7-1 (i.e., encoded by exons 1-2-3-4-5) and expression of an alternative second cytoplasmic domain form of a costimulatory molecule (i.e., encoded by exons 1-2-3-4-6) (e.g., see Example 2).

The probes of the invention can be used to detect an alteration in the expression of an alternatively spliced form of a T cell costimulatory molecule, such as in a disease state. For example, detection of a defect in the expression of an alternatively spliced form of a T cell costimulatory molecule that is associated with an immunodeficiency disorder can be used to diagnose the disorder (i.e., the probes of the invention can be used for diagnostic purposes). Many congenital immunodeficiency diseases result from lack of expression of a cell-surface antigen important for interactions between T cells and antigen presenting cells. For example, the bare lymphocyte syndrome results from lack of expression of MHC class II antigens (see e.g., Rijkers, G.T. et al. (1987) *J. Clin. Immunol.* 7:98-106; Hume, C.R. et al. (1989) *Hum. Immunol.* 25:1-11)) and X-linked hyperglobulinemia results from defective expression of the ligand for CD40 (gp39) (see e.g. Korthauer, U et al. (1993) *Nature* 361:541; Aruffo, A. et al. (1993) *Cell* 72:291-300). An immunodeficiency disorder which results from lack of expression of an alternatively spliced form of a T cell costimulatory molecule can be diagnosed using a probe of the invention. For example, a disorder resulting from the lack of expression of the Cyt II form of B7-1 can be diagnosed in a patient based upon the inability of a probe which detects this form of B7-1 (e.g., an oligonucleotide spanning the junction of exon 4 and exon 6) to hybridize to mRNA in cells from the patient (e.g., by RT-PCR or by Northern blotting).

B. Recombinant Expression Vectors

An isolated nucleic acid of the invention can be incorporated into an expression vector (i.e., a recombinant expression vector) to direct expression of a novel structural form of a T cell costimulatory molecule encoded by the nucleic acid. The recombinant expression vectors are suitable for transformation of a host cell, and include a nucleic acid (or fragment thereof) of the invention and a regulatory sequence, selected on the basis of the host cells to be used for expression, which is operatively linked to the nucleic acid. Operatively linked is

intended to mean that the nucleic acid is linked to a regulatory sequence in a manner which allows expression of the nucleic acid. Regulatory sequences are art-recognized and are selected to direct expression of the desired protein in an appropriate host cell. Accordingly, the term regulatory sequence includes promoters, enhancers and other expression control elements. Such regulatory sequences are known to those skilled in the art or are described in Goeddel, *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, CA (1990). It should be understood that the design of the expression vector may depend on such factors as the choice of the host cell to be transfected and/or the type of protein desired to be expressed. Such expression vectors can be used to transfect cells to thereby produce proteins or peptides encoded by nucleic acids as described herein.

The recombinant expression vectors of the invention can be designed for expression of encoded proteins in prokaryotic or eukaryotic cells. For example, proteins can be expressed in bacterial cells such as *E. coli*, insect cells (using baculovirus), yeast cells or mammalian cells. Other suitable host cells can be found in Goeddel, *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, CA (1990). Expression in prokaryotes is most often carried out in *E. coli* with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids usually to the amino terminus of the expressed target gene. Such fusion vectors typically serve three purposes: 1) to increase expression of recombinant protein; 2) to increase the solubility of the target recombinant protein; and 3) to aid in the purification of the target recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the target recombinant protein to enable separation of the target recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Amrad Corp., Melbourne, Australia), pMAL (New England Biolabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase, maltose E binding protein, or protein A, respectively, to the target recombinant protein.

Inducible non-fusion prokaryotic expression vectors include pTrc (Amann *et al.*, (1988) *Gene* 69:301-315) and pET11d (Studier *et al.*, *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, California (1990) 60-89). In pTrc, target gene expression relies on host RNA polymerase transcription from a hybrid trp-lac fusion promoter. In pET11d, expression of inserted target genes relies on transcription from the T7 gn10-lac 0 fusion promoter mediated by a coexpressed viral RNA polymerase (T7 gn1). This viral polymerase is supplied by host strains BL21(DE3) or HMS174(DE3) from a resident λ prophage harboring a T7 gn1 under the transcriptional control of the lacUV 5 promoter.

One strategy to maximize recombinant protein expression in *E. coli* is to express the protein in a host bacterial strain with an impaired capacity to proteolytically cleave the

recombinant protein (Gottesman, S., *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, California (1990) 119-128). Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector (e.g., a nucleic acid of the invention) so that the individual codons for each amino acid would be those preferentially utilized in highly expressed *E. coli* proteins (Wada *et al.*, (1992) *Nuc. Acids Res.* 20:2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques and are encompassed by the invention.

Examples of vectors for expression in yeast *S. cerevisiae* include pYepSec1 (Baldari. *et al.*, (1987) *Embo J.* 6:229-234), pMFa (Kurjan and Herskowitz, (1982) *Cell* 30:933-943), pJRY88 (Schultz *et al.*, (1987) *Gene* 54:113-123), and pYES2 (Invitrogen Corporation, San Diego, CA). Baculovirus vectors available for expression of proteins in cultured insect cells (SF 9 cells) include the pAc series (Smith *et al.*, (1983) *Mol. Cell Biol.* 3:2156-2165) and the pVL series (Lucklow, V.A., and Summers, M.D., (1989) *Virology* 170:31-39).

Expression of alternatively spliced forms of T cell costimulatory molecules in mammalian cells is accomplished using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed, B., (1987) *Nature* 329:840) and pMT2PC (Kaufman *et al.* (1987), *EMBO J.* 6:187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral material. For example, commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40. The recombinant expression vector can be designed such that expression of the nucleic acid occurs preferentially in a particular cell type. In this situation, the expression vector's control functions are provided by regulatory sequences which allow for preferential expression of a nucleic acid contained in the vector in a particular cell type, thereby allowing for tissue or cell specific expression of an encoded protein.

The recombinant expression vectors of the invention can be a plasmid or virus, or viral portion which allows for expression of a nucleic acid introduced into the viral nucleic acid. For example, replication defective retroviruses, adenoviruses and adeno-associated viruses can be used. The recombinant expression vectors can be introduced into a host cell, e.g. *in vitro* or *in vivo*. A host cell line can be used to express a protein of the invention. Furthermore, introduction of a recombinant expression vector of the invention into a host cell can be used for therapeutic purposes when the host cell is defective in expressing the novel structural form of the T cell costimulatory molecule. For example, in a recombinant expression vector of the invention can be used for gene therapy purposes in a patient with an immunodeficiency disorder resulting from lack of expression of a novel structural form of a T cell costimulatory molecule.

C. Host Cells

The invention further provides a host cell transfected with a recombinant expression vector of the invention. The term "host cell" is intended to include prokaryotic and

eukaryotic cells into which a recombinant expression vector of the invention can be introduced. The terms "transformed with", "transfected with", "transformation" and "transfection" are intended to encompass introduction of nucleic acid (e.g., a vector) into a cell by one of a number of possible techniques known in the art. Prokaryotic cells can be transformed with nucleic acid by, for example, electroporation or calcium-chloride mediated transformation. Nucleic acid can be introduced into mammalian cells via conventional techniques such as calcium phosphate co-precipitation, DEAE-dextran-mediated transfection, lipofectin, electroporation or microinjection. Suitable methods for transforming and transfecting host cells can be found in Sambrook *et al.* (*Molecular Cloning: A Laboratory Manual*, 2nd Edition, Cold Spring Harbor Laboratory press (1989)), and other laboratory handbooks.

The number of host cells transfected with a recombinant expression vector of the invention by techniques such as those described above will depend upon the type of recombinant expression vector used and the type of transfection technique used. Typically, plasmid vectors introduced into mammalian cells are integrated into host cell DNA at only a low frequency. In order to identify these integrants, a gene that contains a selectable marker (i.e., resistance to antibiotics) can be introduced into the host cells along with the gene of interest. Preferred selectable markers include those which confer resistance to certain drugs, such as G418 and hygromycin. Selectable markers can be introduced on a separate vector (e.g., plasmid) from the nucleic acid of interest or, preferably, are introduced on the same vector (e.g., plasmid). Host cells transformed with one or more recombinant expression vectors containing a nucleic acid of the invention and a gene for a selectable marker can be identified by selecting for cells using the selectable marker. For example, if the selectable marker encoded a gene conferring neomycin resistance, transformant cells can be selected with G418. Cells that have incorporated the selectable marker gene will survive, while the other cells die.

Preferably, the novel cytoplasmic domain form of the T cell costimulatory molecule is expressed on the surface of a host cell (e.g., on the surface of a mammalian cell). This is accomplished by using a recombinant expression vector encoding extracellular domains (e.g., signal peptide, V-like and/or C-like domains), transmembrane and cytoplasmic domains of the T cell costimulatory molecule with appropriate regulatory sequences (e.g., a signal sequence) to allow for surface expression of the translated protein.

In one embodiment, a host cell is transfected with a recombinant expression vector encoding a second, novel cytoplasmic domain form of a T cell costimulatory molecule. In a preferred embodiment, the host cell does not express the first (i.e., previously disclosed) cytoplasmic domain form of the costimulatory molecule. For example, a host cell which does not express a form of murine B7-1 containing Cyt I can be transfected with a recombinant expression vector encoding a form of murine B7-1 containing Cyt II. Such a host cell will thus exclusively express the form of B7-1 containing Cyt II. This type of host

cell is useful for studying signaling events and/or immunological responses which are mediated by the Cyt II domain rather than the Cyt I domain of B7-1. For example, one type of cell which can be used to create a host cell which exclusively expresses the Cyt II-form of murine B7-1 is a non-murine cell, since the non-murine cell does not express murine B7-1.

5 Preferably, the non-murine cell also does not express other costimulatory molecules (e.g., COS cells can be used). Alternatively, a mouse cell which does not express the Cyt-I form of murine B7-1 can be used. For example, a recombinant expression vector of the invention can be introduced into NIH 3T3 fibroblast cells (which are B7-1 negative) or into cells derived from a mutant mouse in which the endogenous B7-1 gene has been disrupted and thus which
10 does not natively express any form of B7-1 molecule (i.e., into cells derived from a "B7-1 knock-out" mouse, such as that described in Freeman, G.J. et al. (1993) *Science* 262:907-909).

In another embodiment, the host cell transfected with a recombinant expression vector encoding a novel structural form of a T cell costimulatory molecule is a tumor cell.

15 Expression of the Cyt-I form of murine B7-1 on the surface of B7-1 negative murine tumor cells has been shown to induce T cell mediated specific immunity against the tumor cells accompanied by tumor rejection and prolonged protection to tumor challenge in mice (see Chen, L., et al. (1992) *Cell* 71, 1093-1102; Townsend, S.E. and Allison, J.P. (1993) *Science* 259, 368-370; Baskar, S., et al. (1993) *Proc. Natl. Acad. Sci.* 90, 5687-5690). Similarly,
20 expression of novel structural forms of costimulatory molecules on the surface of a tumor cell may be useful for increasing the immunogenicity of the tumor cell. For example, tumor cells obtained from a patient can be transfected *ex vivo* with a recombinant expression vector of the invention, e.g., encoding an alternative cytoplasmic domain form of a costimulatory molecule, and the transfected tumor cells can then be returned to the patient. Alternatively,
25 gene therapy techniques can be used to target a tumor cell for transfection *in vivo*. Additionally, the tumor cell can also be transfected with recombinant expression vectors encoding other proteins to be expressed on the tumor cell surface to increase the immunogenicity of the tumor cell. For example, the Cyt-I form of B7-1, B7-2, MHC molecules (e.g., class I and/or class II) and/or adhesion molecules can be expressed on the
30 tumor cells in conjunction with the Cyt-II form of B7-1.

D. Anti-Sense Nucleic Acid Molecules

The isolated nucleic acid molecules of the invention can also be used to design anti-sense nucleic acid molecules, or oligonucleotide fragments thereof, that can be used to
35 modulate the expression of alternative forms of T cell costimulatory molecules. An anti-sense nucleic acid comprises a nucleotide sequence which is complementary to a coding strand of a nucleic acid, e.g. complementary to an mRNA sequence, constructed according to the rules of Watson and Crick base pairing, and can hydrogen bond to the coding strand of the nucleic acid. The hydrogen bonding of an antisense nucleic acid molecule to an mRNA

transcript can prevent translation of the mRNA transcript and thus inhibit the production of the protein encoded therein. Accordingly, an anti-sense nucleic acid molecule can be designed which is complementary to a nucleotide sequence encoding a novel structural domain of a T cell costimulatory molecule to inhibit production of that particular structural form of the T cell costimulatory molecule. For example, an anti-sense nucleic acid molecule can be designed which is complementary to a nucleotide sequence encoding the Cyt-II form of murine B7-1 and used to inhibit the expression of this form of the costimulatory molecule.

An anti-sense nucleic acids molecule, or oligonucleotide fragment thereof, can be constructed by chemical synthesis and enzymatic ligation reactions using procedures known in the art. The anti-sense nucleic acid or oligonucleotide can be chemically synthesized using naturally-occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the ant-sense and sense nucleic acids e.g. phosphorothioate derivatives and acridine substituted nucleotides can be used. Alternatively, the anti-sense nucleic acids and oligonucleotides can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an anti-sense orientation (i.e. nucleic acid transcribed from the inserted nucleic acid will be of an anti-sense orientation to a target nucleic acid of interest). The anti-sense expression vector is introduced into cells in the form of a recombinant plasmid, phagemid or attenuated virus in which anti-sense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using anti-sense genes see Weintraub, H. et al., "Antisense RNA as a molecular tool for genetic analysis", *Reviews - Trends in Genetics*, Vol. 1(1) 1986.

E. Non-Human Transgenic and Homologous Recombinant Animals

The isolated nucleic acids of the invention can further be used to create a non-human transgenic animal. A transgenic animal is an animal having cells that contain a transgene, wherein the transgene was introduced into the animal or an ancestor of the animal at a prenatal, e.g., an embryonic, stage. A transgene is a DNA molecule which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal. Accordingly, the invention provides a non-human transgenic animal which contains cells transfected to express an alternative form of a T cell costimulatory molecule. Preferably, the non-human animal is a mouse. A transgenic animal can be created, for example, by introducing a nucleic acid encoding the protein (typically linked to appropriate regulatory elements, such as a tissue-specific enhancer) into the male pronuclei of a fertilized oocyte, e.g., by microinjection, and allowing the oocyte to develop in a pseudopregnant female foster animal. For example, a transgenic animal (e.g., a mouse) which expresses an mB7-1 protein containing a novel

cytoplasmic domain (e.g. Cyt-II) can be made using the isolated nucleic acid shown in SEQ ID NO: 1 or SEQ ID NO: 3. Alternatively, a transgenic animal (e.g., a mouse) which expresses an mB7-2 protein containing an alternative signal peptide domain can be made using the isolated nucleic acid shown in SEQ ID NO: 12. Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene. These isolated nucleic acids can be linked to regulatory sequences which direct the expression of the encoded protein one or more particular cell types. Methods for generating transgenic animals, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866 and 4,870,009 and Hogan, B. et al., (1986) A Laboratory Manual, Cold Spring Harbor, New York, Cold Spring Harbor Laboratory. A transgenic founder animal can be used to breed additional animals carrying the transgene.

The isolated nucleic acids of the invention can further be used to create a non-human homologous recombinant animal. The term "homologous recombinant animal" as used herein is intended to describe an animal containing a gene which has been modified by homologous recombination. The homologous recombination event may completely disrupt the gene such that a functional gene product can no longer be produced (often referred to as a "knock-out" animal) or the homologous recombination event may modify the gene such that an altered, although still functional, gene product is produced. Preferably, the non-human animal is a mouse. For example, an isolated nucleic acid of the invention can be used to create a homologous recombinant mouse in which a recombination event has occurred in the B7-1 gene at an exon encoding a cytoplasmic domain such that this exon is altered (e.g., exon 5 or exon 6 is altered). Homologous recombinant mice can thus be created which express only the Cyt I or Cyt II domain form of B7-1. Accordingly, the invention provides a non-human knock-out animal which contains a gene encoding a B7-1 protein wherein an exon encoding a novel cytoplasmic domain is disrupted or altered.

To create an animal with homologously recombined nucleic acid, a vector is prepared which contains the DNA sequences which are to replace the endogenous DNA sequences, flanked by DNA sequences homologous to flanking endogenous DNA sequences (see for example Thomas, K.R. and Capecchi, M. R. (1987) *Cell* 51:503). The vector is introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced DNA has homologously recombined with the endogenous DNA are selected (see for example Li, E. et al. (1992) *Cell* 69:915). The selected cells are then injected into a blastocyst of an animal (e.g., a mouse) to form aggregation chimeras (see for example Bradley, A. in *Teratocarcinomas and Embryonic Stem Cells: A Practical Approach*, E.J. Robertson, ed. (IRL, Oxford, 1987) pp. 113-152). A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the homologously recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously recombined DNA.

V. Isolated Novel Forms of Costimulatory Molecules

The invention further provides isolated T cell costimulatory molecules encoded by the nucleic acids of the invention. These molecules have a novel structural form, either containing a novel structural domain or having a structural domain deleted or added. The term "isolated" refers to a T cell costimulatory molecule, e.g., a protein, substantially free of cellular material or culture medium when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized. In one embodiment, the novel T cell costimulatory molecule is a B7-1 protein. In another embodiment, the novel T cell costimulatory molecule is a B7-2 protein.

A. Proteins with a Novel Cytoplasmic Domain

One aspect of the invention pertains to a T cell costimulatory molecule which includes at least one novel cytoplasmic domain. In one embodiment, the invention provides a protein which binds to CD28 and/or CTLA4 and has an amino acid sequence derived from amino acid sequences encoded by at least one T cell costimulatory molecule gene. In this embodiment, the protein comprises a contiguous amino acid sequence represented by a formula A-B-C-D-E, wherein

A, which may or may not be present, comprises an amino acid sequence of a signal peptide domain,

B comprises an amino acid sequence of an immunoglobulin variable region-like domain encoded by at least one exon of a T cell costimulatory molecule gene,

C comprises an amino acid sequence of an immunoglobulin constant region-like domain encoded by at least one exon of a T cell costimulatory molecule gene,

D comprises an amino acid sequence of a transmembrane domain encoded by at least one exon of a T cell costimulatory molecule gene, and

E comprises an amino acid sequence of a cytoplasmic domain encoded by at least one exon of a T cell costimulatory molecule gene,

with the proviso that E does not comprise an amino acid sequence of a cytoplasmic domain selected from the group consisting of SEQ ID NO: 26 (mB7-1), SEQ ID NO: 28 (hB7-1), SEQ ID NO: 30 (mB7-2), and SEQ ID NO: 32 (hB7-2).

In the formula, A, B, C, D, and E are contiguous amino acid residues linked by amide bonds from an N-terminus to a C-terminus. According to the formula, A can be an amino acid sequence of a signal peptide domain of a heterologous protein which efficiently expresses transmembrane or secreted proteins, such as the oncostatin M signal peptide. Preferably, A, if present, comprises an amino acid sequence of a signal peptide domain encoded by at least one exon of a T cell costimulatory molecule gene. In one preferred

embodiment, the isolated protein is a B7-1 or a B7-2 protein. E preferably comprises an amino acid sequence of a murine B7-1 cytoplasmic domain having an amino acid sequence shown in SEQ ID NO: 5 (i.e., the amino acid sequence of the cytoplasmic domain encoded by the novel exon 6 of the invention).

5 Another embodiment of the invention provides an isolated protein which binds CD28 or CTLA4 and is encoded by a T cell costimulatory molecule gene having at least one first exon encoding a first cytoplasmic domain and at least one second exon encoding a second cytoplasmic domain. The at least one first cytoplasmic domain comprises an amino acid sequence selected from the group consisting of amino acid sequence of SEQ ID NO:26 (mB7-1), SEQ ID NO:28 (hB7-1), SEQ ID NO:30 (mB7-2) and SEQ ID NO:32 (hB7-2). In
10 this embodiment, the protein includes an amino acid sequence comprising at least one second cytoplasmic domain. Preferably, the protein does not include an amino acid sequence comprising a first cytoplasmic domain.

Preferred proteins which bind CD28 and/or CTLA4 are derived from B7-1 and B7-2.
15 In a particularly preferred embodiment, the invention provides an isolated protein which binds CD28 or CTLA4 and has a novel cytoplasmic domain comprising an amino acid sequence shown in SEQ ID NO: 2.

A. Proteins with a Novel Signal Peptide Domain

20 In yet another aspect of the invention, T cell costimulatory molecules which include at least one novel signal peptide domain are provided. In one embodiment, the isolated protein binds to CD28 or CTLA4 and has an amino acid sequence derived from amino acid sequences encoded by at least one T cell costimulatory molecule gene. In this embodiment, the protein comprises a contiguous amino acid sequence represented by a formula A-B-C-D-E, wherein
25

A comprises an amino acid sequence of a signal peptide domain encoded by at least one exon of a T cell costimulatory molecule gene,

30 B comprises an amino acid sequence of an immunoglobulin variable region-like domain encoded by at least one exon of a T cell costimulatory molecule gene,

C comprises an amino acid sequence of an immunoglobulin constant region-like domain encoded by at least one exon of a T cell costimulatory molecule gene,

D, which may or may not be present, comprises an amino acid sequence of a transmembrane domain encoded by at least one exon of a T cell costimulatory molecule gene, and
35

E, which may or may not be present, comprises an amino acid sequence of a cytoplasmic domain encoded by at least one exon of a T cell costimulatory molecule gene,

with the proviso that A not comprise an amino acid sequence of a signal peptide domain selected from the group consisting of SEQ ID NO: 34 (mB7-1), SEQ ID NO: 36 (hB7-1), SEQ ID NO: 38 (mB7-2), SEQ ID NO: 40 (hB7-2), SEQ ID NO: 42 (hB7-2).

In the formula, A, B, C, D, and E are contiguous amino acid residues linked by amide bonds from an N-terminus to a C-terminus. To produce a soluble form of the T cell costimulatory molecule D, which comprises an amino acid sequence of a transmembrane domain and E, which comprises an amino acid sequence of a cytoplasmic domain may not be present in the molecule. Preferably, A comprises an amino acid sequence of a novel signal peptide domain shown in SEQ ID NO: 15.

In another embodiment of the invention, the isolated protein which binds CD28 or CTLA4 is encoded by a T cell costimulatory molecule gene having at least one first exon encoding a first signal peptide domain and at least one second exon encoding a second signal peptide domain. The at least one first signal peptide domain comprises an amino acid sequence selected from the group consisting of an amino acid sequence of SEQ ID NO:34 (mB7-1), SEQ ID NO:36 (hB7-1), SEQ ID NO:38 (mB7-2) and SEQ ID NO:40 (hB7-2) and SEQ ID NO:42 (hB7-2). In this embodiment, the protein includes an amino acid sequence comprising at least one second signal peptide domain. Preferably, the protein does not include an amino acid sequence comprising a first signal peptide domain.

Preferred proteins which bind CD28 and/or CTLA4 are derived from B7-1 and B7-2.

In a particularly preferred embodiment, the invention features a murine B7-2 protein comprising an amino acid sequence shown in SEQ ID NO: 13.

C. Isolated Proteins with Structural Domains Deleted or Added

This invention also features costimulatory molecules which have at least one structural domain deleted. In one embodiment, the structural form has at least one IgV-like domain deleted. Accordingly, in one embodiment, the isolated protein has an amino acid sequence derived from amino acid sequences encoded by at least one T cell costimulatory molecule gene and comprises a contiguous amino acid sequence represented by a formula A-B-C-D, wherein

A, which may or may not be present, comprises an amino acid sequence of a signal peptide domain encoded by at least one exon of a T cell costimulatory molecule gene,

B comprises an amino acid sequence of an immunoglobulin constant region-like domain encoded by at least one exon of a T cell costimulatory molecule gene, and

C comprises an amino acid sequence of a transmembrane domain encoded by at least one exon of a T cell costimulatory molecule gene, and

D comprises an amino acid sequence of a cytoplasmic domain encoded by at least one exon of a T cell costimulatory molecule gene.

In the formula, A, B, C and D are contiguous amino acid residues linked by amide bonds from an N-terminus to a C-terminus. In a preferred embodiment, an isolated murine B7-1 protein having an IgV-like domain deleted comprises an amino acid sequence shown in SEQ ID NO: 9 (utilizing Cyt I of mB7-1). Alternatively, an isolated murine B7-1 protein having an IgV-like domain deleted comprises an amino acid sequence shown in SEQ ID NO: 11 (utilizing Cyt II of mB7-1).

In another embodiment, the structural form of the T cell costimulatory molecule has at least one IgC-like domain deleted. Accordingly, in one embodiment, the isolated protein has an amino acid sequence derived from amino acid sequences encoded by at least one T cell costimulatory molecule gene and comprises a contiguous amino acid sequence represented by a formula A-B-C-D, wherein

A, which may or may not be present, comprises an amino acid sequence of a signal peptide domain encoded by at least one exon of a T cell costimulatory molecule gene,

B comprises an amino acid sequence of an immunoglobulin variable region-like domain encoded by at least one exon of a T cell costimulatory molecule gene, and

C comprises an amino acid sequence of a transmembrane domain encoded by at least one exon of a T cell costimulatory molecule gene, and

D comprises an amino acid sequence of a cytoplasmic domain encoded by at least one exon of a T cell costimulatory molecule gene.

In the formula, A, B, C and D are contiguous amino acid residues linked by amide bonds from an N-terminus to a C-terminus. In a preferred embodiment, an isolated murine B7-1 protein having an IgC-like domain deleted comprises an amino acid sequence shown in SEQ ID NO: 63 (utilizing Cyt I of mB7-1). Alternatively, an isolated murine B7-1 protein having an IgC-like domain deleted comprises an amino acid sequence shown in SEQ ID NO: 65 (utilizing Cyt II of mB7-1).

The proteins of the invention can be isolated by expression of the molecules (e.g., proteins or peptide fragments thereof) in a suitable host cell using techniques known in the art. Suitable host cells include prokaryotic or eukaryotic organisms or cell lines, for example, yeast, *E. coli* and insect cells. The recombinant expression vectors of the invention, described above, can be used to express a costimulatory molecule in a host cell in order to isolate the protein. The invention provides a method of preparing an isolated protein of the invention comprising introducing into a host cell a recombinant expression vector encoding the protein, allowing the protein to be expressed in the host cell and isolating the protein. Proteins can be isolated from a host cell expressing the protein according to standard procedures of the art, including ammonium sulfate precipitation, fractionation column

chromatography (e.g. ion exchange, gel filtration, electrophoresis, affinity chromatography, etc.) and ultimately, crystallization (see generally, "Enzyme Purification and Related Techniques", *Methods in Enzymology*, 22, 233-577 (1971)).

Alternatively, the costimulatory molecules of the invention can be prepared by chemical synthesis using techniques well known in the chemistry of proteins such as solid phase synthesis (Merrifield, 1964, J. Am. Chem. Assoc. 85:2149-2154) or synthesis in homogeneous solution (Houbenweyl, 1987, *Methods of Organic Chemistry*, ed. E. Wansch, Vol. 15 I and II, Thieme, Stuttgart).

VI. Uses For the Novel T Cell Costimulatory Molecules of the Invention

A. Costimulation

The novel T cell costimulatory molecules of the invention can be used to trigger a costimulatory signal in T cells. When membrane-bound or in a multivalent form, a T cell costimulatory molecule can trigger a costimulatory signal in a T cell by allowing the costimulatory molecule to interact with its receptor (e.g., CD28) on T cells in the presence of a primary activation signal. A novel T cell costimulatory molecule of the invention can be obtained in membrane-bound form by expressing the molecule in a host cell (e.g., by transfecting the host cell with a recombinant expression vector encoding the molecule). To be expressed on the surface of a host cell, the T cell costimulatory molecule should include extracellular domains (i.e., signal peptide, which may or may not be present in the mature protein, IgV-like and IgC-like domains), a transmembrane domain and a cytoplasmic domain. To trigger a costimulatory signal, T cells are contacted with the cell expressing the costimulatory molecule, preferably together with a primary activation signal (e.g., MHC-associated antigenic peptide, anti-CD3 antibody, phorbol ester etc.). Activation of the T cell can be assayed by standard procedures, for example by measuring T cell proliferation or cytokine production.

The novel T cell costimulatory molecules of the invention can also be used to inhibit or block a costimulatory signal in T cells. A soluble form of a T cell costimulatory molecule can be used to competitively inhibit the interaction of membrane-bound costimulatory molecules with their receptor (e.g., CD28 and/or CTLA4) on T cells. A soluble form of a T cell costimulatory molecule can be expressed in host cell line such that it is secreted by the host cell line and can then be purified. The soluble costimulatory molecule contains extracellular domains (i.e., signal peptide, which may or may not be present in the mature protein, IgV-like and IgC-like domains) but does not contain a transmembrane or cytoplasmic domain. The soluble form of the T cell costimulatory molecule can also be in the form of a fusion protein, e.g. an immunoglobulin fusion protein wherein the extracellular portion of the costimulatory molecule is fused to an immunoglobulin constant region. A soluble form of a

T cell costimulatory molecule can be used to inhibit a costimulatory signal in T cells by contacting the T cells with the soluble molecule.

B. Antibodies

5 A novel structural form of a T cell costimulatory molecule of the invention can be used to produce antibodies directed against the costimulatory molecule. Conventional methods can be used to prepare the antibodies. For example, to produce polyclonal antibodies, a mammal, (e.g., a mouse, hamster, or rabbit) can be immunized with a costimulatory molecule, or an immunogenic portion thereof, which elicits an antibody
10 response in the mammal. Techniques for conferring immunogenicity on a protein include conjugation to carriers or other techniques well known in the art. For example, the protein can be administered in the presence of adjuvant. The progress of immunization can be monitored by detection of antibody titers in plasma or serum. Standard ELISA or other immunoassay can be used with the immunogen as antigen to assess the levels of antibodies. Following immunization, antisera can be obtained and, if desired, polyclonal antibodies
15 isolated from the sera.

In addition to polyclonal antisera, the novel costimulatory molecules of the invention can be used to raise monoclonal antibodies. To produce monoclonal antibodies, antibody producing cells (lymphocytes) can be harvested from an immunized animal and fused with
20 myeloma cells by standard somatic cell fusion procedures thus immortalizing these cells and yielding hybridoma cells. Such techniques are well known in the art. For example, the hybridoma technique originally developed by Kohler and Milstein (*Nature* 256, 495-497 (1975)) as well as other techniques such as the human B-cell hybridoma technique (Kozbor et al., *Immunol. Today* 4, 72 (1983)), the EBV-hybridoma technique to produce human
25 monoclonal antibodies (Cole et al. *Monoclonal Antibodies in Cancer Therapy* (1985) Allen R. Bliss, Inc., pages 77-96), and screening of combinatorial antibody libraries (Huse et al., *Science* 246, 1275 (1989)). Hybridoma cells can be screened immunochemically for production of antibodies specifically reactive with the protein or portion thereof and monoclonal antibodies isolated.

30 The term antibody as used herein is intended to include fragments thereof which are also specifically reactive with an alternative cytoplasmic domain of a costimulatory molecule. Antibodies can be fragmented using conventional techniques and the fragments screened for utility in the same manner as described above for whole antibodies. For example, F(ab')₂ fragments can be generated by treating antibody with pepsin. The resulting F(ab')₂ fragment
35 can be treated to reduce disulfide bridges to produce Fab' fragments.

Chimeric and humanized antibodies are also within the scope of the invention. It is expected that chimeric and humanized antibodies would be less immunogenic in a human subject than the corresponding non-chimeric antibody. A variety of approaches for making chimeric antibodies, comprising for example a non-human variable region and a human

constant region, have been described. See, for example, Morrison et al., *Proc. Natl. Acad. Sci. U.S.A.* 81, 6851 (1985); Takeda et al., *Nature* 314, 452 (1985), Cabilly et al., U.S. Patent No. 4,816,567; Boss et al., U.S. Patent No. 4,816,397; Tanaguchi et al., European Patent Publication EP171496; European Patent Publication 0173494, United Kingdom Patent GB 2177096B. Additionally, a chimeric antibody can be further "humanized" antibodies such that parts of the variable regions, especially the conserved framework regions of the antigen-binding domain, are of human origin and only the hypervariable regions are of non-human origin. Such altered immunoglobulin molecules may be made by any of several techniques known in the art, (e.g., Teng et al., *Proc. Natl. Acad. Sci. U.S.A.*, 80, 7308-7312 (1983); Kozbor et al., *Immunology Today*, 4, 7279 (1983); Olsson et al., *Meth. Enzymol.*, 92, 3-16 (1982)), and are preferably made according to the teachings of PCT Publication WO92/06193 or EP 0239400. Humanized antibodies can be commercially produced by, for example, Scotgen Limited, 2 Holly Road, Twickenham, Middlesex, Great Britain.

Another method of generating specific antibodies, or antibody fragments, reactive against an alternative cytoplasmic domain of the invention is to screen phage expression libraries encoding immunoglobulin genes, or portions thereof, with proteins produced from the nucleic acid molecules of the present invention (e.g., with all or a portion of the amino acid sequence of SEQ ID NO: 7). For example, complete Fab fragments, V_H regions and F_V regions can be expressed in bacteria using phage expression libraries. See for example Ward et al., *Nature* 341, 544-546: (1989); Huse et al., *Science* 246, 1275-1281 (1989); and McCafferty et al. *Nature* 348, 552-554 (1990).

In a preferred embodiment, the invention provides an antibody which binds to a novel structural domain of a T cell costimulatory molecule provided by the invention. Such antibodies, and uses therefor, are described in greater detail below in subsection VI, part B.

C. Screening Assays

A T cell costimulatory molecule of the invention containing a novel cytoplasmic domain can be used in a screening assay to identify components of the intracellular signal transduction pathway induced in antigen presenting cells upon binding of the T cell costimulatory molecule to its receptor on a T cell. In addition to triggering a costimulatory signal in T cells, engagement of the costimulatory molecule with a receptor on T cells is likely to deliver distinct signals to the antigen presenting cell (i.e., the cell expressing the T cell costimulatory molecule), e.g. through the cytoplasmic domain. Signals delivered through a novel cytoplasmic domain of the invention may be of particular importance in the thymus, e.g., during positive selection of T cells during development, since structural forms of costimulatory molecules comprising a novel cytoplasmic domain are preferentially expressed in the thymus. A host cell which exclusively expresses a Cyt-II form of a costimulatory molecule (e.g., mB7-1) is especially useful for elucidating such intracellular signal transduction pathways. For example, a host cell which expresses only a Cyt-II form of the

costimulatory molecule can be stimulated through the costimulatory molecule, e.g., by crosslinking the costimulatory molecules on the cell surface with an antibody, and intracellular signals and/or other cellular changes (e.g., changes in surface expression of proteins etc.) induced thereupon can be identified.

5 Additionally, an isolated T cell costimulatory molecule of the invention comprising a novel cytoplasmic domain can be used in methods of identifying other molecules (e.g., proteins) which interact with (i.e., bind to) the costimulatory molecule using standard *in vitro* assays (e.g., incubating the isolated costimulatory molecule with a cellular extract and determining by immunoprecipitation if any molecules within the cellular extract bind to the
10 costimulatory molecule). It is of particular interest to identify molecules which can interact with the novel cytoplasmic domain since such molecules may also be involved in intracellular signaling. For example, it is known that the cytoplasmic domains of many cell-surface receptors can interact intracellularly with other members of the signal transduction machinery, e.g., tyrosine kinases.

15 The invention further provides a method for screening agents to identify an agent which upregulates or downregulates expression of a novel structural domain form of a T cell costimulatory molecule. The method involves contacting a cell which expresses or can be induced to express a T cell costimulatory molecule with an agent to be tested and determining expression of a novel structural domain form of the T cell costimulatory molecule by the cell.

20 The term "upregulates" encompasses inducing the expression of a novel form of a T cell costimulatory molecule by a cell which does not constitutively express such a molecule or increasing the level of expression of a novel form of a T cell costimulatory molecule by a cell which already expresses such a molecule. The term "downregulates" encompasses decreasing or eliminating expression of an a novel form of a T cell costimulatory molecule by

25 a cell which already expresses such a molecule. The term "agent" is intended to include molecules which trigger an upregulatory or downregulatory response in a cell. For example, an agent can be a small organic molecule, a biological response modifier (e.g., a cytokine) or a molecule which can crosslink surface structures on the cell (e.g., an antibody). For example, expression of the a novel cytoplasmic domain form of the T cell costimulatory
30 molecule by the cell can be determined by detecting an mRNA transcript encoding the novel cytoplasmic domain form of the T cell costimulatory molecule in the cell. For example, mRNA from the cell can be reverse transcribed and used as a template in PCR reactions utilizing PCR primers which can distinguish between a Cyt I cytoplasmic domain form and a novel Cyt II cytoplasmic domain form of the T cell costimulatory molecule (see e.g.,

35 Example 2). Alternatively, a novel cytoplasmic domain-containing T cell costimulatory molecule can be detected in the cell using an antibody directed against the novel cytoplasmic domain (e.g., by immunoprecipitation or immunohistochemistry). A preferred T cell costimulatory molecule for use in the method is B7-1. Cell types which are known to express the Cyt-I form of B7-1, or which can be induced to express the Cyt-I form of B7-1, include B

960E80 52520280

lymphocytes, T lymphocytes and monocytes. Such cell types can be screened with agents according to the method of the invention to identify an agent which upregulates or downregulates expression of the Cyt-II form of B7-1.

5 VI. Isolated Novel Structural Domains of T Cell Costimulatory Molecules and Uses Therefor

Another aspect of the invention pertains to isolated nucleic acids encoding novel structural domains of T cell costimulatory molecules provided by the invention. In one embodiment, the structural domain encoded by the nucleic acid is a cytoplasmic domain. A preferred nucleic acid encoding a novel cytoplasmic domain comprises a nucleotide sequence shown in SEQ ID NO: 4. In another embodiment, the structural domain encoded by the nucleic acid is a signal peptide domain. A preferred nucleic acid encoding a novel signal peptide domain comprises a nucleotide sequence shown in SEQ ID NO: 14.

The invention also provides isolated polypeptides corresponding to novel structural domains of T cell costimulatory molecules, encoded by nucleic acids of the invention. In one embodiment, the structural domain is a cytoplasmic domain. A preferred novel cytoplasmic domain comprises an amino acid sequence shown in SEQ ID NO: 5. In another embodiment, the structural domain is a signal peptide domain. A preferred novel signal peptide domain comprises an amino acid sequence shown in SEQ ID NO: 15.

The uses of the novel structural domains of the invention include the creation of chimeric proteins. The domains can further be used to raise antibodies specifically directed against the domains.

A. Chimeric Proteins

The invention provides a fusion protein comprised of two peptides, a first peptide and a second peptide, wherein the second peptide is a novel structural domain of a T cell costimulatory molecule provided by the invention. In one embodiment, the novel structural domain is a cytoplasmic domain, preferably comprising an amino acid sequence shown in SEQ ID NO: 5. In another embodiment, the novel structural domain is a signal peptide domain, preferably comprising an amino acid sequence shown in SEQ ID NO: 15. For example, a fusion protein can be made which contains extracellular and transmembrane portions from a protein other than murine B7-1 and which contains a novel cytoplasmic domain (e.g., Cyt-II) of murine B7-1. This type of fusion protein can be made using standard recombinant DNA techniques in which a nucleic acid molecule encoding the cytoplasmic domain (e.g., SEQ ID NO:4) is linked in-frame to the 3' end of a nucleic acid molecule encoding the extracellular and transmembrane domains of the protein. The recombinant nucleic acid molecule can be incorporated into an expression vector and the encoded fusion protein can be expressed by standard techniques, e.g., by transfecting the recombinant expression vector into an appropriate host cell and allowing expression of the fusion protein.

A fusion protein of the invention, comprising a first peptide fused to a second peptide comprising a novel cytoplasmic domain of the invention, can be used to transfer the signal transduction function of the novel cytoplasmic domain to another protein. For example, a novel cytoplasmic domain of B7-1 (e.g., Cyt-II) can be fused to the extracellular and transmembrane domains of another protein (e.g., an immunoglobulin protein, a T cell receptor protein, a growth factor receptor protein etc.) and the fusion protein can be expressed in a host cell by standard techniques. The extracellular domain of the fusion protein can be crosslinked (e.g., by binding of a ligand or antibody to the extracellular domain) to generate an intracellular signal(s) mediated by the novel cytoplasmic domain.

Additionally, a fusion protein of the invention can be used in methods of identifying and isolating other molecules (e.g., proteins) which can interact intracellularly (i.e., within the cell cytoplasm) with a novel cytoplasmic domain of the invention. One approach to identifying molecules which interact intracellularly with the cytoplasmic domain of a cell-surface receptor is to metabolically label cells which express the receptor, immunoprecipitate the receptor, usually with an antibody against the extracellular domain of the receptor, and identify molecules which are co-immunoprecipitated along with the receptor. In the case of mB7-1, however, the cells which have been found to express the naturally-occurring Cyt-II form of B7-1 have also been found to express the naturally-occurring Cyt-I form of B7-1 (e.g., thymocytes, see Example 2). Thus, immunoprecipitation with an antibody against the extracellular domain of mB7-1 would immunoprecipitate both forms of the protein since the extracellular domain is common to both the Cyt-I and Cyt-II containing forms. Thus, molecules which interact with either Cyt-I or Cyt-II would be co-immunoprecipitate. A fusion protein comprising a non-B7-1 extracellular domain (to which an antibody can bind), a transmembrane domain (derived either from the non-B7-1 molecule or from B7-1) and a B7-1 alternative cytoplasmic domain (e.g., Cyt-II) can be constructed and expressed in a host cell which naturally expresses the Cyt-II form of B7-1. The antibody directed against the "heterologous" extracellular domain of the fusion protein can then be used to immunoprecipitate the fusion protein and to co-immunoprecipitate any other proteins which interact intracellularly with the novel cytoplasmic domain.

B. Antibodies

An antibody which binds to a novel structural domain of the invention can be prepared by using the domain, or a portion thereof, as an immunogen. Polyclonal antibodies or monoclonal antibodies can be prepared by standard techniques described above. In a preferred approach, peptides comprising amino acid sequences of the domain are used as immunogens, e.g. overlapping peptides encompassing the amino acid sequence of the domain. For example, polyclonal antisera against a novel cytoplasmic domain (e.g., Cyt II of mB7-1) can be made by preparing overlapping peptides encompassing the amino acid

sequence of the domain and immunizing an animal (e.g., rabbit) with the peptides by standard techniques.

An antibody of the invention can be used to detect novel structural forms of T cell costimulatory molecules. Such an antibody is thus useful for distinguishing between expression by a cell of different forms of T cell costimulatory molecules. For example, a cell which is known to express a costimulatory molecule, such as B7-1, (for example, by the ability of an antibody directed against the extracellular portion of the costimulatory molecule to bind to the cell) can be examined to determine whether the costimulatory molecule includes a novel cytoplasmic domain of the invention. The cell can be reacted with an antibody of the invention by standard immunohistochemical techniques. For example, the antibody can be labeled with a detectable substance and the cells can be permeabilized to allow entry of the antibody into the cell cytoplasm. The antibody is then incubated with the cell and unbound antibody washed away. The presence of the detectable substance associated with the cell is detected as an indication of the binding of the antibody to a novel cytoplasmic domain expressed in the cell. Suitable detectable substances with which to label an antibody include various enzymes, prosthetic groups, fluorescent materials, luminescent materials and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; and examples of suitable radioactive material include ^{125}I , ^{131}I , ^{35}S or ^3H .

C. Kinase Substrates

A novel cytoplasmic domain of the invention which contains a consensus phosphorylation site (i.e., Cyt-II of mB7-1) can be used as a substrate for a protein kinases which phosphorylates the phosphorylation site. Kinase reactions can be performed by standard techniques *in vitro*, e.g., by incubating a polypeptide comprising the cytoplasmic domain (or a T cell costimulatory molecule which includes the novel cytoplasmic domain) with the kinase. The kinase reactions can be performed in the presence of radiolabeled ATP (e.g., ^{32}P - γ -ATP) to radiolabel the novel cytoplasmic domain.

This invention is further illustrated by the following examples which should not be construed as limiting. The contents of all references and published patents and patent applications cited throughout the application are hereby incorporated by reference.

The following methodology was used in the Examples.

Genomic cloning

A mouse 129 lambda genomic library was kindly provided by Drs. Hong Wu and Rudolf Jaenisch of the Whitehead Institute for Biomedical Research, Cambridge, MA. Genomic DNA was prepared from the J1 embryonic stem cell line (derived from the 129/sv mouse strain), partially digested with MboI, sized (17-21 kb), and ligated into the BamHI site of lambda-DASH II arms (Stratagene, La Jolla CA). The library was probed with the coding region of mB7-1 cDNA to yield four clones (λ 4, λ 9, λ 15, and λ 16). These lambda clones were subcloned into Bluescript-pKS II (Stratagene, La Jolla CA) for subsequent restriction mapping.

Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)

Total cellular RNA was prepared from SWR/J mouse spleen and thymus using RNA-Stat-60 (Tel-Test "B", Inc, Friendswood, Texas). Random hexamer primed reverse transcription (RT) was performed with Superscript-RT (Gibco BRL, Gaithersburg MD) using 1-10 μ g total RNA in a 20 μ l reaction. All PCR reactions were performed in 25 μ l volumes using a manual "hot start", wherein 10X deoxynucleotide triphosphates (dNTPs) were added to the samples at 80 °C. Final reaction conditions were: 60 mM Tris-HCl, pH 8.5, 15 mM $(\text{NH}_4)_2\text{SO}_4$, 2.5 mM MgCl_2 , 200 μ M dNTPs, and 2 μ g/ml each of the specific primers. Cycling conditions for all amplifications were 94° C, 4 minutes prior to 35 cycles of 94° C for 45 seconds, 58° C for 45 seconds, and 72° C for 3 minutes, followed by a final extension at 72° C for 7 minutes. The template for primary PCR was 2 μ l of the RT reaction product and the template for secondary nested PCR was 1 μ l of the primary PCR reaction product.

Oligonucleotides

All oligonucleotides were synthesized on an Applied Biosystems 381A DNA Synthesizer. The oligonucleotides used in this study are listed in Table I and their uses for primary or secondary PCR, as well as sense, also are indicated.

Rapid Amplification of cDNA Ends (RACE) Procedure

Polyadenylated RNA purified by two cycles of oligo-dT selection was obtained from CH1 B lymphoma cells, which express high levels of mB7-1. Primers designed to the most 5' end of the cDNA were employed with the 5' RACE Kit (Gibco BRL, Gaithersburg, MD) according to the manufacturer's instructions. In brief, RNA was reverse transcribed with a gene-specific oligonucleotide, the cDNA purified, and a poly-dCTP tail was added with terminal deoxynucleotide transferase. PCR was performed using a nested primer and an oligonucleotide complimentary to the poly-dCTP tail. PCR bands were cloned, sequenced, and correlated with the genomic sequences.

Oligonucleotide hybridization

Oligonucleotide(s) were 5' end-labeled with polynucleotide kinase and $\gamma^{32}\text{P}$ -ATP. Hybridizations were carried out in 5X SSC and 5% SDS at 55 °C overnight and subsequently washed 3 times for 15 minutes with 2X SSC at 55 °C. Blots were exposed to Kodak XAR-5 film with an intensifying screen at -80 °C.

The oligonucleotides used for the PCR studies in Examples 1-4 are shown in Table I:

Table I. Oligonucleotides used for PCR studies

Designation	Sequence (5' to 3')	sense	PCR
10 B7.27	CCAACATAACTGAGTCTGGAAA	+	secondary (SEQ ID NO: 43)
B7.36	CTGGATTCTGACTCACCTTCA	-	secondary (SEQ ID NO: 44)
B7.37	AGGTAAAGAGTGGTAGAGCCA	-	primary (SEQ ID NO: 45)
B7.38	AATACCATGTATCCCACATGG	-	secondary (SEQ ID NO: 46)
B7.42	CTGAAGCTATGGCTTGCAATT	+	primary (SEQ ID NO: 47)
15 B7.44	TGGCTTCTCTTTCCTTACCTT	+	secondary (SEQ ID NO: 48)
B7.48	GCAAATGGTAGATGAGACTGT	-	secondary (SEQ ID NO: 49)
B7.62	CAACCGAGAAATCTACCAGTAA	-	probe (SEQ ID NO: 50)
B7.68	GCCGGTAACAAGTCTCTTCA	+	primary (SEQ ID NO: 51)
B7.71	AAAAGCTCTATAGCATTCTGTC	+	primary (SEQ ID NO: 52)
20 B7.80	ACTGACTTGGACAGTTGTTCA	+	secondary (SEQ ID NO: 53)
B7.547	TTTGATGGACAACCTTACTA	-	primary (SEQ ID NO: 54)

EXAMPLE 1: Characterization of the mB7-1 genomic locus

Lambda clones containing mB7-1 genomic DNA were isolated using a probe consisting of the coding region of mB7-1. Four representative lambda clones (designated clones $\lambda 4$, $\lambda 9$, $\lambda 15$, and $\lambda 16$) were selected for further analysis. These lambda clones were subcloned and subjected to restriction mapping with HindIII and BamHI. Regions containing exons were further characterized with XbaI and PstI. Fine mapping studies indicate that the mB7-1 locus is comprised of 6 exons arranged in the following 5' to 3' order: 5' UT plus signal peptide domain, Ig-V-like domain, Ig-C-like domain, transmembrane domain, cytoplasmic domain I, and the alternative cytoplasmic domain II, to be discussed below. The 4 lambda clones spanned over 40 kb of the mB7-1 locus, excluding a gap of undetermined size between exon 1 (signal exon) and exon 2 (Ig-V-like exon). The gap between clones $\lambda 15$ (transmembrane domain exon) and $\lambda 16$ (cytoplasmic domain exon) was determined to be less than 100 base pairs by PCR using a sense primer (B7.71) designed to the 3' end of clone $\lambda 15$ and an antisense primer (B7.38) located at the 5' end of clone $\lambda 16$. Clones $\lambda 9$ and $\lambda 15$ overlapped in a region spanning exon 2.

EXAMPLE 2: Identification of mB7-1 exon 6: An alternately spliced exon encoding a novel second cytoplasmic domain

Analysis of mB7-1 cDNAs isolated from an A20 B cell cDNA library showed that one cDNA contained additional sequence not previously described for the mB7-1 cDNA.

5 This sequence was mapped to the mB7-1 locus approximately 7-kb downstream of exon 5. A canonical splice site was present immediately upstream of this sequence and a poly-adenylation site was present downstream. Taken together, these data suggested that this novel sequence represents an additional exon, encoding 46 amino acids, which may be alternatively spliced in place of exon 5. This alternative cytoplasmic domain is notable for
10 two casein kinase II phosphorylation sites (amino acid positions 11-15 (SAKDF) and amino acid positions 28-32 (SLGEA) of SEQ ID NO: 5) (for a description of casein kinase II phosphorylation sites see Pinna (1990) *Biochimica et Biophysica Acta* 1054:267-284) and one protein kinase C phosphorylation site (amino acid positions 11-14 (SAKD) of SEQ ID NO: 5) (for a description of protein kinase C phosphorylation sites see Woodgett et al. (1986)
15 *Biochemistry* 161:177-184; and Kishimoto et al. (1985) *J. Biol. Chem.* 260:12492-12499).

In order to assess whether exon 6 also could be used in an alternative fashion, an antisense primer (B7.48) was designed to the predicted exon 4/6 splice junction such that only the alternatively spliced product would give rise to an amplified product. This primer overhangs the putative exon 4/6 junction by 3 bp at its 3' end. The 3 bp overhang is
20 insufficient to permit direct priming in exon 4 outside the context of an exon 4/6 splice (Figure 1, lane 9, negative control is a cDNA clone containing only mB7-1 CytI). The expected amplified product for the alternately spliced transcript (Figure 1, transcript C) would be 399 bp. Interestingly, this transcript was observed only in thymic, but not splenic RNA.

25 [In Figure 1, lanes 1, 2 and 3 represent nested PCR products from murine splenic RNA using PCR primers B7.27-B7.36, B7.27-B7.38, and B7.27-B7.48, respectively. Lanes 4, 5 and 6 represent nested PCR products from murine thymic RNA using PCR primers B7.27-B7.36, B7.27-B7.38 and B7.27-B7.48, respectively. Lane 7 represents a negative control (no input RNA). Lane 8 represents a positive control (mB7-1 cDNA clone). Lane 9 represents a
30 negative control for B7.27-B7.48 amplification comprised of the mB7-1 cDNA containing cytoplasmic domain I, which does not have the correct exon 4-6 splice junction. Lane M is a 100 bp ladder with the lower bright band equal to 600 bp. Letters A, B and C refer to the transcripts detected and are further illustrated in Figure 1. Note that exon 6 splicing as an alternative cytoplasmic domain is present only in the thymus, but not in the spleen].

35 To further investigate the use of exon 6 in mB7-1 mRNA transcripts, nested RT-PCR spanning exons 3 through 6 was performed using spleen RNA (Figure 1, PCR product A). A PCR product longer than predicted from the use of exon 6 as an alternatively spliced exon also was observed. Subsequent sequence analysis indicated that in this transcript, exons 5 and 6 were spliced in tandem, rather than in an alternative fashion (Figure 1, transcript A),

making use of a previously unrecognized splice donor site downstream of the termination codon in exon 5. Thus, this alternative transcript would not change the encoded protein. Subsequent sequence analysis of a larger than expected product observed from spleen RNA (Figure 1, lane 3) revealed an additional example of the tandem splicing of exon 6 to exon 5 using an alternative noncanonical splice site. Transcripts with tandem splicing of exon 6 to exon 5 were observed in the spleen and the thymus.

Figure 2 is a schematic diagram of the three mB7-1 transcripts (A, B, and C) detected by nested RT-PCR. Exons are depicted in different shades of gray and untranslated sequences are white. Oligonucleotide primers used for the initial RT-PCR and subsequent nested PCR are indicated above their respective locations in the transcripts. Only B7.48 spans an exon-exon junction as indicated. The scale bar above indicates the length in base pairs.

EXAMPLE 3: Identification of additional mB7-1 5' untranslated sequences

Rapid amplification of cDNA ends (RACE) is a PCR-based strategy to determine the 5' end of a transcript. Three distinct rounds of 5' RACE were performed on polyadenylated RNA from CH1 B lymphoma cells, which express high levels of mB7-1 RNA. The resulting sequences extended the 5' UT of the known mB7-1 cDNA by 1505 bp, beyond the transcriptional start site reported by Selvakumar et al. ((1993) *Immunogenetics* 38:292-295). In order to confirm that this long 5' UT sequence was indeed in the mB7-1 mRNA and not generated by PCR amplification of genomic DNA, a nested RT-PCR amplification (B7.68-B7.547 followed by B7.44-B7.80) was performed. This amplification spans exon 2 (primer B7.80) and the novel 5' UT sequences in exon 1 (B7.44), and should yield an 840 bp PCR product. It should be noted that exon 2 is separated from exon 1 by greater than 12 kb in genomic DNA, thus making a genomic DNA-derived PCR product of almost 13kb. The predicted band of 840 bp, indeed, was observed when this nested PCR amplification was performed. To further confirm the nature of the PCR product, hybridization was performed with an oligonucleotide (B7.62) derived from sequences in exon 1 located 5' of the transcriptional start site reported by Selvakumar et al. ((1993) *Immunogenetics* 38:292-295). This probe hybridized to the PCR product. In addition, sequencing of the RACE product revealed that it contained sequences identical to the previously known genomic sequences immediately upstream of the known exon 1 and was contiguous with exon 1. Thus, it did not identify an additional exon.

EXAMPLE 4: Fine mapping of mB7-1 intron-exon boundaries

In order to characterize intron-exon boundaries, oligonucleotide primers were synthesized to mB7-1 cDNA sequences (described in Freeman et al. (1991) *J. Exp. Med.* 174:625-631), as well as to sequences determined from PCR products characterized during amplifications from tissue RNA. Sequences for exons 1 through 5, as well as exon-intron

junctions have been reported previously (Selvakumar et al. (1993) *Immunogenetics* 38:292-295). The coding region of the exon 1 signal peptide domain is 115 bp and is flanked at the 3' end with a canonical splice site. Exons 2 (318 bp), 3 (282 bp), and 4 (114 bp), are separated by 6.0 and 3.8 kb, respectively, and all 3 exons are flanked on both their 5' and 3' ends with canonical splice sites. Exon 5 is located 4 kb downstream of exon 4, and contains a termination codon after the first 97 bp. An additional functional canonical splice site was observed 43 bp downstream of the termination codon in exon 5, since this site was used to generate the transcript outlined in Figure 1 (transcript A). Exon 6 is located 7.2 kb downstream of exon 5 and encodes an open reading frame with a termination codon after 140 bp. Both exons 5 and 6 are followed by polyadenylation sequences, ATTAAA and AATAAA respectively.

EXAMPLE 5: Identification of Additional Novel Cytoplasmic Domains by Exon Trapping

In this example, an exon trapping approach is used to identify a novel exon encoding an alternative cytoplasmic domain for human B7-1. The basic strategy of exon trapping is to create an expression vector encoding a recombinant protein, wherein the encoded protein cannot be functionally expressed unless an appropriate exon, with flanking intron sequences that allow proper mRNA splicing, is cloned into the expression vector. A recombinant expression vector is created comprising transcriptional regulatory sequences (e.g., a strong promoter) linked to nucleic acid encoding the human B7-1 signal peptide exon, IgV-like and IgC-like exons followed by a transmembrane exon with flanking 3' intron donor splice sequences. These splice sequences are immediately followed by translational stop codons in all three frames. A polyadenylation recognition site is not included in the recombinant expression vector. Following the stop codons are restriction enzyme sites which allow genomic DNA fragments to be cloned into the expression vector to create a library of recombinant expression vectors.

As a negative control, the parental recombinant expression vector is transfected into a host cell line which is hB7-1⁻ (e.g., COS cells) and the absence of surface expression of hB7-1 is demonstrated, confirming that the parental expression vector alone is unable to direct stable surface expression of hB7-1 in the absence of a cytoplasmic domain encoding exon. As a positive control, the known hB7-1 cytoplasmic domain with a flanking 5' intron acceptor splice sequence is cloned into a restriction enzyme site downstream of the transmembrane exon such that the transmembrane domain exon can be spliced to the cytoplasmic domain exon. This positive control vector is transfected into a host cell (e.g., COS cells) and the surface expression of hB7-1 on the cells is demonstrated, confirming that the cloning into the vector of a cytoplasmic domain encoding exon with the proper splice sequences produces an hB7-1 molecule that can be stably expressed on the cell surface.

To identify an alternative hB7-1 cytoplasmic domain exon, genomic DNA fragments for the hB7-1 gene are cloned into the parental recombinant expression at the restriction enzyme sites downstream of the transmembrane domain exon. Cloning of genomic fragments into the vector will "trap" DNA fragments which encompass a functional exon preceded by an intron-splice acceptor site and followed by a polyadenylation signal, since cloning of such fragments into the vector allows for expression of a functional recombinant protein on the surface of transfected host cells. The diversity of the genomic DNA fragments cloned into the vector directly impacts the variety of sequences "trapped". Were total genomic DNA to be used in such an approach, a variety of exons would be trapped, including cytoplasmic domains from proteins other than T cell costimulatory molecules. However, instead of using total genomic DNA for subcloning into the expression vector, only genomic DNA fragments located in the vicinity of the exon encoding a known cytoplasmic domain of the T cell costimulatory molecule of interest are subcloned into the vector. For example, for human B7-1, genomic DNA clones can be isolated by standard techniques which contain DNA located within several kilobases 5' or 3' of the hB7-1 exon which encodes the known cytoplasmic domain. These fragments are cloned into the parental recombinant expression vector to create a library of expression vectors. The library of expression vectors is then transfected into a host cell (e.g., COS cells) and the transfectants are screened for surface expression of hB7-1. Cell clones which express a functional B7-1 molecule on their surface are identified and affinity purified (e.g., by reacting the cells with a molecule which binds to B7-1, such as an anti-B7-1 monoclonal antibody (e.g., mAb 133 describe in Freedman, A.S. et al. (1987) *J. Immunol.* 137:3260; and Freeman, G.J. et al. (1989) *J. Immunol.* 143:2714) or a CTLA4Ig protein (described in Linsley, P.S. et al., (1991) *J. Exp. Med.* 174:561-569). Cell clones which express a B7-1 molecule on their surface will have incorporated into the expression vector DNA encoding a functional cytoplasmic domain (e.g., an alternative cytoplasmic domain encoded by a different exon than the known cytoplasmic domain). DNA from positive clones encoding the alternative cytoplasmic domain can then be amplified by PCR using a sense primer corresponding to the transmembrane domain and an antisense primer corresponding to vector sequences.

This same approach can be adapted by the skilled artisan to identify alternative cytoplasmic domains for other T cell costimulatory molecules (e.g., B7-2) or to "trap" exons encoding other alternative structural domains of T cell costimulatory molecules.

EXAMPLE 6: Identification of a Novel B7-2 Signal Peptide Domain

cDNA fragments corresponding to the 5' ends of naturally-occurring murine B7-2 mRNA transcripts were prepared by 5' RACE: polyadenylated RNA isolated from murine spleen cells was reverse transcribed with a gene-specific oligonucleotide, the cDNA was isolated, and a poly-dCT tail was added to the 5' end with terminal deoxynucleotide transferase. PCR was performed using a nested primer and an oligonucleotide primer

complementary to the poly-dCTP tail to amplify 5' cDNA fragments of mB7-2 transcripts. The gene-specific oligonucleotide primers used for PCR were as follows:

CAGCTCACTCAGGCTTATGT reverse transcription, - sense (SEQ ID NO: 55)

AAACAGCATCTGAGATCAGCA primary PCR, - sense (SEQ ID NO: 56)

CTGAGATCAGCAAGACTGTC secondary PCR, - sense (SEQ ID NO: 57)

The amplified fragments were subcloned into a plasmid vector and sequenced. Of approximately 100 individual clones examined, ~75 % of the clones had a 5' nucleotide sequence corresponding to that reported for the 5' end of an mB7-2 cDNA (see Freeman, G.J. et al. (1993) *J. Exp. Med.* 178:2185-2192). Approximately 25 % of the clones had a 5' nucleotide sequence shown in SEQ ID NO:14, which encodes a novel signal peptide domain having an amino acid sequence shown in SEQ ID NO:15.

**EXAMPLE 7: Identification of Alternatively Spliced Forms of B7-1
Having a Structural Domain Deleted**

Reverse-transcriptase polymerase chain reaction was used to amplify mB7-1 cDNA fragments derived from murine spleen cell RNA. Oligonucleotide primers used for PCR were as follows:

CTGAAGCTATGGCTTGCAATT primary PCR, + sense (SEQ ID NO: 58)

ACAAGTGTCTTCAGATGTTGAT secondary PCR, + sense (SEQ ID NO: 59)

CTGGATTCTGACTCACCTTCA primary PCR, - sense (SEQ ID NO: 60)

CCAGGTGAAGTCCTCTGACA secondary PCR, - sense (SEQ ID NO: 61)

A cDNA fragment was detected which comprises a nucleotide sequence (SEQ ID NO:8) encoding a murine B7-1 molecule in which the signal peptide domain was spliced directly to the IgC-like domain (i.e., the IgV-like domain was deleted). The amino acid sequence of mB7-1 encoded by this cDNA is shown in SEQ ID NO:9.

Another cDNA fragment was detected with comprises a nucleotide sequence (SEQ ID NO: 62) encoding a murine B7-1 molecule in which the IgV-like domain was spliced directly to the transmembrane domain (i.e., the IgC-like domain was deleted). The amino acid sequence encoded by this cDNA is shown in SEQ ID NO: 63). This protein is referred to herein as an IgV-like isoform of mB7-1. To examine the functional activity of the IgV-like

isoform of mB7-1, its cDNA was cloned into an expression vector, pBK-CMV, in which transcription of the cDNA is placed under the control of the CMV promoter. The expression vector was cotransfected into Chinese Hamster Ovary (CHO) cells, along with a puromycin resistance gene, and drug resistant clones were selected. The resultant clones expressing the IgV-like isoform of mB7-1 on their surface are referred to herein as CHO-sV clones.

Expression of the IgV-like isoform of mB7-1 on the surface of the CHO-sV cells was confirmed by FACS analysis using either murine CTLA4Ig, murine CD28Ig or anti-B7-1 antibody as the primary staining reagent. Each of these reagents stained the CHO-sV cells. Positive staining of CHO-sV with both mCTLA4Ig and mCD28Ig indicate that the IgV-like isoform of mB7-1 is capable of interacting with both CTLA4 and CD28. In contrast to the results with mouse CTLA4Ig, human CTLA4Ig failed to stain the CHO-sV cells, although this reagent was able to stain CHO cells expressing the full-length mouse B7-1 molecule (CHO-B7-1 cells). These data implicate the IgC domain of mB7-1 in the binding to human CTLA4Ig, whereas the IgC domain of mB7-1 is not required for binding to mouse CTLA4Ig. These results suggest species differences in the binding parameters for human and murine CTLA4.

The ability of the IgV-like isoform of mB7-1 on CHO-sV cells to deliver a costimulatory signal to T cells was tested in standard T cell proliferation and interleukin-2 (IL-2) production assays. T cells that received a primary activation signal were stimulated to produce IL-2 when incubated with either CHO-B7-1 cells or CHO-sV cells but not when incubated with untransfected CHO cells. The results of this experiment is illustrated graphically in Figure 3, in which IL-2 production by T cells is expressed as a function of the number of CHO cells used to costimulate the T cells. The data demonstrate that CHO-sV cells can trigger a costimulatory signal in T cells, although the level of IL-2 production by cells stimulated with CHO-sV was approximately 25-50% of the level of IL-2 production by cells stimulated with CHO-B7-1. Similar results were observed when T cell proliferation was assayed as an indicator of T cell costimulation.

EQUIVALENTS

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

- (A) NAME: BRIGHAM AND WOMEN'S HOSPITAL
(B) STREET: 75 FRANCIS STREET
(C) CITY: BOSTON
(D) STATE: MASSACHUSETTS
(E) COUNTRY: USA
(F) POSTAL CODE (ZIP): 02115
(A) NAME: DANA-FARBER CANCER INSTITUTE
(B) STREET: 44 BINNEY STREET
(C) CITY: BOSTON
(D) STATE: MASSACHUSETTS
(E) COUNTRY: USA
(F) POSTAL CODE (ZIP): 02115

(ii) TITLE OF INVENTION: Novel Forms of T Cell Costimulatory Molecules
and Uses Therefor

(iii) NUMBER OF SEQUENCES: 65

(iv) CORRESPONDENCE ADDRESS:

- (A) ADDRESSEE: LAHIVE & COCKFIELD
(B) STREET: 60 State Street, suite 510
(C) CITY: Boston
(D) STATE: Massachusetts
(E) COUNTRY: USA
(F) ZIP: 02109-1875

(v) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: ASCII Text

(vi) CURRENT APPLICATION DATA:

- (A) APPLICATION NUMBER:
(B) FILING DATE:

(vi) PRIOR APPLICATION DATA:

- (A) APPLICATION NUMBER: US 08/205,697
(B) FILING DATE: 02-Mar-1994

(viii) ATTORNEY/AGENT INFORMATION:

- (A) NAME: Mandragouras, Amy E.
(B) REGISTRATION NUMBER: 36,207
(C) REFERENCE/DOCKET NUMBER: BWI-120CPPC

(ix) TELECOMMUNICATION INFORMATION:

- (A) TELEPHONE: (617) 227-7400
(B) TELEFAX: (617) 227-5941

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1888 base pairs

(B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

5 (ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

10 (A) NAME/KEY: CDS
 (B) LOCATION: 249..1208

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

15 GAGTTTTATA CCTCAATAGA CTCTTACTAG TTTCTCTTTT TCAGGTTGTG AAACCTCAACC 60
 TTCAAAGACA CTCTGTTCCA TTTCTGTGGA CTAATAGGAT CATCTTTAGC ATCTGCCGGG 120
 TGGATGCCAT CCAGGCTTCT TTTCTACAT CTCTGTTTCT CGATTTTTGT GAGCCTAGGA 180
 20 GGTGCCTAAG CTCCATTGGC TCTAGATTCC TGGCTTTCCC CATCATGTTC TCCAAAGCAT 240
 CTGAAGCT ATG GCT TGC AAT TGT CAG TTG ATG CAG GAT ACA CCA CTC CTC 290
 Met Ala Cys Asn Cys Gln Leu Met Gln Asp Thr Pro Leu Leu
 25 1 5 10
 AAG TTT CCA TGT CCA AGG CTC AAT CTT CTC TTT GTG CTG CTG ATT CGT 338
 Lys Phe Pro Cys Pro Arg Leu Asn Leu Leu Phe Val Leu Leu Ile Arg
 15 20 25 30
 30 CTT TCA CAA GTG TCT TCA GAT GTT GAT GAA CAA CTG TCC AAG TCA GTG 386
 Leu Ser Gln Val Ser Ser Asp Val Asp Glu Gln Leu Ser Lys Ser Val
 35 35 40 45
 AAA GAT AAG GTA TTG CTG CCT TGC CGT TAC AAC TCT CCT CAT GAA GAT 434
 Lys Asp Lys Val Leu Leu Pro Cys Arg Tyr Asn Ser Pro His Glu Asp
 50 55 60
 40 GAG TCT GAA GAC CGA ATC TAC TGG CAA AAA CAT GAC AAA GTG GTG CTG 482
 Glu Ser Glu Asp Arg Ile Tyr Trp Gln Lys His Asp Lys Val Val Leu
 65 70 75
 TCT GTC ATT GCT GGG AAA CTA AAA GTG TGG CCC GAG TAT AAG AAC CGG 530
 Ser Val Ile Ala Gly Lys Leu Lys Val Trp Pro Glu Tyr Lys Asn Arg
 45 80 85 90
 ACT TTA TAT GAC AAC ACT ACC TAC TCT CTT ATC ATC CTG GGC CTG GTC 578
 Thr Leu Tyr Asp Asn Thr Thr Tyr Ser Leu Ile Ile Leu Gly Leu Val
 95 100 105 110
 50 CTT TCA GAC CGG GGC ACA TAC AGC TGT GTC GTT CAA AAG AAG GAA AGA 626
 Leu Ser Asp Arg Gly Thr Tyr Ser Cys Val Val Gln Lys Lys Glu Arg
 115 120 125
 55 GGA ACG TAT GAA GTT AAA CAC TTG GCT TTA GTA AAG TTG TCC ATC AAA 674
 Gly Thr Tyr Glu Val Lys His Leu Ala Leu Val Lys Leu Ser Ile Lys
 130 135 140

960330 52520/30

	GCT GAC TTC TCT ACC CCC AAC ATA ACT GAG TCT GGA AAC CCA TCT GCA	722
	Ala Asp Phe Ser Thr Pro Asn Ile Thr Glu Ser Gly Asn Pro Ser Ala	
	145 150 155	
5	GAC ACT AAA AGG ATT ACC TGC TTT GCT TCC GGG GGT TTC CCA AAG CCT	770
	Asp Thr Lys Arg Ile Thr Cys Phe Ala Ser Gly Gly Phe Pro Lys Pro	
	160 165 170	
10	CGC TTC TCT TGG TTG GAA AAT GGA AGA GAA TTA CCT GGC ATC AAT ACG	818
	Arg Phe Ser Trp Leu Glu Asn Gly Arg Glu Leu Pro Gly Ile Asn Thr	
	175 180 185 190	
15	ACA ATT TCC CAG GAT CCT GAA TCT GAA TTG TAC ACC ATT AGT AGC CAA	866
	Thr Ile Ser Gln Asp Pro Glu Ser Glu Leu Tyr Thr Ile Ser Ser Gln	
	195 200 205	
20	CTA GAT TTC AAT ACG ACT CGC AAC CAC ACC ATT AAG TGT CTC ATT AAA	914
	Leu Asp Phe Asn Thr Thr Arg Asn His Thr Ile Lys Cys Leu Ile Lys	
	210 215 220	
25	TAT GGA GAT GCT CAC GTG TCA GAG GAC TTC ACC TGG GAA AAA CCC CCA	962
	Tyr Gly Asp Ala His Val Ser Glu Asp Phe Thr Trp Glu Lys Pro Pro	
	225 230 235	
30	GAA GAC CCT CCT GAT AGC AAG AAC ACA CTT GTG CTC TTT GGG GCA GGA	1010
	Glu Asp Pro Pro Asp Ser Lys Asn Thr Leu Val Leu Phe Gly Ala Gly	
	240 245 250	
35	TTC GGC GCA GTA ATA ACA GTC GTC GTC ATC GTT GTC ATC ATC AAA TGC	1058
	Phe Gly Ala Val Ile Thr Val Val Val Ile Val Val Ile Ile Lys Cys	
	255 260 265 270	
40	TTC TGT AAG CAC GGT CTC ATC TAC CAT TTG CAA CTG ACC TCT TCT GCA	1106
	Phe Cys Lys His Gly Leu Ile Tyr His Leu Gln Leu Thr Ser Ser Ala	
	275 280 285	
45	AAG GAC TTC AGA AAC CTA GCA CTA CCC TGG CTC TGC AAA CAC GGT TCT	1154
	Lys Asp Phe Arg Asn Leu Ala Leu Pro Trp Leu Cys Lys His Gly Ser	
	290 295 300	
50	CTA GGT GAA GCC TCT GCA GTG ATT TGC AGA AGT ACT CAG ACG AAT GAA	1202
	Leu Gly Glu Ala Ser Ala Val Ile Cys Arg Ser Thr Gln Thr Asn Glu	
	305 310 315	
55	CCA CAG TAGTTCTGCT GTTCTGAGG ACGTAGTTTA GAGACTGAAT TCTTTGGAAA	1258
	Pro Gln	
	320	
55	GGACATAGGG ACAGTTTGCA CATTTGCTTG CACATCACAC ACACACACAC ACACACACAC	1318
	ACACACACAC ACACACACAC ACACACACAC ACACACACAC TCTCTCTCTC TCTCTCTCTC	1378
	GATACCTTAG GATAGGGTTC TACCCTGTTG CTCAGTGACA AAGAATCACT CTGTGGCGGA	1438
55	GGCAGGCTTC AAGCTTGCAG CAATCCTCCT GCACCAGTTT CCTGAGTGCC AGACTTCCAG	1498
	GTGTAAGCTA TGGCACTTAG CAGAACAATA GCTGAATCAA TGAAGACACT GAGGTTCCAA	1558
	GAGGGAACCT GAATTATGAA GGTGAGTCAG AATCCAGATT TCCTGGCTCT ACCACTCTTA	1618

960E80 92920280

ACCTGTATCT GTTAGACCCC AAGCTCTGAG CTCATAGACA AGCTAATTTA AAATGCTTTT 1678
 TAATAAGCAG AAGGCTCAGT TAGTACGGGG TTCAGGATAC TGCTTACTGG CAATATTTGA 1738
 5 CTAGCCTCTA TTTTGTTTGT TTTTAAAGG CCTACTGACT GTAGTGTAAT TTGTAGGAAA 1798
 CATGTTGCTA TGTATAACCA TTTGAGGGTA ATAAAAATGT TGGTAATTTT CAGCCAGCAC 1858
 10 TTTCCAGGTA TTTCCCTTTT TATCCTTCAT 1888

(2) INFORMATION FOR SEQ ID NO:2:

15 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 320 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

20 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

25 Met Ala Cys Asn Cys Gln Leu Met Gln Asp Thr Pro Leu Leu Lys Phe
 1 5 10 15
 Pro Cys Pro Arg Leu Asn Leu Leu Phe Val Leu Leu Ile Arg Leu Ser
 20 25 30
 30 Gln Val Ser Ser Asp Val Asp Glu Gln Leu Ser Lys Ser Val Lys Asp
 35 40 45
 Lys Val Leu Leu Pro Cys Arg Tyr Asn Ser Pro His Glu Asp Glu Ser
 50 55 60
 35 Glu Asp Arg Ile Tyr Trp Gln Lys His Asp Lys Val Val Leu Ser Val
 65 70 75 80
 40 Ile Ala Gly Lys Leu Lys Val Trp Pro Glu Tyr Lys Asn Arg Thr Leu
 85 90 95
 Tyr Asp Asn Thr Thr Tyr Ser Leu Ile Ile Leu Gly Leu Val Leu Ser
 100 105 110
 45 Asp Arg Gly Thr Tyr Ser Cys Val Val Gln Lys Lys Glu Arg Gly Thr
 115 120 125
 Tyr Glu Val Lys His Leu Ala Leu Val Lys Leu Ser Ile Lys Ala Asp
 130 135 140
 50 Phe Ser Thr Pro Asn Ile Thr Glu Ser Gly Asn Pro Ser Ala Asp Thr
 145 150 155 160
 55 Lys Arg Ile Thr Cys Phe Ala Ser Gly Gly Phe Pro Lys Pro Arg Phe
 165 170 175
 Ser Trp Leu Glu Asn Gly Arg Glu Leu Pro Gly Ile Asn Thr Thr Ile
 180 185 190

960380 52520230

Ser Gln Asp Pro Glu Ser Glu Leu Tyr Thr Ile Ser Ser Gln Leu Asp
 195 200 205
 5 Phe Asn Thr Thr Arg Asn His Thr Ile Lys Cys Leu Ile Lys Tyr Gly
 210 215 220
 Asp Ala His Val Ser Glu Asp Phe Thr Trp Glu Lys Pro Pro Glu Asp
 225 230 235 240
 10 Pro Pro Asp Ser Lys Asn Thr Leu Val Leu Phe Gly Ala Gly Phe Gly
 245 250 255
 Ala Val Ile Thr Val Val Val Ile Val Val Ile Ile Lys Cys Phe Cys
 260 265 270
 15 Lys His Gly Leu Ile Tyr His Leu Gln Leu Thr Ser Ser Ala Lys Asp
 275 280 285
 20 Phe Arg Asn Leu Ala Leu Pro Trp Leu Cys Lys His Gly Ser Leu Gly
 290 295 300
 Glu Ala Ser Ala Val Ile Cys Arg Ser Thr Gln Thr Asn Glu Pro Gln
 305 310 315 320
 25 (2) INFORMATION FOR SEQ ID NO:3:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 2516 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear
 30 (ii) MOLECULE TYPE: cDNA
 35 (ix) FEATURE:
 (A) NAME/KEY: CDS
 (B) LOCATION: 249..1166
 40 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:
 45 GAGTTTTATA CCTCAATAGA CTCTTACTAG TTTCTCTTTT TCAGGTTGTG AAACCTCAACC 60
 TTCAAAGACA CTCTGTTCCA TTTCTGTGGA CTAATAGGAT CATCTTTAGC ATCTGCCGGG 120
 TGGATGCCAT CCAGGCTTCT TTTTCTACAT CTCTGTTTCT CGATTTTTGT GAGCCTAGGA 180
 50 GGTGCCTAAG CTCCATTGGC TCTAGATTCC TGGCTTTCCC CATCATGTTC TCCAAAGCAT 240
 CTGAAGCT ATG GCT TGC AAT TGT CAG TTG ATG CAG GAT ACA CCA CTC CTC 290
 Met Ala Cys Asn Cys Gln Leu Met Gln Asp Thr Pro Leu Leu
 1 5 10
 55 AAG TTT CCA TGT CCA AGG CTC AAT CTT CTC TTT GTG CTG CTG AAT CGT 338
 Lys Phe Pro Cys Pro Arg Leu Asn Leu Leu Phe Val Leu Leu Asn Arg
 15 20 25 30

960E30 52520/30

	CTT TCA CAA GTG TCT TCA GAT GTT GAT GAA CAA CTG TCC AAG TCA GTG Leu Ser Gln Val Ser Ser Asp Val Asp Glu Gln Leu Ser Lys Ser Val	386
	35 40 45	
5	AAA GAT AAG GTA TTG CTG CCT TGC CGT TAC AAC TCT CCT CAT GAA GAT Lys Asp Lys Val Leu Leu Pro Cys Arg Tyr Asn Ser Pro His Glu Asp	434
	50 55 60	
10	GAG TCT GAA GAC CGA ATC TAC TGG CAA AAA CAT GAC AAA GTG GTG CTG Glu Ser Glu Asp Arg Ile Tyr Trp Gln Lys His Asp Lys Val Val Leu	482
	65 70 75	
15	TCT GTC ATT GCT GGG AAA CTA AAA GTG TGG CCC GAG TAT AAG AAC CGG Ser Val Ile Ala Gly Lys Leu Lys Val Trp Pro Glu Tyr Lys Asn Arg	530
	80 85 90	
20	ACT TTA TAT GAC AAC ACT ACC TAC TCT CTT ATC ATC CTG GGC CTG GTC Thr Leu Tyr Asp Asn Thr Thr Tyr Ser Leu Ile Ile Leu Gly Leu Val	578
	95 100 105 110	
25	CTT TCA GAC CGG GGC ACA TAC AGC TGT GTC GTT CAA AAG AAG GAA AGA Leu Ser Asp Arg Gly Thr Tyr Ser Cys Val Val Gln Lys Lys Glu Arg	626
	115 120 125	
30	GGA ACG TAT GAA GTT AAA CAC TTG GCT TTA GTA AAG TTG TCC ATC AAA Gly Thr Tyr Glu Val Lys His Leu Ala Leu Val Lys Leu Ser Ile Lys	674
	130 135 140	
35	GCT GAC TTC TCT ACC CCC AAC ATA ACT GAG TCT GGA AAC CCA TCT GCA Ala Asp Phe Ser Thr Pro Asn Ile Thr Glu Ser Gly Asn Pro Ser Ala	722
	145 150 155	
40	GAC ACT AAA AGG ATT ACC TGC TTT GCT TCC GGG GGT TTC CCA AAG CCT Asp Thr Lys Arg Ile Thr Cys Phe Ala Ser Gly Gly Phe Pro Lys Pro	770
	160 165 170	
45	CGC TTC TCT TGG TTG GAA AAT GGA AGA GAA TTA CCT GGC ATC AAT ACG Arg Phe Ser Trp Leu Glu Asn Gly Arg Glu Leu Pro Gly Ile Asn Thr	818
	175 180 185 190	
50	ACA ATT TCC CAG GAT CCT GAA TCT GAA TTG TAC ACC ATT AGT AGC CAA Thr Ile Ser Gln Asp Pro Glu Ser Glu Leu Tyr Thr Ile Ser Ser Gln	866
	195 200 205	
55	CTA GAT TTC AAT ACG ACT CGC AAC CAC ACC ATT AAG TGT CTC ATT AAA Leu Asp Phe Asn Thr Thr Arg Asn His Thr Ile Lys Cys Leu Ile Lys	914
	210 215 220	
60	TAT GGA GAT GCT CAC GTG TCA GAG GAC TTC ACC TGG GAA AAA CCC CCA Tyr Gly Asp Ala His Val Ser Glu Asp Phe Thr Trp Glu Lys Pro Pro	962
	225 230 235	
65	GAA GAC CCT CCT GAT AGC AAG AAC ACA CTT GTG CTC TTT GGG GCA GGA Glu Asp Pro Pro Asp Ser Lys Asn Thr Leu Val Leu Phe Gly Ala Gly	1010
	240 245 250	
70	TTC GGC GCA GTA ATA ACA GTC GTC GTC ATC GTT GTC ATC ATC AAA TGC Phe Gly Ala Val Ile Thr Val Val Val Ile Val Val Ile Ile Lys Cys	1058
	255 260 265 270	

550000 550000 550000

	TTC TGT AAG CAC AGA AGC TGT TTC AGA AGA AAT GAG GCA AGC AGA GAA	1106
	Phe Cys Lys His Arg Ser Cys Phe Arg Arg Asn Glu Ala Ser Arg Glu	
	275 280 285	
5	ACA AAC AAC AGC CTT ACC TTC GGG CCT GAA GAA GCA TTA GCT GAA CAG	1154
	Thr Asn Asn Ser Leu Thr Phe Gly Pro Glu Glu Ala Leu Ala Glu Gln	
	290 295 300	
10	ACC GTC TTC CTT TAGTTCTTCT CTGTCCATGT GGGATACATG GTATTATGTG	1206
	Thr Val Phe Leu	
	305	
15	GCTCATGAGG TACAATCTTT CTTTCAGCAC CGTGCTAGCT GATCTTTCGG ACAACTTGAC	1266
	ACAAGATAGA GTTAACTGGG AAGAGAAAGC CTTGAATGAG GATTTCTTTC CATCAGGAAG	1326
	CTACGGGCAA GTTTGCTGGG CCTTTGATTG CTTGATGACT GAAGTGGAAA GGCTGAGCCC	1386
20	ACTGTGGGTG GTGCTAGCCC TGGGCAGGGG CAGGTGACCC TGGGTGGTAT AAGAAAAAGA	1446
	GCTGTCACTA AAAGGAGAGG TGCCTAGTCT TACTGCAACT TGATATGTCA TGTTTGTTG	1506
	GTGTCTGTGG GAGGCCTGCC CTTTTCTGAA GAGAAGTGGT GGGAGAGTGG ATGGGGTGGG	1566
25	GGCAGAGGAA AAGTGGGGGA GAGGGCCTGG GAGGAGAGGA GGGAGGGGGA CGGGGTGGGG	1626
	GTGGGGAAAA CTATGGTTGG GATGTAAAAA CGGATAATAA TATAAATATT AAATAAAAAG	1686
30	AGAGTATTGA GCGGTCTCAT CTACCATTTC CAACTGACCT CTTCTGCAA GGACTTCAGA	1746
	AACCTAGCAC TACCCTGGCT CTGCAAACAC GGTTCCTAG GTGAAGCCTC TGCAGTGATT	1806
	TGCAGAAGTA CTCAGACGAA TGAACCACAG TAGTTCTGCT GTTTCTGAGG ACGTAGTTTA	1866
35	GAGACTGAAT TCTTTGGAAA GGACATAGGG ACAGTTTGCA CATTTGCTTG CACATCACAC	1926
	ACACACACAC ACACACACAC ACACACACAC ACACACACAC ACACACACAC ACACACACAC	1986
40	TCTCTCTCTC TCTCTCTCTC GATACCTTAG GATAGGGTTC TACCCTGTTG CTCAGTGACA	2046
	AAGAATCACT CTGTGGCGGA GGCAGGCTTC AAGCTTGCAG CAATCCTCCT GCACCAGTTT	2106
	CCTGAGTGCC AGACTTCCAG GTGTAAGCTA TGGCACTTAG CAGAACACTA GCTGAATCAA	2166
45	TGAAGACACT GAGGTTCCAA GAGGGAACCT GAATTATGAA GGTGAGTCAG AATCCAGATT	2226
	TCCTGGCTCT ACCACTCTTA ACCTGTATCT GTTAGACCCC AAGCTCTGAG CTCATAGACA	2286
50	AGCTAATTTA AAATGCTTTT TAATAAGCAG AAGGCTCAGT TAGTACGGGG TTCAGGATAC	2346
	TGCTTACTGG CAATATTTGA CTAGCCTCTA TTTTGTGTTGT TTTTAAAGG CCTACTGACT	2406
	GTAGTGTAAT TTGTAGGAAA CATGTTGCTA TGTATACCCA TTTGAGGGTA ATAAAAATGT	2466
55	TGGTAATTTT CAGCCAGCAC TTTCCAGGTA TTTCCCTTTT TATCCTTCAT	2516

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 818 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
 (B) LOCATION: 1..138

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

GGT CTC ATC TAC CAT TTG CAA CTG ACC TCT TCT GCA AAG GAC TTC AGA 48
 Gly Leu Ile Tyr His Leu Gln Leu Thr Ser Ser Ala Lys Asp Phe Arg
 1 5 10 15

AAC CTA GCA CTA CCC TGG CTC TGC AAA CAC GGT TCT CTA GGT GAA GCC 96
 Asn Leu Ala Leu Pro Trp Leu Cys Lys His Gly Ser Leu Gly Glu Ala
 20 25 30

TCT GCA GTG ATT TGC AGA AGT ACT CAG ACG AAT GAA CCA CAG 138
 Ser Ala Val Ile Cys Arg Ser Thr Gln Thr Asn Glu Pro Gln
 35 40 45

TAGTTCTGCT GTTTCTGAGG ACGTAGTTTA GAGACTGAAT TCTTTGGAAA GGACATAGGG 198
 ACAGTTTGCA CATTTGCTTG CACATCACAC ACACACACAC ACACACACAC ACACACACAC 258
 ACACACACAC ACACACACAC ACACACACAC TCTCTCTCTC TCTCTCTCTC GATACCTTAG 318
 GATAGGGTTC TACCCTGTTG CTCAGTGACA AAGAATCACT CTGTGGCGGA GGCAGGCTTC 378
 AAGCTTGACAG CAATCCTCCT GCACCAGTTT CCTGAGTGCC AGACTTCCAG GTGTAAGCTA 438
 TGGCACTTAG CAGAACACTA GCTGAATCAA TGAAGACACT GAGGTTCCAA GAGGGAACCT 498
 GAATTATGAA GGTGAGTCAG AATCCAGATT TCCTGGCTCT ACCACTCTTA ACCTGTATCT 558
 GTTAGACCCC AAGCTCTGAG CTCATAGACA AGCTAATTTA AAATGCTTTT TAATAAGCAG 618
 AAGGCTCAGT TAGTACGGGG TTCAGGATAC TGCTTACTGG CAATATTTGA CTAGCCTCTA 678
 TTTTGTTTGT TTTTAAAGG CCTACTGACT GTAGTGTAAT TTGTAGGAAA CATGTTGCTA 738
 TGTATACCCA TTTGAGGGTA ATAAAAATGT TGGTAATTTT CAGCCAGCAC TTTCCAGGTA 798
 TTTCCCTTTT TATCCTTCAT 818

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 46 amino acids
 (B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Gly Leu Ile Tyr His Leu Gln Leu Thr Ser Ser Ala Lys Asp Phe Arg
 1 5 10 15

10 Asn Leu Ala Leu Pro Trp Leu Cys Lys His Gly Ser Leu Gly Glu Ala
 20 25 30

15 Ser Ala Val Ile Cys Arg Ser Thr Gln Thr Asn Glu Pro Gln
 35 40 45

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

20 (A) LENGTH: 1753 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

25 (ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

30 GTTTTAGTAA CCAGAGGCCG CAAGAAGAGA TCACTTGTAT ATACACGGGC CCCATCTTTT 60
 GCTTTTTTAAG ACAAAGAAA AAGAATCTTC TTCAACAAGT AAGTAAATGC ATTTACTATT 120
 TATCATGCTA TGGGACACCT TAGTAGAACA CGCTATCTCC AGCCTTATCA TATGCATATT 180
 35 TTGTTGTTGT TGTTGTTGTT GTTGTTAAAG ACAGGGTCTC ATATATGCCA GGCTGGTCCC 240
 AAACCTTTCAG TGTAACCCAA GATAATCTGG AACTCCCGAC TCCTCTGCTC CCACCTCTCC 300
 AGTGCAGGAC ACTGTTTATA CCGTGCTGGG GAATTGAACT CAGAGCACCC TGCATGTCAG 360
 40 CTAAGCATTG TACCGACCAA GTCCCATGCC CAGTCCCTAA CTCCCCAACT TCACTGCTTT 420
 TTAAACATAC ATACAATCAT AACTTGCCCT CAGAGCAGTC TCCTGGGGTC TCTTATTCTC 480
 45 AAGGCTGCGG CATTCCAACA CTGTTAGAAA AACACCATCA GGATTCTTTT GTGTTTCCTA 540
 GATGCAAACA TTTTGTAGG GCGAAGTTGA GGTTTTCTA ATCAAGAAAA TGCCGGTAAC 600
 AAGTCTCTTC AAGCTAACTG GTTGGCTAAG GGGTATCTCT CCAAAGAAG AGATCCACAT 660
 50 GTCAGGCCAG TTGTAGGCAT GATGTCAGGT CTCCCTCCCT TTCTTTCTTT CTTTCTTTTT 720
 TTCTTTCTTT CTTTTTTTCT TTCTTTCTTA CTTTCTTACT TTCTTTCTTT TCTGTTTTTT 780
 55 GGTTTTTCGA GACAGGGTTT CTTTGTATAG CCCTGGCTGT CCTGGAATC GCTCTGTAGA 840
 CCAGGCTGGC CTCGAACTCA GAAATCTGCC TCTGCCTTTA CCTCCTGAGT GCTGGGAATT 900
 AAAGGTGTGC ACCACCATGC CCGGCTGGGA TGTATTCTGT TTTCATTTCT CAATTTTGAT 960

950950 52520/230

ACTTTATGGA AGAAAAAAGA AAAGATAGAC AAGCCTCTTC ATGTAATACC CCATAGTCTC 1020
AATAAGTGGT GTTCGTAACG TGGCTTCTCT TTCCTTACCT TTTACTGGTA GATTTCTCGG 1080
TTGATTGATG TCCCTGTAGG ACTTACTGGG TTTAAGATTC TTGGTTTCCT GTTTTAAGAT 1140
ATAAAGAAAC CATTTCTAA CTAAACACT GCCTTGGACA AATATACTTT TGGCAGTCAC 1200
TCTGTGTCCA GAATGGAATT TAAGCTTTCA TGGCCTAGCT GCTAGTGAAG GTTCTTTGCT 1260
TTTTTTTGGC TGTGTATGT GAAATGGGGT TGGGTGGGAA CCACCTCACT GTGTTCTAGT 1320
GTTAGTCACC CCACCCCCGC AAGCAGAATC CTTTTACCCA GCTTTTTCAC CCAGCTGTGC 1380
TCACCCGGTG CTCAGAACAG GCCTGGACAA GTCACCTCCC CTAGAGTTCT GGGGACCTTT 1440
GAGTTGCCCT CATGGCCACA CCCTGATTCA GAACTCTCAC TCTGTCGTAA GATAGAGCTA 1500
CTGGGGAGTT TTATACCTCA ATAGACTCTT ACTAGTTTCT CTTTTTCAGG TTGTGAAACT 1560
CAACCTTCAA AGACACTCTG TTCCATTTCT GTGGACTAAT AGGATCATCT TTAGCATCTG 1620
CCGGGTGGAT GCCATCCAGG CTTCTTTTTTC TACATCTCTG TTTCTCGATT TTTGTGAGCC 1680
TAGGAGGTGC CTAAGCTCCA TTGGCTCTAG ATTCTGGCT TTCCCATCA TGTCTCTCAA 1740
AGCATCTGAA GCT 1753

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 158 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: genomic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

TGTCCAGGCA GAGCTAGTGG CTGCCCCTAG CGCTTCCTCT TCTTTGATAC CCCAAAGTCT 60
GAGTTTATTA CACATCCTTG GTGACCAAAT CACATGGGAG CTCCTCCGA GGTCTTAGTA 120
AAGGGAAGTT GGAAAGGGGA AATTCCTGCC CCCCTGCC 158

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1398 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS

(B) LOCATION: 249..848

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

5 GAGTTTTATA CCTCAATAGA CTCTTACTAG TTTCTCTTTT TCAGGTTGTG AAACCTCAACC 60
 TTCAAAGACA CTCTGTTCCA TTTCTGTGGA CTAATAGGAT CATCTTTAGC ATCTGCCGGG 120
 10 TGGATGCCAT CCAGGCTTCT TTTTCTACAT CTCTGTTTCT CGATTTTGTG GAGCCTAGGA 180
 GGTGCCTAAG CTCCATTGGC TCTAGATTCC TGGCTTTCCC CATCATGTTC TCCAAAGCAT 240
 15 CTGAAGCT ATG GCT TGC AAT TGT CAG TTG ATG CAG GAT ACA CCA CTC CTC 290
 Met Ala Cys Asn Cys Gln Leu Met Gln Asp Thr Pro Leu Leu
 1 5 10
 AAG TTT CCA TGT CCA AGG CTC AAT CTT CTC TTT GTG CTG CTG ATT CGT 338
 Lys Phe Pro Cys Pro Arg Leu Asn Leu Leu Phe Val Leu Leu Ile Arg
 20 15 20 25 30
 CTT TCA CAA GTG TCT TCA GCT GAC TTC TCT ACC CCC AAC ATA ACT GAG 386
 Leu Ser Gln Val Ser Ser Ala Asp Phe Ser Thr Pro Asn Ile Thr Glu
 35 40 45
 25 TCT GGA AAC CCA TCT GCA GAC ACT AAA AGG ATT ACC TGC TTT GCT TCC 434
 Ser Gly Asn Pro Ser Ala Asp Thr Lys Arg Ile Thr Cys Phe Ala Ser
 50 55 60
 30 GGG GGT TTC CCA AAG CCT CGC TTC TCT TGG TGG GAA AAT GGA AGA GAA 482
 Gly Gly Phe Pro Lys Pro Arg Phe Ser Trp Trp Glu Asn Gly Arg Glu
 65 70 75
 35 TTA CCT GGC ATC AAT ACG ACA ATT TCC CAG GAT CCT GAA TCT GAA TTG 530
 Leu Pro Gly Ile Asn Thr Thr Ile Ser Gln Asp Pro Glu Ser Glu Leu
 80 85 90
 TAC ACC ATT AGT AGC CAA CTA GAT TTC AAT ACG ACT CGC AAC CAC ACC 578
 Tyr Thr Ile Ser Ser Gln Leu Asp Phe Asn Thr Thr Arg Asn His Thr
 40 95 100 105 110
 ATT AAG TGT CTC ATT AAA TAT GGA GAT GCT CAC GTG TCA GAG GAC TTC 626
 Ile Lys Cys Leu Ile Lys Tyr Gly Asp Ala His Val Ser Glu Asp Phe
 115 120 125
 45 ACC TGG GAA AAA CCC CCA GAA GAC CCT CCT GAT AGC AAG AAC ACA CTT 674
 Thr Trp Glu Lys Pro Pro Glu Asp Pro Pro Asp Ser Lys Asn Thr Leu
 130 135 140
 50 GTG CTC TTT GGG GCA GGA TTC GGC GCA GTA ATA ACA GTC GTC GTC ATC 722
 Val Leu Phe Gly Ala Gly Phe Gly Ala Val Ile Thr Val Val Val Ile
 145 150 155
 55 GTT GTC ATC ATC AAA TGC TTC TGT AAG CAC AGA AGC TGT TTC AGA AGA 770
 Val Val Ile Ile Lys Cys Phe Cys Lys His Arg Ser Cys Phe Arg Arg
 160 165 170

960E80 62520480

AAT GAG GCA AGC AGA GAA ACA AAC AAC AGC CTT ACC TTC GGG CCT GAA 818
 Asn Glu Ala Ser Arg Glu Thr Asn Asn Ser Leu Thr Phe Gly Pro Glu
 175 180 185 190

5 GAA GCA TTA GCT GAA CAG ACC GTC TTC CTT TAGTTCTTCT CTGTCCATGT 868
 Glu Ala Leu Ala Glu Gln Thr Val Phe Leu
 195 200

10 GGGATACATG GTATTATGTG GCTCATGAGG TACAATCTTT CTTTCAGCAC CGTGCTAGCT 928
 GATCTTTTCGG ACAACTTGAC ACAAGATAGA GTTAACTGGG AAGAGAAAGC CTTGAATGAG 988
 GATTTCTTTC CATCAGGAAG CTACGGGCAA GTTTGCTGGG CCTTTGATTG CTTGATGACT 1048

15 GAAGTGGAAG GGCTGAGCCC ACTGTGGGTG GTGCTAGCCC TGGGCAGGGG CAGGTGACCC 1108
 TGGGTGGTAT AAGAAAAAGA GCTGTCACTA AAAGGAGAGG TGCCTAGTCT TACTGCAACT 1168
 TGATATGTCA TGTGTGGTTG GTGTCTGTGG GAGGCCTGCC CTTTCTTGAA GAGAAGTGGT 1228

20 GGGAGAGTGG ATGGGGTGGG GGCAGAGGAA AAGTGGGGGA GAGGCCTGG GAGGAGAGGA 1288
 GGGAGGGGGA CGGGGTGGGG GTGGGGAAAA CTATGGTTGG GATGTAAAAA CGGATAATAA 1348

25 TATAAATATT AAATAAAAAG AGAGTATTGA GCAAAAAAAA AAAAAAAAAA 1398

(2) INFORMATION FOR SEQ ID NO:9:

30 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 200 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

35 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

40 Met Ala Cys Asn Cys Gln Leu Met Gln Asp Thr Pro Leu Leu Lys Phe
 1 5 10 15

Pro Cys Pro Arg Leu Ile Leu Leu Phe Val Leu Leu Ile Arg Leu Ser
 20 25 30

45 Gln Val Ser Ser Ala Asp Phe Ser Thr Pro Asn Ile Thr Glu Ser Gly
 35 40 45

Asn Pro Ser Ala Asp Thr Lys Arg Ile Thr Cys Phe Ala Ser Gly Gly
 50 55 60

Phe Pro Lys Pro Arg Phe Ser Trp Leu Glu Asn Gly Arg Glu Leu Pro
 65 70 75 80

55 Gly Ile Asn Thr Thr Ile Ser Gln Asp Pro Glu Ser Glu Leu Tyr Thr
 85 90 95

Ile Ser Ser Gln Leu Asp Phe Asn Thr Thr Arg Asn His Thr Ile Lys
 100 105 110

960E80 52520280



Cys Leu Ile Lys Tyr Gly Asp Ala His Val Ser Glu Asp Phe Thr Trp
115 120 125

Glu Lys Pro Pro Glu Asp Pro Pro Asp Ser Lys Asn Thr Leu Val Leu
5 130 135 140

Phe Gly Ala Gly Phe Gly Ala Val Ile Thr Val Val Val Ile Val Val
145 150 155 160

10 Ile Ile Lys Cys Phe Cys Lys His Arg Ser Cys Phe Arg Arg Asn Glu
165 170 175

Ala Ser Arg Glu Thr Asn Asn Ser Leu Thr Phe Gly Pro Glu Glu Ala
180 185 190

15 Leu Ala Glu Gln Thr Val Phe Leu
195 200

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1570 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 249..890

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

GAGTTTTATA CCTCAATAGA CTCTTACTAG TTTCTCTTTT TCAGGTTGTG AACTCAACC 60

TTCAAAGACA CTCTGTTCCA TTTCTGTGGA CTAATAGGAT CATCTTTAGC ATCTGCCGGG 120

TGGATGCCAT CCAGGCTTCT TTTTCTACAT CTCTGTTTCT CGATTTTGTG GAGCCTAGGA 180

GGTGCCTAAG CTCCATTGGC TCTAGATTCC TGGCTTTCCC CATCATGTTC TCCAAAGCAT 240

45 CTGAAGCT ATG GCT TGC AAT TGT CAG TTG ATG CAG GAT ACA CCA CTC CTC 290
Met Ala Cys Asn Cys Gln Leu Met Gln Asp Thr Pro Leu Leu
1 5 10

50 AAG TTT CCA TGT CCA AGG CTC AAT CTT CTC TTT GTG CTG CTG ATT CGT 338
 Lys Phe Pro Cys Pro Arg Leu Asn Leu Leu Phe Val Leu Leu Ile Arg
 15 20 25 30

55 CTT TCA CAA GTG TCT TCA GCT GAC TTC TCT ACC CCC AAC ATA ACT GAG 386
Leu Ser Gln Val Ser Ser Ala Asp Phe Ser Thr Pro Asn Ile Thr Glu
35 40 45

TCT GGA AAC CCA TCT GCA GAC ACT AAA AGG ATT ACC TGC TTT GCT TCC 434
Ser Gly Asn Pro Ser Ala Asp Thr Lys Arg Ile Thr Cys Phe Ala Ser
50 55 60

[illegible]

	GGG GGT TTC CCA AAG CCT CGC TTC TCT TGG TTG GAA AAT GGA AGA GAA	482
	Gly Gly Phe Pro Lys Pro Arg Phe Ser Trp Leu Glu Asn Gly Arg Glu	
	65 70 75	
5	TTA CCT GGC ATC AAT ACG ACA ATT TCC CAG GAT CCT GAA TCT GAA TTG	530
	Leu Pro Gly Ile Asn Thr Thr Ile Ser Gln Asp Pro Glu Ser Glu Leu	
	80 85 90	
10	TAC ACC ATT AGT AGC CAA CTA GAT TTC AAT ACG ACT CGC AAC CAC ACC	578
	Tyr Thr Ile Ser Ser Gln Leu Asp Phe Asn Thr Thr Arg Asn His Thr	
	95 100 105 110	
15	ATT AAG TGT CTC ATT AAA TAT GGA GAT GCT CAC GTG TCA GAG GAC TTC	626
	Ile Lys Cys Leu Ile Lys Tyr Gly Asp Ala His Val Ser Glu Asp Phe	
	115 120 125	
20	ACC TGG GAA AAA CCC CCA GAA GAC CCT CCT GAT AGC AAG AAC ACA CTT	674
	Thr Trp Glu Lys Pro Pro Glu Asp Pro Pro Asp Ser Lys Asn Thr Leu	
	130 135 140	
25	GTG CTC TTT GGG GCA GGA TTC GGC GCA GTA ATA ACA GTC GTC GTC ATC	722
	Val Leu Phe Gly Ala Gly Phe Gly Ala Val Ile Thr Val Val Val Ile	
	145 150 155	
30	GTT GTC ATC ATC AAA TGC TTC TGT AAG CAC GGT CTC ATC TAC CAT TTG	770
	Val Val Ile Ile Lys Cys Phe Cys Lys His Gly Leu Ile Tyr His Leu	
	160 165 170	
35	CAA CTG ACC TCT TCT GCA AAG GAC TTC AGA AAC CTA GCA CTA CCC TGG	818
	Gln Leu Thr Ser Ser Ala Lys Asp Phe Arg Asn Leu Ala Leu Pro Trp	
	175 180 185 190	
40	CTC TGC AAA CAC GGT TCT CTA GGT GAA GCC TCT GCA GTG ATT TGC AGA	866
	Leu Cys Lys His Gly Ser Leu Gly Glu Ala Ser Ala Val Ile Cys Arg	
	195 200 205	
45	AGT ACT CAG ACG AAT GAA CCA CAG TAGTTCTGCT GTTTCTGAGG ACGTAGTTTA	920
	Ser Thr Gln Thr Asn Glu Pro Gln	
	210	
50	GAGACTGAAT TCTTTGGAAA GGACATAGGG ACAGTTTGCA CATTTGCTTG CACATCACAC	980
	ACACACACAC ACACACACAC ACACACACAC ACACACACAC ACACACACAC ACACACACAC	1040
	TCTCTCTCTC TCTCTCTCTC GATACCTTAG GATAGGGTTC TACCCTGTTG CTCAGTGACA	1100
	AAGAATCACT CTGTGGCGGA GGCAGGCTTC AAGCTTGACAG CAATCCTCCT GCACCAGTTT	1160
55	CCTGAGTGCC AGACTTCCAG GTGTAAGCTA TGGCACTTAG CAGAACACTA GCTGAATCAA	1220
	TGAAGACACT GAGGTTCCAA GAGGGAACCT GAATTATGAA GGTGAGTCAG AATCCAGATT	1280
	TCCTGGCTCT ACCACTCTTA ACCTGTATCT GTTAGACCCC AAGCTCTGAG CTCATAGACA	1340
	AGCTAATTTA AAATGCTTTT TAATAAGCAG AAGGCTCAGT TAGTACGGGG TTCAGGATAC	1400
	TGCTTACTGG CAATATTTGA CTAGCCTCTA TTTTGTGTTGT TTTTAAAGG CCTACTGACT	1460

960E80 52520280

GTAGTGTAAT TTGTAGGAAA CATGTTGCTA TGTATACCCA TTTGAGGGTA ATAAAAATGT 1520

TGGTAATTTT CAGCCAGCAC TTTCCAGGTA TTTCCCTTTT TATCCTTCAT 1570

5

(2) INFORMATION FOR SEO ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 214 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

Met Ala Cys Asn Cys Gln Leu Met Gln Asp Thr Pro Leu Leu Lys Phe
1 5 10 15

20 Pro Cys Pro Arg Leu Ile Leu Leu Phe Val Leu Leu Ile Arg Leu Ser
 20 25 30

Gln Val Ser Ser Ala Asp Phe Ser Thr Pro Asn Ile Thr Glu Ser Gly
35 40 45

25 Asn Pro Ser Ala Asp Thr Lys Arg Ile Thr Cys Phe Ala Ser Gly Gly
50 55 60

30 Phe Pro Lys Pro Arg Phe Ser Trp Leu Glu Asn Gly Arg Glu Leu Pro
65 70 75 80

Gly Ile Asn Thr Thr Ile Ser Gln Asp Pro Glu Ser Glu Leu Tyr Thr
85 90 95

35 Ile Ser Ser Gln Leu Asp Phe Asn Thr Thr Arg Asn His Thr Ile Lys
100 105 110

Cys Leu Ile Lys Tyr Gly Asp Ala His Val Ser Glu Asp Phe Thr Trp
115 120 125

40 Glu Lys Pro Pro Glu Asp Pro Pro Asp Ser Lys Asn Thr Leu Val Leu
 130 135 140

45 Phe Gly Ala Gly Phe Gly Ala Val Ile Thr Val Val Val Ile Val Val
 145 150 155 160

Ile Ile Lys Cys Phe Cys Lys His Gly Leu Ile Tyr His Leu Gln Leu
165 170 175

50 Thr Ser Ser Ala Lys Asp Phe Arg Asn Leu Ala Leu Pro Trp Leu Cys
180 185 190

Lys His Gly Ser Leu Gly Glu Ala Ser Ala Val Ile Cys Arg Ser Thr
195 200 205

55

Gln Thr Asn Glu Pro Gln
210

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1261 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
 (B) LOCATION: 194..1135

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

AGNCCCNAGA TTATTTCTCC CTGTATAAGG GACGCCCAGG AGGCCTGGGG AGCGGACAAG 60
 GCTCCTTTTA CTTTCTTCT TCTTCTATTT TTTTACCTT CTATTTTTTTT CTCATGTTC 120
 CTGTGATCTT CGGGAATGCT GCTGTGCTTG TGTGTGTGGT CCCTGAGCGC CGAGGTGGAG 180
 AGGCACTGGT GAC ATG TAT GTC ATC AAG ACA TGT GCA ACC TGC ACC ATG 229
 Met Tyr Val Ile Lys Thr Cys Ala Thr Cys Thr Met
 1 5 10
 GGC TTG GCA ATC CTT ATC TTT GTG ACA GTC TTG CTG ATC TCA GAT GCT 277
 Gly Leu Ala Ile Leu Ile Phe Val Thr Val Leu Leu Ile Ser Asp Ala
 15 20 25
 GTT TCC GTG GAG ACG CAA GCT TAT TTC AAT GGG ACT GCA TAT CTG CCG 325
 Val Ser Val Glu Thr Gln Ala Tyr Phe Asn Gly Thr Ala Tyr Leu Pro
 30 35 40
 TGC CCA TTT ACA AAG GCT CAA AAC ATA AGC CTG AGT GAG CTG GTA GTA 373
 Cys Pro Phe Thr Lys Ala Gln Asn Ile Ser Leu Ser Glu Leu Val Val
 45 50 55 60
 TTT TGG CAG GAC CAG CAA AAG TTG GTT CTG TAC GAG CAC TAT TTG GGC 421
 Phe Trp Gln Asp Gln Gln Lys Leu Val Leu Tyr Glu His Tyr Leu Gly
 65 70 75
 ACA GAG AAA CTT GAT AGT GTG AAT GCC AAG TAC CTG GGC CGC ACG AGC 469
 Thr Glu Lys Leu Asp Ser Val Asn Ala Lys Tyr Leu Gly Arg Thr Ser
 80 85 90
 TTT GAC AGG AAC AAC TGG ACT CTA CGA CTT CAC AAT GTT CAG ATC AAG 517
 Phe Asp Arg Asn Asn Trp Thr Leu Arg Leu His Asn Val Gln Ile Lys
 95 100 105
 GAC ATG GGC TCG TAT GAT TGT TTT ATA CAA AAA AAG CCA CCC ACA GGA 565
 Asp Met Gly Ser Tyr Asp Cys Phe Ile Gln Lys Lys Pro Pro Thr Gly
 110 115 120
 TCA ATT ATC CTC CAA CAG ACA TTA ACA GAA CTG TCA GTG ATC GCC AAC 613
 Ser Ile Ile Leu Gln Gln Thr Leu Thr Glu Leu Ser Val Ile Ala Asn
 125 130 135 140

960690 52520280

	TTC AGT GAA CCT GAA ATA AAA CTG GCT CAG AAT GTA ACA GGA AAT TCT	661
	Phe Ser Glu Pro Glu Ile Lys Leu Ala Gln Asn Val Thr Gly Asn Ser	
	145 150 155	
5	GGC ATA AAT TTG ACC TGC ACG TCT AAG CAA GGT CAC CCG AAA CCT AAG	709
	Gly Ile Asn Leu Thr Cys Thr Ser Lys Gln Gly His Pro Lys Pro Lys	
	160 165 170	
10	AAG ATG TAT TTT CTG ATA ACT AAT TCA ACT AAT GAG TAT GGT GAT AAC	757
	Lys Met Tyr Phe Leu Ile Thr Asn Ser Thr Asn Glu Tyr Gly Asp Asn	
	175 180 185	
15	ATG CAG ATA TCA CAA GAT AAT GTC ACA GAA CTG TTC AGT ATC TCC AAC	805
	Met Gln Ile Ser Gln Asp Asn Val Thr Glu Leu Phe Ser Ile Ser Asn	
	190 195 200	
20	AGC CTC TCT CTT TCA TTC CCG GAT GGT GTG TGG CAT ATG ACC GTT GTG	853
	Ser Leu Ser Leu Ser Phe Pro Asp Gly Val Trp His Met Thr Val Val	
	205 210 215 220	
	TGT GTT CTG GAA ACG GAG TCA ATG AAG ATT TCC TCC AAA CCT CTC AAT	901
	Cys Val Leu Glu Thr Glu Ser Met Lys Ile Ser Ser Lys Pro Leu Asn	
	225 230 235	
25	TTC ACT CAA GAG TTT CCA TCT CCT CAA ACG TAT TGG AAG GAG ATT ACA	949
	Phe Thr Gln Glu Phe Pro Ser Pro Gln Thr Tyr Trp Lys Glu Ile Thr	
	240 245 250	
30	GCT TCA GTT ACT GTG GCC CTC CTC CTT GTG ATG CTG CTC ATC ATT GTA	997
	Ala Ser Val Thr Val Ala Leu Leu Leu Val Met Leu Leu Ile Ile Val	
	255 260 265	
35	TGT CAC AAG AAG CCG AAT CAG CCT AGC AGG CCC AGC AAC ACA GCC TCT	1045
	Cys His Lys Lys Pro Asn Gln Pro Ser Arg Pro Ser Asn Thr Ala Ser	
	270 275 280	
40	AAG TTA GAG CGG GAT AGT AAC GCT GAC AGA GAG ACT ATC AAC CTG AAG	1093
	Lys Leu Glu Arg Asp Ser Asn Ala Asp Arg Glu Thr Ile Asn Leu Lys	
	285 290 295 300	
	GAA CTT GAA CCC CAA ATT GCT TCA GCA AAA CCA AAT GCA GAG	1135
	Glu Leu Glu Pro Gln Ile Ala Ser Ala Lys Pro Asn Ala Glu	
	305 310	
45	TGAAGGCAGT GAGAGCCTGA GGAAAGAGTT AAAAATTGCT TTGCCTGAAA TAAGAAGTGC	1195
	AGAGTTTCTC AGAATTCAAA AATGTTCTCA GCTGATTGGA ATTCTACAGT TGAATAATTA	1255
50	AAGAAC	1261

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 314 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

5 Met Tyr Val Ile Lys Thr Cys Ala Thr Cys Thr Met Gly Leu Ala Ile
 1 5 10 15
 Leu Ile Phe Val Thr Val Leu Leu Ile Ser Asp Ala Val Ser Val Glu
 20 25 30
 10 Thr Gln Ala Tyr Phe Asn Gly Thr Ala Tyr Leu Pro Cys Pro Phe Thr
 35 40 45
 Lys Ala Gln Asn Ile Ser Leu Ser Glu Leu Val Val Phe Trp Gln Asp
 50 55 60
 15 Gln Gln Lys Leu Val Leu Tyr Glu His Tyr Leu Gly Thr Glu Lys Leu
 65 70 75 80
 Asp Ser Val Asn Ala Lys Tyr Leu Gly Arg Thr Ser Phe Asp Arg Asn
 85 90 95
 Asn Trp Thr Leu Arg Leu His Asn Val Gln Ile Lys Asp Met Gly Ser
 100 105 110
 25 Tyr Asp Cys Phe Ile Gln Lys Lys Pro Pro Thr Gly Ser Ile Ile Leu
 115 120 125
 Gln Gln Thr Leu Thr Glu Leu Ser Val Ile Ala Asn Phe Ser Glu Pro
 130 135 140
 30 Glu Ile Lys Leu Ala Gln Asn Val Thr Gly Asn Ser Gly Ile Asn Leu
 145 150 155 160
 Thr Cys Thr Ser Lys Gln Gly His Pro Lys Pro Lys Lys Met Tyr Phe
 165 170 175
 35 Leu Ile Thr Asn Ser Thr Asn Glu Tyr Gly Asp Asn Met Gln Ile Ser
 180 185 190
 40 Gln Asp Asn Val Thr Glu Leu Phe Ser Ile Ser Asn Ser Leu Ser Leu
 195 200 205
 Ser Phe Pro Asp Gly Val Trp His Met Thr Val Val Cys Val Leu Glu
 210 215 220
 45 Thr Glu Ser Met Lys Ile Ser Ser Lys Pro Leu Asn Phe Thr Gln Glu
 225 230 235 240
 Phe Pro Ser Pro Gln Thr Tyr Trp Lys Glu Ile Thr Ala Ser Val Thr
 245 250 255
 50 Val Ala Leu Leu Leu Val Met Leu Leu Ile Ile Val Cys His Lys Lys
 260 265 270
 55 Pro Asn Gln Pro Ser Arg Pro Ser Asn Thr Ala Ser Lys Leu Glu Arg
 275 280 285
 Asp Ser Asn Ala Asp Arg Glu Thr Ile Asn Leu Lys Glu Leu Glu Pro
 290 295 300

950630 5250230

Gln Ile Ala Ser Ala Lys Pro Asn Ala Glu
305 310

5 (2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 223 base pairs
(B) TYPE: nucleic acid
10 (C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

15 (ix) FEATURE:

- (A) NAME/KEY: CDS
(B) LOCATION: 194..223

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

AGNCCCNAGA TTATTTCTCC CTGTATAAGG GACGCCCAGG AGGCCTGGGG AGCGGACAAG 60
25 GCTCCTTTTIA CTTTCTTCT TCTTCTATTT TTTTACCTT CTATTTTTTT CTTCATGTTC 120
CTGTGATCTT CGGGAATGCT GCTGTGCTTG TGTGTGTGGT CCCTGAGCGC CGAGGTGGAG 180
AGGCACTGGT GAC ATG TAT GTC ATC AAG ACA TGT GCA ACC TGC 223
30 Met Tyr Val Ile Lys Thr Cys Ala Thr Cys
1 5 10

35 (2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
(B) TYPE: amino acid
40 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

45 Met Tyr Val Ile Lys Thr Cys Ala Thr Cys
1 5 10

(2) INFORMATION FOR SEQ ID NO:16:

50 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1716 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
55 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 249..1166

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

	GAGTTTTATA CCTCAATAGA CTCTTACTAG TTTCTCTTTT TCAGGTTGTG AAACCTCAACC	60
10	TTCAAAGACA CTCTGTTCCA TTTCTGTGGA CTAATAGGAT CATCTTTAGC ATCTGCCGGG	120
	TGGATGCCAT CCAGGCTTCT TTTTCTACAT CTCTGTTTCT CGATTTTGTG GAGCCTAGGA	180
	GGTGCCTAAG CTCCATTGGC TCTAGATTCC TGGCTTTCCC CATCATGTTC TCCAAAGCAT	240
15	CTGAAGCT ATG GCT TGC AAT TGT CAG TTG ATG CAG GAT ACA CCA CTC CTC	290
	Met Ala Cys Asn Cys Gln Leu Met Gln Asp Thr Pro Leu Leu	
	1 5 10	
20	AAG TTT CCA TGT CCA AGG CTC AAT CTT CTC TTT GTG CTG CTG ATT CGT	338
	Lys Phe Pro Cys Pro Arg Leu Asn Leu Leu Phe Val Leu Leu Ile Arg	
	15 20 25 30	
25	CTT TCA CAA GTG TCT TCA GAT GTT GAT GAA CAA CTG TCC AAG TCA GTG	386
	Leu Ser Gln Val Ser Ser Asp Val Asp Glu Gln Leu Ser Lys Ser Val	
	35 40 45	
30	AAA GAT AAG GTA TTG CTG CCT TGC CGT TAC AAC TCT CCT CAT GAA GAT	434
	Lys Asp Lys Val Leu Leu Pro Cys Arg Tyr Asn Ser Pro His Glu Asp	
	50 55 60	
	GAG TCT GAA GAC CGA ATC TAC TGG CAA AAA CAT GAC AAA GTG GTG CTG	482
	Glu Ser Glu Asp Arg Ile Tyr Trp Gln Lys His Asp Lys Val Val Leu	
	65 70 75	
35	TCT GTC ATT GCT GGG AAA CTA AAA GTG TGG CCC GAG TAT AAG AAC CGG	530
	Ser Val Ile Ala Gly Lys Leu Lys Val Trp Pro Glu Tyr Lys Asn Arg	
	80 85 90	
40	ACT TTA TAT GAC AAC ACT ACC TAC TCT CTT ATC ATC CTG GGC CTG GTC	578
	Thr Leu Tyr Asp Asn Thr Thr Tyr Ser Leu Ile Ile Leu Gly Leu Val	
	95 100 105 110	
45	CTT TCA GAC CGG GGC ACA TAC AGC TGT GTC GTT CAA AAG AAG GAA AGA	626
	Leu Ser Asp Arg Gly Thr Tyr Ser Cys Val Val Gln Lys Lys Glu Arg	
	115 120 125	
50	GGA ACG TAT GAA GTT AAA CAC TTG GCT TTA GTA AAG TTG TCC ATC AAA	674
	Gly Thr Tyr Glu Val Lys His Leu Ala Leu Val Lys Leu Ser Ile Lys	
	130 135 140	
	GCT GAC TTC TCT ACC CCC AAC ATA ACT GAG TCT GGA AAC CCA TCT GCA	722
	Ala Asp Phe Ser Thr Pro Asn Ile Thr Glu Ser Gly Asn Pro Ser Ala	
	145 150 155	
55	GAC ACT AAA AGG ATT ACC TGC TTT GCT TCC GGG GGT TTC CCA AAG CCT	770
	Asp Thr Lys Arg Ile Thr Cys Phe Ala Ser Gly Gly Phe Pro Lys Pro	
	160 165 170	

960525-08096

	CGC TTC TCT TGG TTG GAA AAT GGA AGA GAA TTA CCT GGC ATC AAT ACG	818
	Arg Phe Ser Trp Leu Glu Asn Gly Arg Glu Leu Pro Gly Ile Asn Thr	
	175 180 185 190	
5	ACA ATT TCC CAG GAT CCT GAA TCT GAA TTG TAC ACC ATT AGT AGC CAA	866
	Thr Ile Ser Gln Asp Pro Glu Ser Glu Leu Tyr Thr Ile Ser Ser Gln	
	195 200 205	
10	CTA GAT TTC AAT ACG ACT CGC AAC CAC ACC ATT AAG TGT CTC ATT AAA	914
	Leu Asp Phe Asn Thr Thr Arg Asn His Thr Ile Lys Cys Leu Ile Lys	
	210 215 220	
15	TAT GGA GAT GCT CAC GTG TCA GAG GAC TTC ACC TGG GAA AAA CCC CCA	962
	Tyr Gly Asp Ala His Val Ser Glu Asp Phe Thr Trp Glu Lys Pro Pro	
	225 230 235	
20	GAA GAC CCT CCT GAT AGC AAG AAC ACA CTT GTG CTC TTT GGG GCA GGA	1010
	Glu Asp Pro Pro Asp Ser Lys Asn Thr Leu Val Leu Phe Gly Ala Gly	
	240 245 250	
25	TTC GGC GCA GTA ATA ACA GTC GTC GTC ATC GTT GTC ATC ATC AAA TGC	1058
	Phe Gly Ala Val Ile Thr Val Val Val Ile Val Val Ile Ile Lys Cys	
	255 260 265 270	
30	TTC TGT AAG CAC AGA AGC TGT TTC AGA AGA AAT GAG GCA AGC AGA GAA	1106
	Phe Cys Lys His Arg Ser Cys Phe Arg Arg Asn Glu Ala Ser Arg Glu	
	275 280 285	
35	ACA AAC AAC AGC CTT ACC TTC GGG CCT GAA GAA GCA TTA GCT GAA CAG	1154
	Thr Asn Asn Ser Leu Thr Phe Gly Pro Glu Glu Ala Leu Ala Glu Gln	
	290 295 300	
40	ACC GTC TTC CTT TAGTTCTTCT CTGTCCATGT GGGATACATG GTATTATGTG	1206
	Thr Val Phe Leu	
	305	
45	GCTCATGAGG TACAATCTTT CTTTCAGCAC CGTGCTAGCT GATCTTTTCGG ACAACTTGAC	1266
	ACAAGATAGA GTTAAGTGGG AAGAGAAAGC CTTGAATGAG GATTTCTTTC CATCAGGAAG	1326
	CTACGGGCAA GTTTGCTGGG CCTTTGATTG CTTGATGACT GAAGTGGAAA GGCTGAGCCC	1386
	ACTGTGGGTG GTGCTAGCCC TGGGCAGGGG CAGGTGACCC TGGGTGGTAT AAGAAAAAGA	1446
50	GCTGTCACTA AAAGGAGAGG TGCCTAGTCT TACTGCAACT TGATATGTCA TGTTTGGTTG	1506
	GTGTCTGTGG GAGGCCTGCC CTTTTCTGAA GAGAAGTGGT GGGAGAGTGG ATGGGGTGGG	1566
	GGCAGAGGAA AAGTGGGGGA GAGGCCTGG GAGGAGAGGA GGGAGGGGGA CGGGGTGGGG	1626
	GTGGGGAAAA CTATGGTTGG GATGTAAAAA CGGATAATAA TATAAATATT AAATAAAAAG	1686
55	AGAGTATTGA GCAAAAAAAA AAAAAAAAAA	1716

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 306 amino acids

9502576 52520280

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

5 Met Ala Cys Asn Cys Gln Leu Met Gln Asp Thr Pro Leu Leu Lys Phe
 1 5 10 15
 10 Pro Cys Pro Arg Leu Ile Leu Leu Phe Val Leu Leu Ile Arg Leu Ser
 20 25 30
 15 Gln Val Ser Ser Asp Val Asp Glu Gln Leu Ser Lys Ser Val Lys Asp
 35 40 45
 Lys Val Leu Leu Pro Cys Arg Tyr Asn Ser Pro His Glu Asp Glu Ser
 50 55 60
 20 Glu Asp Arg Ile Tyr Trp Gln Lys His Asp Lys Val Val Leu Ser Val
 65 70 75 80
 Ile Ala Gly Lys Leu Lys Val Trp Pro Glu Tyr Lys Asn Arg Thr Leu
 85 90 95
 25 Tyr Asp Asn Thr Thr Tyr Ser Leu Ile Ile Leu Gly Leu Val Leu Ser
 100 105 110
 30 Asp Arg Gly Thr Tyr Ser Cys Val Val Gln Lys Lys Glu Arg Gly Thr
 115 120 125
 Tyr Glu Val Lys His Leu Ala Leu Val Lys Leu Ser Ile Lys Ala Asp
 130 135 140
 35 Phe Ser Thr Pro Asn Ile Thr Glu Ser Gly Asn Pro Ser Ala Asp Thr
 145 150 155 160
 Lys Arg Ile Thr Cys Phe Ala Ser Gly Gly Phe Pro Lys Pro Arg Phe
 165 170 175
 40 Ser Trp Leu Glu Asn Gly Arg Glu Leu Pro Gly Ile Asn Thr Thr Ile
 180 185 190
 45 Ser Gln Asp Pro Glu Ser Glu Leu Tyr Thr Ile Ser Ser Gln Leu Asp
 195 200 205
 Phe Asn Thr Thr Arg Asn His Thr Ile Lys Cys Leu Ile Lys Tyr Gly
 210 215 220
 50 Asp Ala His Val Ser Glu Asp Phe Thr Trp Glu Lys Pro Pro Glu Asp
 225 230 235 240
 Pro Pro Asp Ser Lys Asn Thr Leu Val Leu Phe Gly Ala Gly Phe Gly
 245 250 255
 55 Ala Val Ile Thr Val Val Val Ile Val Val Ile Ile Lys Cys Phe Cys
 260 265 270

0870255-080
 960E90-52520480

Lys His Arg Ser Cys Phe Arg Arg Asn Glu Ala Ser Arg Glu Thr Asn
 275 280 285

Asn Ser Leu Thr Phe Gly Pro Glu Glu Ala Leu Ala Glu Gln Thr Val
 290 295 300

Phe Leu
 305

10 (2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1491 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 318..1181

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

CCAAAGAAAA AGTGATTTGT CATTGCTTTA TAGACTGTAA GAAGAGAACA TCTCAGAAGT 60
 GGAGTCTTAC CCTGAAATCA AAGGATTTAA AGAAAAAGTG GAATTTTTCT TCAGCAAGCT 120
 GTGAAACTAA ATCCACAACC TTTGGAGACC CAGGAACACC CTCCAATCTC TGTGTGTTTT 180
 GTAAACATCA CTGGAGGGTC TTCTACGTGA GCAATTGGAT TGTCATCAGC CCTGCCTGTT 240
 TTGCACCTGG GAAGTGCCCT GGTCTTACTT GGGTCCAAAT TGTGGCTTT CACTTTTGAC 300
 CCTAAGCATC TGAAGCC ATG GGC CAC ACA CGG AGG CAG GGA ACA TCA CCA 350
 Met Gly His Thr Arg Arg Gln Gly Thr Ser Pro
 1 5 10
 TCC AAG TGT CCA TAC CTG AAT TTC TTT CAG CTC TTG GTG CTG GCT GGT 398
 Ser Lys Cys Pro Tyr Leu Asn Phe Phe Gln Leu Leu Val Leu Ala Gly
 15 20 25
 CTT TCT CAC TTC TGT TCA GGT GTT ATC CAC GTG ACC AAG GAA GTG AAA 446
 Leu Ser His Phe Cys Ser Gly Val Ile His Val Thr Lys Glu Val Lys
 30 35 40
 GAA GTG GCA ACG CTG TCC TGT GGT CAC AAT GTT TCT GTT GAA GAG CTG 494
 Glu Val Ala Thr Leu Ser Cys Gly His Asn Val Ser Val Glu Glu Leu
 45 50 55
 GCA CAA ACT CGC ATC TAC TGG CAA AAG GAG AAG AAA ATG GTG CTG ACT 542
 Ala Gln Thr Arg Ile Tyr Trp Gln Lys Glu Lys Lys Met Val Leu Thr
 60 65 70 75

960300 52520230

	ATG ATG TCT GGG GAC ATG AAT ATA TGG CCC GAG TAC AAG AAC CGG ACC	590
	Met Met Ser Gly Asp Met Asn Ile Trp Pro Glu Tyr Lys Asn Arg Thr	
	80 85 90	
5	ATC TTT GAT ATC ACT AAT AAC CTC TCC ATT GTG ATC CTG GCT CTG CGC	638
	Ile Phe Asp Ile Thr Asn Asn Leu Ser Ile Val Ile Leu Ala Leu Arg	
	95 100 105	
10	CCA TCT GAC GAG GGC ACA TAC GAG TGT GTT GTT CTG AAG TAT GAA AAA	686
	Pro Ser Asp Glu Gly Thr Tyr Glu Cys Val Val Leu Lys Tyr Glu Lys	
	110 115 120	
15	GAC GCT TTC AAG CGG GAA CAC CTG GCT GAA GTG ACG TTA TCA GTC AAA	734
	Asp Ala Phe Lys Arg Glu His Leu Ala Glu Val Thr Leu Ser Val Lys	
	125 130 135	
20	GCT GAC TTC CCT ACA CCT AGT ATA TCT GAC TTT GAA ATT CCA ACT TCT	782
	Ala Asp Phe Pro Thr Pro Ser Ile Ser Asp Phe Glu Ile Pro Thr Ser	
	140 145 150 155	
25	AAT ATT AGA AGG ATA ATT TGC TCA ACC TCT GGA GGT TTT CCA GAG CCT	830
	Asn Ile Arg Arg Ile Ile Cys Ser Thr Ser Gly Gly Phe Pro Glu Pro	
	160 165 170	
30	CAC CTC TCC TGG TTG GAA AAT GGA GAA GAA TTA AAT GCC ATC AAC ACA	878
	His Leu Ser Trp Leu Glu Asn Gly Glu Glu Leu Asn Ala Ile Asn Thr	
	175 180 185	
35	ACA GTT TCC CAA GAT CCT GAA ACT GAG CTC TAT GCT GTT AGC AGC AAA	926
	Thr Val Ser Gln Asp Pro Glu Thr Glu Leu Tyr Ala Val Ser Ser Lys	
	190 195 200	
40	CTG GAT TTC AAT ATG ACA ACC AAC CAC AGC TTC ATG TGT CTC ATC AAG	974
	Leu Asp Phe Asn Met Thr Thr Asn His Ser Phe Met Cys Leu Ile Lys	
	205 210 215	
45	TAT GGA CAT TTA AGA GTG AAT CAG ACC TTC AAC TGG AAT ACA ACC AAG	1022
	Tyr Gly His Leu Arg Val Asn Gln Thr Phe Asn Trp Asn Thr Thr Lys	
	220 225 230 235	
50	CAA GAG CAT TTT CCT GAT AAC CTG CTC CCA TCC TGG GCC ATT ACC TTA	1070
	Gln Glu His Phe Pro Asp Asn Leu Leu Pro Ser Trp Ala Ile Thr Leu	
	240 245 250	
55	ATC TCA GTA AAT GGA ATT TTT GTG ATA TGC TGC CTG ACC TAC TGC TTT	1118
	Ile Ser Val Asn Gly Ile Phe Val Ile Cys Cys Leu Thr Tyr Cys Phe	
	255 260 265	
60	GCC CCA AGA TGC AGA GAG AGA AGG AGG AAT GAG AGA TTG AGA AGG GAA	1166
	Ala Pro Arg Cys Arg Glu Arg Arg Arg Asn Glu Arg Leu Arg Arg Glu	
	270 275 280	
65	AGT GTA CGC CCT GTA TAACAGTGTC CGCAGAAGCA AGGGGCTGAA AAGATCTGAA	1221
	Ser Val Arg Pro Val	
	285	
70	GGTAGCCTCC GTCATCTCTT CTGGGATACA TGGATCGTGG GGATCATGAG GCATTCTTCC	1281
75	CTTAACAAAT TTAAGCTGTT TTACCCACTA CCTCACCTTC TTAAAAACCT CTTTCAGATT	1341

95023859 WO 95/23859

AAGCTGAACA GTTACAAGAT GGCTGGCATC CCTCTCCTTT CTCCCCATAT GCAATTGCT 1401
 TAATGTAACC TCTTCTTTTG CCATGTTTCC ATTCTGCCAT CTTGAATTGT CTTGTCAGCC 1461
 AATTCATTAT CTATTAAACA CTAATTTGAG 1491

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 288 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

20 Met Gly His Thr Arg Arg Gln Gly Thr Ser Pro Ser Lys Cys Pro Tyr
 1 5 10 15
 Leu Asn Phe Phe Gln Leu Leu Val Leu Ala Gly Leu Ser His Phe Cys
 20 25 30
 25 Ser Gly Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu
 35 40 45
 30 Ser Cys Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile
 50 55 60
 Tyr Trp Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp
 65 70 75 80
 35 Met Asn Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr
 85 90 95
 Asn Asn Leu Ser Ile Val Ile Leu Ala Leu Arg Pro Ser Asp Glu Gly
 100 105 110
 40 Thr Tyr Glu Cys Val Val Leu Lys Tyr Glu Lys Asp Ala Phe Lys Arg
 115 120 125
 45 Glu His Leu Ala Glu Val Thr Leu Ser Val Lys Ala Asp Phe Pro Thr
 130 135 140
 Pro Ser Ile Ser Asp Phe Glu Ile Pro Thr Ser Asn Ile Arg Arg Ile
 145 150 155 160
 50 Ile Cys Ser Thr Ser Gly Gly Phe Pro Glu Pro His Leu Ser Trp Leu
 165 170 175
 Glu Asn Gly Glu Glu Leu Asn Ala Ile Asn Thr Thr Val Ser Gln Asp
 180 185 190
 55 Pro Glu Thr Glu Leu Tyr Ala Val Ser Ser Lys Leu Asp Phe Asn Met
 195 200 205

950520 52520/230

- 70 -

Thr Thr Asn His Ser Phe Met Cys Leu Ile Lys Tyr Gly His Leu Arg
 210 215 220

5 Val Asn Gln Thr Phe Asn Trp Asn Thr Thr Lys Gln Glu His Phe Pro
 225 230 235 240

Asp Asn Leu Leu Pro Ser Trp Ala Ile Thr Leu Ile Ser Val Asn Gly
 245 250 255

10 Ile Phe Val Ile Cys Cys Leu Thr Tyr Cys Phe Ala Pro Arg Cys Arg
 260 265 270

Glu Arg Arg Arg Asn Glu Arg Leu Arg Arg Glu Ser Val Arg Pro Val
 275 280 285

15

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1151 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
 (B) LOCATION: 99..1025

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

35 GGAGCAAGCA GACGCGTAAG AGTGGCTCCT GTAGGCAGCA CGGACTTGAA CAACCAGACT 60
 CCTGTAGACG TGTTCCAGAA CTTACGGAAG CACCCACG ATG GAC CCC AGA TGC 113
 Met Asp Pro Arg Cys
 1 5

40 ACC ATG GGC TTG GCA ATC CTT ATC TTT GTG ACA GTC TTG CTG ATC TCA 161
 Thr Met Gly Leu Ala Ile Leu Ile Phe Val Thr Val Leu Leu Ile Ser
 10 15 20

45 GAT GCT GTT TCC GTG GAG ACG CAA GCT TAT TTC AAT GGG ACT GCA TAT 209
 Asp Ala Val Ser Val Glu Thr Gln Ala Tyr Phe Asn Gly Thr Ala Tyr
 25 30 35

50 CTG CCG TGC CCA TTT ACA AAG GCT CAA AAC ATA AGC CTG AGT GAG CTG 257
 Leu Pro Cys Pro Phe Thr Lys Ala Gln Asn Ile Ser Leu Ser Glu Leu
 40 45 50

55 GTA GTA TTT TGG CAG GAC CAG CAA AAG TTG GTT CTG TAC GAG CAC TAT 305
 Val Val Phe Trp Gln Asp Gln Gln Lys Leu Val Leu Tyr Glu His Tyr
 55 60 65

TTG GGC ACA GAG AAA CTT GAT AGT GTG AAT GCC AAG TAC CTG GGC CGC 353
 Leu Gly Thr Glu Lys Leu Asp Ser Val Asn Ala Lys Tyr Leu Gly Arg
 70 75 80 85

360E30' 52520/230

5	ACG AGC TTT GAC AGG AAC AAC TGG ACT CTA CGA CTT CAC AAT GTT CAG	401
	Thr Ser Phe Asp Arg Asn Asn Trp Thr Leu Arg Leu His Asn Val Gln	
	90 95 100	
	ATC AAG GAC ATG GGC TCG TAT GAT TGT TTT ATA CAA AAA AAG CCA CCC	449
	Ile Lys Asp Met Gly Ser Tyr Asp Cys Phe Ile Gln Lys Lys Pro Pro	
10	105 110 115	
	ACA GGA TCA ATT ATC CTC CAA CAG ACA TTA ACA GAA CTG TCA GTG ATC	497
	Thr Gly Ser Ile Ile Leu Gln Gln Thr Leu Thr Glu Leu Ser Val Ile	
	120 125 130	
	GCC AAC TTC AGT GAA CCT GAA ATA AAA CTG GCT CAG AAT GTA ACA GGA	545
15	Ala Asn Phe Ser Glu Pro Glu Ile Lys Leu Ala Gln Asn Val Thr Gly	
	135 140 145	
	AAT TCT GGC ATA AAT TTG ACC TGC ACG TCT AAG CAA GGT CAC CCG AAA	593
	Asn Ser Gly Ile Asn Leu Thr Cys Thr Ser Lys Gln Gly His Pro Lys	
	150 155 160 165	
20	CCT AAG AAG ATG TAT TTT CTG ATA ACT AAT TCA ACT AAT GAG TAT GGT	641
	Pro Lys Lys Met Tyr Phe Leu Ile Thr Asn Ser Thr Asn Glu Tyr Gly	
	170 175 180	
	GAT AAC ATG CAG ATA TCA CAA GAT AAT GTC ACA GAA CTG TTC AGT ATC	689
	Asp Asn Met Gln Ile Ser Gln Asp Asn Val Thr Glu Leu Phe Ser Ile	
25	185 190 195	
	TCC AAC AGC CTC TCT CTT TCA TTC CCG GAT GGT GTG TGG CAT ATG ACC	737
	Ser Asn Ser Leu Ser Leu Ser Phe Pro Asp Gly Val Trp His Met Thr	
	200 205 210	
	GTT GTG TGT GTT CTG GAA ACG GAG TCA ATG AAG ATT TCC TCC AAA CCT	785
30	Val Val Cys Val Leu Glu Thr Glu Ser Met Lys Ile Ser Ser Lys Pro	
	215 220 225	
	CTC AAT TTC ACT CAA GAG TTT CCA TCT CCT CAA ACG TAT TGG AAG GAG	833
	Leu Asn Phe Thr Gln Glu Phe Pro Ser Pro Gln Thr Tyr Trp Lys Glu	
	230 235 240 245	
35	ATT ACA GCT TCA GTT ACT GTG GCC CTC CTC CTT GTG ATG CTG CTC ATC	881
	Ile Thr Ala Ser Val Thr Val Ala Leu Leu Leu Val Met Leu Leu Ile	
	250 255 260	
	ATT GTA TGT CAC AAG AAG CCG AAT CAG CCT AGC AGG CCC AGC AAC ACA	929
	Ile Val Cys His Lys Lys Pro Asn Gln Pro Ser Arg Pro Ser Asn Thr	
40	265 270 275	
	GCC TCT AAG TTA GAG CGG GAT AGT AAC GCT GAC AGA GAG ACT ATC AAC	977
	Ala Ser Lys Leu Glu Arg Asp Ser Asn Ala Asp Arg Glu Thr Ile Asn	
	280 285 290	
	CTG AAG GAA CTT GAA CCC CAA ATT GCT TCA GCA AAA CCA AAT GCA GAG	1025
45	Leu Lys Glu Leu Glu Pro Gln Ile Ala Ser Ala Lys Pro Asn Ala Glu	
	295 300 305	
	TGAAGGCAGT GAGAGCCTGA GGAAAGAGTT AAAAATTGCT TTGCCTGAAA TAAGAAGTGC	1085

52330230

AGAGTTTCTC AGAATTCAAA AATGTTCTCA GCTGATTGGA ATTCTACAGT TGAATAATTA	1145
AAGAAC	1151

5

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 309 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

Met Asp Pro Arg Cys Thr Met Gly Leu Ala Ile Leu Ile Phe Val Thr
1 5 10 15

20 Val Leu Leu Ile Ser Asp Ala Val Ser Val Glu Thr Gln Ala Tyr Phe
20 25 30

Asn Gly Thr Ala Tyr Leu Pro Cys Pro Phe Thr Lys Ala Gln Asn Ile
35 40 45

25

Ser Leu Ser Glu Leu Val Val Phe Trp Gln Asp Gln Gln Lys Leu Val
50 55 60

30

Leu Tyr Glu His Tyr Leu Gly Thr Glu Lys Leu Asp Ser Val Asn Ala
65 70 75 80

Lys Tyr Leu Gly Arg Thr Ser Phe Asp Arg Asn Asn Trp Thr Leu Arg
85 90 95

35

Leu His Asn Val Gln Ile Lys Asp Met Gly Ser Tyr Asp Cys Phe Ile
100 105 110

Gln Lys Lys Pro Pro Thr Gly Ser Ile Ile Leu Gln Gln Thr Leu Thr
115 120 125

40

Glu Leu Ser Val Ile Ala Asn Phe Ser Glu Pro Glu Ile Lys Leu Ala
130 135 140

45

Gln Asn Val Thr Gly Asn Ser Gly Ile Asn Leu Thr Cys Thr Ser Lys
145 150 155 160

Gln Gly His Pro Lys Pro Lys Lys Met Tyr Phe Leu Ile Thr Asn Ser
165 170 175

50

Thr Asn Glu Tyr Gly Asp Asn Met Gln Ile Ser Gln Asp Asn Val Thr
180 185 190

Glu Leu Phe Ser Ile Ser Asn Ser Leu Ser Leu Ser Phe Pro Asp Gly
195 200 205

55

Val Trp His Met Thr Val Val Cys Val Leu Glu Thr Glu Ser Met Lys
210 215 220

Ile Ser Ser Lys Pro Leu Asn Phe Thr Gln Glu Phe Pro Ser Pro Gln
225 230 235 240

Thr Tyr Trp Lys Glu Ile Thr Ala Ser Val Thr Val Ala Leu Leu Leu
245 250 255

Val Met Leu Leu Ile Ile Val Cys His Lys Lys Pro Asn Gln Pro Ser
260 265 270

Arg Pro Ser Asn Thr Ala Ser Lys Leu Glu Arg Asp Ser Asn Ala Asp
275 280 285

Arg Glu Thr Ile Asn Leu Lys Glu Leu Glu Pro Gln Ile Ala Ser Ala
290 295 300

Lys Pro Asn Ala Glu
305

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1120 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 107..1093

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

CACAGGGTGA AAGCTTTGCT TCTCTGCTGC TGTAACAGGG ACTAGCACAG ACACACGGAT 60

GAGTGGGGTC ATTTCCAGAT ATTAGGTCAC AGCAGAAGCA GCCAAA ATG GAT CCC 115
Met Asp Pro
1

CAG TGC ACT ATG GGA CTG AGT AAC ATT CTC TTT GTG ATG GCC TTC CTG 163
Gln Cys Thr Met Gly Leu Ser Asn Ile Leu Phe Val Met Ala Phe Leu
5 10 15

CTC TCT GGT GCT GCT CCT CTG AAG ATT CAA GCT TAT TTC AAT GAG ACT 211
Leu Ser Gly Ala Ala Pro Leu Lys Ile Gln Ala Tyr Phe Asn Glu Thr
20 25 30 35

GCA GAC CTG CCA TGC CAA TTT GCA AAC TCT CAA AAC CAA AGC CTG AGT 259
Ala Asp Leu Pro Cys Gln Phe Ala Asn Ser Gln Asn Gln Ser Leu Ser
40 45 50

GAG CTA GTA GTA TTT TGG CAG GAC CAG GAA AAC TTG GTT CTG AAT GAG 307
Glu Leu Val Val Phe Trp Gln Asp Gln Glu Asn Leu Val Leu Asn Glu
55 60 65

52520280

	GTA TAC TTA GGC AAA GAG AAA TTT GAC AGT GTT CAT TCC AAG TAT ATG	355
	Val Tyr Leu Gly Lys Glu Lys Phe Asp Ser Val His Ser Lys Tyr Met	
	70 75 80	
5	GGC CGC ACA AGT TTT GAT TCG GAC AGT TGG ACC CTG AGA CTT CAC AAT	403
	Gly Arg Thr Ser Phe Asp Ser Asp Ser Trp Thr Leu Arg Leu His Asn	
	85 90 95	
10	CTT CAG ATC AAG GAC AAG GGC TTG TAT CAA TGT ATC ATC CAT CAC AAA	451
	Leu Gln Ile Lys Asp Lys Gly Leu Tyr Gln Cys Ile Ile His His Lys	
	100 105 110 115	
15	AAG CCC ACA GGA ATG ATT CGC ATC CAC CAG ATG AAT TCT GAA CTG TCA	499
	Lys Pro Thr Gly Met Ile Arg Ile His Gln Met Asn Ser Glu Leu Ser	
	120 125 130	
20	GTG CTT GCT AAC TTC AGT CAA CCT GAA ATA GTA CCA ATT TCT AAT ATA	547
	Val Leu Ala Asn Phe Ser Gln Pro Glu Ile Val Pro Ile Ser Asn Ile	
	135 140 145	
25	ACA GAA AAT GTG TAC ATA AAT TTG ACC TGC TCA TCT ATA CAC GGT TAC	595
	Thr Glu Asn Val Tyr Ile Asn Leu Thr Cys Ser Ser Ile His Gly Tyr	
	150 155 160	
30	CCA GAA CCT AAG AAG ATG AGT GTT TTG CTA AGA ACC AAG AAT TCA ACT	643
	Pro Glu Pro Lys Lys Met Ser Val Leu Leu Arg Thr Lys Asn Ser Thr	
	165 170 175	
35	ATC GAG TAT GAT GGT ATT ATG CAG AAA TCT CAA GAT AAT GTC ACA GAA	691
	Ile Glu Tyr Asp Gly Ile Met Gln Lys Ser Gln Asp Asn Val Thr Glu	
	180 185 190 195	
40	CTG TAC GAC GTT TCC ATC AGC TTG TCT GTT TCA TTC CCT GAT GTT ACG	739
	Leu Tyr Asp Val Ser Ile Ser Leu Ser Val Ser Phe Pro Asp Val Thr	
	200 205 210	
45	AGC AAT ATG ACC ATC TTC TGT ATT CTG GAA ACT GAC AAG ACG CGG CTT	787
	Ser Asn Met Thr Ile Phe Cys Ile Leu Glu Thr Asp Lys Thr Arg Leu	
	215 220 225	
50	TTA TCT TCA CCT TTC TCT ATA GAG CTT GAG GAC CCT CAG CCT CCC CCA	835
	Leu Ser Ser Pro Phe Ser Ile Glu Leu Glu Asp Pro Gln Pro Pro Pro	
	230 235 240	
55	GAC CAC ATT CCT TGG ATT ACA GCT GTA CTT CCA ACA GTT ATT ATA TGT	883
	Asp His Ile Pro Trp Ile Thr Ala Val Leu Pro Thr Val Ile Ile Cys	
	245 250 255	
60	GTG ATG GTT TTC TGT CTA ATT CTA TGG AAA TGG AAG AAG AAG AAG CGG	931
	Val Met Val Phe Cys Leu Ile Leu Trp Lys Trp Lys Lys Lys Lys Arg	
	260 265 270 275	
65	CCT CGC AAC TCT TAT AAA TGT GGA ACC AAC ACA ATG GAG AGG GAA GAG	979
	Pro Arg Asn Ser Tyr Lys Cys Gly Thr Asn Thr Met Glu Arg Glu Glu	
	280 285 290	
70	AGT GAA CAG ACC AAG AAA AGA GAA AAA ATC CAT ATA CCT GAA AGA TCT	1027
	Ser Glu Gln Thr Lys Lys Arg Glu Lys Ile His Ile Pro Glu Arg Ser	
	295 300 305	

960E80 92520280

GAT GAA GCC CAG CGT GTT TTT AAA AGT TCG AAG ACA TCT TCA TGC GAC 1075
 Asp Glu Ala Gln Arg Val Phe Lys Ser Ser Lys Thr Ser Ser Cys Asp
 310 315 320

5

AAA AGT GAT ACA TGT TTT TAATTAAAGA GTAAAGCCCA AAAAAAA 1120
 Lys Ser Asp Thr Cys Phe
 325

10

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:

15

- (A) LENGTH: 329 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

Met Asp Pro Gln Cys Thr Met Gly Leu Ser Asn Ile Leu Phe Val Met
 1 5 10 15

25

Ala Phe Leu Leu Ser Gly Ala Ala Pro Leu Lys Ile Gln Ala Tyr Phe
 20 25 30

Asn Glu Thr Ala Asp Leu Pro Cys Gln Phe Ala Asn Ser Gln Asn Gln
 35 40 45

30

Ser Leu Ser Glu Leu Val Val Phe Trp Gln Asp Gln Glu Asn Leu Val
 50 55 60

35

Leu Asn Glu Val Tyr Leu Gly Lys Glu Lys Phe Asp Ser Val His Ser
 65 70 75 80

Lys Tyr Met Gly Arg Thr Ser Phe Asp Ser Asp Ser Trp Thr Leu Arg
 85 90 95

40

Leu His Asn Leu Gln Ile Lys Asp Lys Gly Leu Tyr Gln Cys Ile Ile
 100 105 110

His His Lys Lys Pro Thr Gly Met Ile Arg Ile His Gln Met Asn Ser
 115 120 125

45

Glu Leu Ser Val Leu Ala Asn Phe Ser Gln Pro Glu Ile Val Pro Ile
 130 135 140

50

Ser Asn Ile Thr Glu Asn Val Tyr Ile Asn Leu Thr Cys Ser Ser Ile
 145 150 155 160

His Gly Tyr Pro Glu Pro Lys Lys Met Ser Val Leu Leu Arg Thr Lys
 165 170 175

55

Asn Ser Thr Ile Glu Tyr Asp Gly Ile Met Gln Lys Ser Gln Asp Asn
 180 185 190

Val Thr Glu Leu Tyr Asp Val Ser Ile Ser Leu Ser Val Ser Phe Pro
 195 200 205

52520280

Asp Val Thr Ser Asn Met Thr Ile Phe Cys Ile Leu Glu Thr Asp Lys
210 215 220

5 Thr Arg Leu Leu Ser Ser Pro Phe Ser Ile Glu Leu Glu Asp Pro Gln
225 230 235 240

Pro Pro Pro Asp His Ile Pro Trp Ile Thr Ala Val Leu Pro Thr Val
245 250 255

10

Ile Ile Cys Val Met Val Phe Cys Leu Ile Leu Trp Lys Trp Lys Lys
260 265 270

15

Lys Lys Arg Pro Arg Asn Ser Tyr Lys Cys Gly Thr Asn Thr Met Glu
275 280 285

Arg Glu Glu Ser Glu Gln Thr Lys Lys Arg Glu Lys Ile His Ile Pro
290 295 300

20

Glu Arg Ser Asp Glu Ala Gln Arg Val Phe Lys Ser Ser Lys Thr Ser
305 310 315 320

Ser Cys Asp Lys Ser Asp Thr Cys Phe
325

25

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:

30

- (A) LENGTH: 1161 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

35

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 148..1134

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

45

AGGAGCCTTA GGAGGTACGG GGAGCTCGCA AATACTCCTT TTGGTTTATT CTTACCACCT 60

TGCTTCTGTG TTCCTTGGGA ATGCTGCTGT GCTTATGCAT CTGGTCTCTT TTTGGAGCTA 120

CAGTGGACAG GCATTTGTGA CAGCACT ATG GAT CCC CAG TGC ACT ATG GGA 171
Met Asp Pro Gln Cys Thr Met Gly

50

1

5

CTG AGT AAC ATT CTC TTT GTG ATG GCC TTC CTG CTC TCT GGT GCT GCT 219
Leu Ser Asn Ile Leu Phe Val Met Ala Phe Leu Leu Ser Gly Ala Ala
10 15 20

55

CCT CTG AAG ATT CAA GCT TAT TTC AAT GAG ACT GCA GAC CTG CCA TGC 267
Pro Leu Lys Ile Gln Ala Tyr Phe Asn Glu Thr Ala Asp Leu Pro Cys
25 30 35 40

560E30 52520/230

	CAA	TTT	GCA	AAC	TCT	CAA	AAC	CAA	AGC	CTG	AGT	GAG	CTA	GTA	GTA	TTT	315
	Gln	Phe	Ala	Asn	Ser	Gln	Asn	Gln	Ser	Leu	Ser	Glu	Leu	Val	Val	Phe	
				45					50						55		
5	TGG	CAG	GAC	CAG	GAA	AAC	TTG	GTT	CTG	AAT	GAG	GTA	TAC	TTA	GGC	AAA	363
	Trp	Gln	Asp	Gln	Glu	Asn	Leu	Val	Leu	Asn	Glu	Val	Tyr	Leu	Gly	Lys	
				60					65						70		
10	GAG	AAA	TTT	GAC	AGT	GTT	CAT	TCC	AAG	TAT	ATG	GGC	CGC	ACA	AGT	TTT	411
	Glu	Lys	Phe	Asp	Ser	Val	His	Ser	Lys	Tyr	Met	Gly	Arg	Thr	Ser	Phe	
				75					80						85		
15	GAT	TCG	GAC	AGT	TGG	ACC	CTG	AGA	CTT	CAC	AAT	CTT	CAG	ATC	AAG	GAC	459
	Asp	Ser	Asp	Ser	Trp	Thr	Leu	Arg	Leu	His	Asn	Leu	Gln	Ile	Lys	Asp	
		90						95					100				
20	AAG	GGC	TTG	TAT	CAA	TGT	ATC	ATC	CAT	CAC	AAA	AAG	CCC	ACA	GGA	ATG	507
	Lys	Gly	Leu	Tyr	Gln	Cys	Ile	Ile	His	His	Lys	Lys	Pro	Thr	Gly	Met	
		105				110					115					120	
25	ATT	CGC	ATC	CAC	CAG	ATG	AAT	TCT	GAA	CTG	TCA	GTG	CTT	GCT	AAC	TTC	555
	Ile	Arg	Ile	His	Gln	Met	Asn	Ser	Glu	Leu	Ser	Val	Leu	Ala	Asn	Phe	
					125					130					135		
30	AGT	CAA	CCT	GAA	ATA	GTA	CCA	ATT	TCT	AAT	ATA	ACA	GAA	AAT	GTG	TAC	603
	Ser	Gln	Pro	Glu	Ile	Val	Pro	Ile	Ser	Asn	Ile	Thr	Glu	Asn	Val	Tyr	
				140					145						150		
35	ATA	AAT	TTG	ACC	TGC	TCA	TCT	ATA	CAC	GGT	TAC	CCA	GAA	CCT	AAG	AAG	651
	Ile	Asn	Leu	Thr	Cys	Ser	Ser	Ile	His	Gly	Tyr	Pro	Glu	Pro	Lys	Lys	
				155					160						165		
40	ATG	AGT	GTT	TTG	CTA	AGA	ACC	AAG	AAT	TCA	ACT	ATC	GAG	TAT	GAT	GGT	699
	Met	Ser	Val	Leu	Leu	Arg	Thr	Lys	Asn	Ser	Thr	Ile	Glu	Tyr	Asp	Gly	
		170						175					180				
45	ATT	ATG	CAG	AAA	TCT	CAA	GAT	AAT	GTC	ACA	GAA	CTG	TAC	GAC	GTT	TCC	747
	Ile	Met	Gln	Lys	Ser	Gln	Asp	Asn	Val	Thr	Glu	Leu	Tyr	Asp	Val	Ser	
					185			190				195				200	
50	ATC	AGC	TTG	TCT	GTT	TCA	TTC	CCT	GAT	GTT	ACG	AGC	AAT	ATG	ACC	ATC	795
	Ile	Ser	Leu	Ser	Val	Ser	Phe	Pro	Asp	Val	Thr	Ser	Asn	Met	Thr	Ile	
					205					210					215		
55	TTC	TGT	ATT	CTG	GAA	ACT	GAC	AAG	ACG	CGG	CTT	TTA	TCT	TCA	CCT	TTC	843
	Phe	Cys	Ile	Leu	Glu	Thr	Asp	Lys	Thr	Arg	Leu	Leu	Ser	Ser	Pro	Phe	
				220					225						230		
60	TCT	ATA	GAG	CTT	GAG	GAC	CCT	CAG	CCT	CCC	CCA	GAC	CAC	ATT	CCT	TGG	891
	Ser	Ile	Glu	Leu	Glu	Asp	Pro	Gln	Pro	Pro	Pro	Asp	His	Ile	Pro	Trp	
				235					240					245			
65	ATT	ACA	GCT	GTA	CTT	CCA	ACA	GTT	ATT	ATA	TGT	GTG	ATG	GTT	TTC	TGT	939
	Ile	Thr	Ala	Val	Leu	Pro	Thr	Val	Ile	Ile	Cys	Val	Met	Val	Phe	Cys	
				250				255							260		
70	CTA	ATT	CTA	TGG	AAA	TGG	AAG	AAG	AAG	AAG	CGG	CCT	CGC	AAC	TCT	TAT	987
	Leu	Ile	Leu	Trp	Lys	Trp	Lys	Lys	Lys	Lys	Arg	Pro	Arg	Asn	Ser	Tyr	
				265			270				275					280	

960E80 52530280



AAA TGT GGA ACC AAC ACA ATG GAG AGG GAA GAG AGT GAA CAG ACC AAG 1035
Lys Cys Gly Thr Asn Thr Met Glu Arg Glu Glu Ser Glu Gln Thr Lys
285 290 295

5

AAA AGA GAA AAA ATC CAT ATA CCT GAA AGA TCT GAT GAA GCC CAG CGT 1083
Lys Arg Glu Lys Ile His Ile Pro Glu Arg Ser Asp Glu Ala Gln Arg
300 305 310

10 GTT TTT AAA AGT TCG AAG ACA TCT TCA TGC GAC AAA AGT GAT ACA TGT 1131
Val Phe Lys Ser Ser Lys Thr Ser Ser Cys Asp Lys Ser Asp Thr Cys
315 320 325

15 TTT TAATTAAAGA GTAAAGCCCA AAAAAAA 1161
Phe

(2) INFORMATION FOR SEQ ID NO:25:

20

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 629 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

25

(ii) MOLECULE TYPE: cDNA

30

- ```
(ix) FEATURE:
 (A) NAME/KEY: CDS
 (B) LOCATION: 1..96
```

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

AGA AGC TGT TTC AGA AGA AAT GAG GCA AGC AGA GAA ACA AAC AAC AGC 48  
Arg Ser Cys Phe Arg Arg Asn Glu Ala Ser Arg Glu Thr Asn Asn Ser  
1 5 10 15

40

CTT ACC TTC GGG CTT GAA GAA GCA TTA GCT GAA CAG ACC GTC TTC CTT 96  
Leu Thr Phe Gly Pro Glu Glu Ala Leu Ala Glu Gln Thr Val Phe Leu  
20 25 30

45

TAGTTCTTCT CTGTCCATGT GGGATACATG GTATTATGTG GCTCATGAGG TACAATCTTT 156

CTTTCAGCAC CGTGCTAGCT GATCTTTCGG ACAACTTGAC ACAAGATAGA GTTAACTGGG 216

AAGAGAAAGC CTTGAATGAG GATTTCTTTC CATCAGGAAG CTACGGGCAA GTTTGCTGGG 276

50

CCTTTGATTG CTTGATGACT GAAGTGGAAA GGCTGAGCCC ACTGTGGGTG GTGCTAGAAA 336

TGGGCAGGGG CAGGTGACCC TGGGTGGTAT AAGAAAAGA GCTGTCATA AAAGGAGAGG 396

55

TGCCTAGTCT TACTGCAACT TGATATGTCA TGTTTGGTTG GTGTCTGTGG GAGGCCTGCC 456

CTTTTCTGAA GAGAAGTGGT GGGAGAGTGG ATGGGGTGGG GGCAGAGGAA AAGTGGGGGA 516

GAGGGCCTGG GAGGAGAGGA GGGAGGGGGA CGGGGTGGGG GTGGGGAAAA CTATGGTTGG 576

[illegible]

GATGTAAAAA CGGATAATAA TATAAATATT AAATAAAAAG AGAGTATTGA GCA

629

## 5 (2) INFORMATION FOR SEQ ID NO:26:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 32 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

Arg Ser Cys Phe Arg Arg Asn Glu Ala Ser Arg Glu Thr Asn Asn Ser  
1 5 10 15  
Leu Thr Phe Gly Pro Glu Glu Ala Leu Ala Glu Gln Thr Val Phe Leu  
20 25 30

## (2) INFORMATION FOR SEQ ID NO:27:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 379 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

## (ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..69

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

TGC TTT GCC CCA AGA TGC AGA GAG AGA AGG AGG AAT GAG AGA TTG AGA  
Cys Phe Ala Pro Arg Cys Arg Glu Arg Arg Arg Asn Glu Arg Leu Arg  
1 5 10 15 48  
AGG GAA AGT GTA CGC CCT GTA TAACAGTGTC CGCAGAAGCA AGGGGCTGAA  
Arg Glu Ser Val Arg Pro Val  
20 99  
AAGATCTGAA GGTAGCCTCC GTCATCTCTT CTGGGATACA TGGATCGTGG GGATCATGAG  
GCATTCTTCC CTTAACAAAT TTAAGCTGTT TTACCCACTA CCTCACCTTC TTAAAAACCT  
CTTTCAGATT AAGCTGAACA GTTACAAGAT GGCTGGCATC CCTCTCCTTT CTCCCCATAT  
GCAATTTGCT TAATGTAACC TCTTCTTTTG CCATGTTTCC ATTCTGCCAT CTTGAATTGT  
CTTGTCAGCC AATTCATTAT CTATTAAACA CTAATTTGAG  
159 219 279 339 379

## (2) INFORMATION FOR SEQ ID NO:28:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

Cys Phe Ala Pro Arg Cys Arg Glu Arg Arg Arg Asn Glu Arg Leu Arg  
 1 5 10 15  
 Arg Glu Ser Val Arg Pro Val  
 20

## (2) INFORMATION FOR SEQ ID NO:29:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 261 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: double  
 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

## (ix) FEATURE:

- (A) NAME/KEY: CDS  
 (B) LOCATION: 1..135

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

CAC AAG AAG CCG AAT CAG CCT AGC AGG CCC AGC AAC ACA GCC TCT AAG 48  
 His Lys Lys Pro Asn Gln Pro Ser Arg Pro Ser Asn Thr Ala Ser Lys  
 1 5 10 15  
 TTA GAG CGG GAT AGT AAC GCT GAC AGA GAG ACT ATC AAC CTG AAG GAA 96  
 Leu Glu Arg Asp Ser Asn Ala Asp Arg Glu Thr Ile Asn Leu Lys Glu  
 20 25 30  
 CTT GAA CCC CAA ATT GCT TCA GCA AAA CCA AAT GCA GAG TGAAGGCAGT 145  
 Leu Glu Pro Gln Ile Ala Ser Ala Lys Pro Asn Ala Glu  
 35 40 45  
 GAGAGCCTGA GGAAAGAGTT AAAAATTGCT TTGCCTGAAA TAAGAAGTGC AGAGTTTCTC 205  
 AGAATTCAAA AATGTTCTCA GCTGATTGGA ATTCTACAGT TGAATAATTA AAGAAC 261

## (2) INFORMATION FOR SEQ ID NO:30:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 45 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

0870555 093096

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

5 His Lys Lys Pro Asn Gln Pro Ser Arg Pro Ser Asn Thr Ala Ser Lys  
 1 5 10 15  
 Leu Glu Arg Asp Ser Asn Ala Asp Arg Glu Thr Ile Asn Leu Lys Glu  
 20 25 30  
 10 Leu Glu Pro Gln Ile Ala Ser Ala Lys Pro Asn Ala Glu  
 35 40 45

(2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 210 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: double  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: CDS  
 (B) LOCATION: 1..183

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

AAA TGG AAG AAG AAG AAG CGG CCT CGC AAC TCT TAT AAA TGT GGA ACC 48  
 Lys Trp Lys Lys Lys Lys Arg Pro Arg Asn Ser Tyr Lys Cys Gly Thr  
 1 5 10 15  
 35 AAC ACA ATG GAG AGG GAA GAG AGT GAA CAG ACC AAG AAA AGA GAA AAA 96  
 Asn Thr Met Glu Arg Glu Glu Ser Glu Gln Thr Lys Lys Arg Glu Lys  
 20 25 30  
 40 ATC CAT ATA CCT GAA AGA TCT GAT GAA GCC CAG CGT GTT TTT AAA AGT 144  
 Ile His Ile Pro Glu Arg Ser Asp Glu Ala Gln Arg Val Phe Lys Ser  
 35 40 45  
 45 TCG AAG ACA TCT TCA TGC GAC AAA AGT GAT ACA TGT TTT TAATTAAAGA 193  
 Ser Lys Thr Ser Ser Cys Asp Lys Ser Asp Thr Cys Phe  
 50 55 60  
 GTAAAGCCCA AAAAAAA 210

(2) INFORMATION FOR SEQ ID NO:32:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 61 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

560520 52520/80

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

Lys Trp Lys Lys Lys Lys Arg Pro Arg Asn Ser Tyr Lys Cys Gly Thr  
 1 5 10 15  
 Asn Thr Met Glu Arg Glu Glu Ser Glu Gln Thr Lys Lys Arg Glu Lys  
 20 25 30  
 Ile His Ile Pro Glu Arg Ser Asp Glu Ala Gln Arg Val Phe Lys Ser  
 35 40 45  
 Ser Lys Thr Ser Ser Cys Asp Lys Ser Asp Thr Cys Phe  
 50 55 60

## (2) INFORMATION FOR SEQ ID NO:33:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 359 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: double  
 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

## (ix) FEATURE:

- (A) NAME/KEY: CDS  
 (B) LOCATION: 249..359

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

GAGTTTATA CCTCAATAGA CTCTTACTAG TTTCTCTTTT TCAGGTTGTG AAACCTCAACC 60  
 TTCAAAGACA CTCTGTTCCA TTTCTGTGGA CTAATAGGAT CATCTTTAGC ATCTGCCGGG 120  
 TGGATGCCAT CCAGGCTTCT TTTTCTACAT CTCTGTTTCT CGATTTTTGT GAGCCTAGGA 180  
 GGTGCCTAAG CTCCATTGGC TCTAGATTCC TGGCTTTCCC CATCATGTTC TCAAAGCAT 240  
 CTGAAGCT ATG GCT TGC AAT TGT CAG TTG ATG CAG GAT ACA CCA CTC CTC 290  
 Met Ala Cys Asn Cys Gln Leu Met Gln Asp Thr Pro Leu Leu  
 1 5 10  
 AAG TTT CCA TGT CCA AGG CTC AAT CTT CTC TTT GTG CTG CTG ATT CGT 338  
 Lys Phe Pro Cys Pro Arg Leu Asn Leu Leu Phe Val Leu Leu Ile Arg  
 15 20 25 30  
 CTT TCA CAA GTG TCT TCA GAT 359  
 Leu Ser Gln Val Ser Ser Asp  
 35

## (2) INFORMATION FOR SEQ ID NO:34:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 37 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

96080" 52520/BD

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

Met Ala Cys Asn Cys Gln Leu Met Gln Asp Thr Pro Leu Leu Lys Phe  
 1 5 10 15  
 Pro Cys Pro Arg Leu Ile Leu Leu Phe Val Leu Leu Ile Arg Leu Ser  
 20 25 30  
 Gln Val Ser Ser Asp  
 35

(2) INFORMATION FOR SEQ ID NO:35:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 416 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: double  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS  
 (B) LOCATION: 318..416

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

CCAAAGAAAA AGTGATTGT CATTCCTTTA TAGACTGTAA GAAGAGAACA TCTCAGAAGT 60  
 GGAGTCTTAC CCTGAAATCA AAGGATTAA AGAAAAAGTG GAATTTTCT TCAGCAAGCT 120  
 GTGAAACTAA ATCCACAACC TTTGGAGACC CAGGAACACC CTCCAATCTC TGTGTGTTTT 180  
 GTAAACATCA CTGGAGGGTC TTCTACGTGA GCAATTGGAT TGTCATCAGC CCTGCCTGTT 240  
 TTGCACCTGG GAAGTGCCCT GGTCTTACTT GGGTCCAAAT TGTGGGCTTT CACTTTTGAC 300  
 CCTAAGCATC TGAAGCC ATG GGC CAC ACA CGG AGG CAG GGA ACA TCA CCA 350  
 Met Gly His Thr Arg Arg Gln Gly Thr Ser Pro  
 1 5 10  
 TCC AAG TGT CCA TAC CTG AAT TTC TTT CAG CTC TTG GTG CTG GCT GGT 398  
 Ser Lys Cys Pro Tyr Leu Asn Phe Phe Gln Leu Leu Val Leu Ala Gly  
 15 20 25  
 CTT TCT CAC TTC TGT TCA 416  
 Leu Ser His Phe Cys Ser  
 30

(2) INFORMATION FOR SEQ ID NO:36:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 33 amino acids

950920 52520280

(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

Met Gly His Thr Arg Arg Gln Gly Thr Ser Pro Ser Lys Cys Pro Tyr  
1 5 10 15  
Leu Asn Phe Phe Gln Leu Leu Val Leu Ala Gly Leu Ser His Phe Cys  
20 25 30  
Ser

(2) INFORMATION FOR SEQ ID NO:37:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 113 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: CDS  
(B) LOCATION: 99..113

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

GGAGCAAGCA GACGCGTAAG AGTGGCTCCT GTAGGCAGCA CGGACTTGAA CAACCAGACT 60  
CCTGTAGACG TGTTCAGAA CTTACGGAAG CACCCACG ATG GAC CCC AGA TGC 113  
Met Asp Pro Arg Cys  
1 5

(2) INFORMATION FOR SEQ ID NO:38:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

Met Asp Pro Arg Cys  
1 5

(2) INFORMATION FOR SEQ ID NO:39:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 124 base pairs

560550 52520280

(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear

5 (ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

10 (A) NAME/KEY: CDS  
(B) LOCATION: 107..124

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

15 CACAGGGTGA AAGCTTTGCT TCTCTGCTGC TGTAACAGGG ACTAGCACAG ACACACGGAT 60

GAGTGGGGTC ATTTCCAGAT ATTAGGTCAC AGCAGAAGCA GCCAAA ATG GAT CCC 115  
Met Asp Pro  
1

20 CAG TGC ACT 124  
Gln Cys Thr  
5

25 (2) INFORMATION FOR SEQ ID NO:40:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 6 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

Met Asp Pro Gln Cys Thr  
1 5

40 (2) INFORMATION FOR SEQ ID NO:41:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 195 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

50 (ix) FEATURE:

(A) NAME/KEY: CDS  
(B) LOCATION: 148..195

55 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

AGGAGCCTTA GGAGGTACGG GGAGCTCGCA AATACTCCTT TTGGTTTATT CTTACCACCT 60

960220 52520280

TGCTTCTGTG TTCCTTGGGA ATGCTGCTGT GCTTATGCAT CTGGTCTCTT TTTGGAGCTA 120

CAGTGGACAG GCATTTGTGA CAGCACT ATG GGA CTG AGT AAC ATT CTC TTT 171

Met Gly Leu Ser Asn Ile Leu Phe  
1 5

GTG ATG GCC TTC CTG CTC TCT GGT 195

Val Met Ala Phe Leu Leu Ser Gly  
10 15

(2) INFORMATION FOR SEQ ID NO:42:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

Met Gly Leu Ser Asn Ile Leu Phe Val Met Ala Phe Leu Leu Ser Gly  
1 5 10 15

(2) INFORMATION FOR SEQ ID NO: 43:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 43:

CCAACATAAC TGAGTCTGGA AA 22

(2) INFORMATION FOR SEQ ID NO: 44:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 44:

CTGGATTCTG ACTCACCTTC A 21

(2) INFORMATION FOR SEQ ID NO: 45:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

5 (ii) MOLECULE TYPE: oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 45:

AGGTTAAGAG TGGTAGAGCC A

21

10 (2) INFORMATION FOR SEQ ID NO: 46:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

15 (ii) MOLECULE TYPE: oligonucleotide

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 46:

AATACCATGT ATCCACATG G

21

25 (2) INFORMATION FOR SEQ ID NO: 47:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: oligonucleotide

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 47:

CTGAAGCTAT GGCTTGCAAT T

21

40 (2) INFORMATION FOR SEQ ID NO: 48:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

45 (ii) MOLECULE TYPE: oligonucleotide

50 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 48:

TGGCTTCTCT TTCCTTACCT T

21

(2) INFORMATION FOR SEQ ID NO: 49:

55 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 49:

5

GCAAATGGTA GATGAGACTG T

21

(2) INFORMATION FOR SEQ ID NO: 50:

10

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

15

(ii) MOLECULE TYPE: oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 50:

20

CAACCGAGAA ATCTACCA GT AA

22

(2) INFORMATION FOR SEQ ID NO: 51:

25

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

30

(ii) MOLECULE TYPE: oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 51:

GCCGGTAACA AGTCTCTTCA

35

20

(2) INFORMATION FOR SEQ ID NO: 52:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

40

(ii) MOLECULE TYPE: oligonucleotide

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 52:

AAAAGCTCTA TAGCATTCTG TC

22

50

(2) INFORMATION FOR SEQ ID NO: 53:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

55

(ii) MOLECULE TYPE: oligonucleotide

960E80-9990/80

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 53:

ACTGACTTGG ACAGTTGTTC A

21

5 (2) INFORMATION FOR SEQ ID NO: 54:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: oligonucleotide

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 54:

TTTGATGGAC AACTTTACTA

20

20 (2) INFORMATION FOR SEQ ID NO: 55:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 55:

CAGCTCACTC AGGCTTATGT

20

(2) INFORMATION FOR SEQ ID NO: 56:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 56:

AAACAGCATC TGAGATCAGC A

21

(2) INFORMATION FOR SEQ ID NO: 57:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 57:

CTGAGATCAG CAAGACTGTC

20

960E80" 53520/80

## (2) INFORMATION FOR SEQ ID NO: 58:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 21 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 58:

CTGAAGCTAT GGCTTGCAAT T

## (2) INFORMATION FOR SEQ ID NO: 59:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 22 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 59:

ACAAGTGTCT TCAGATGTTG AT

## (2) INFORMATION FOR SEQ ID NO: 60:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 21 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 60:

CTGGATTCTG ACTCACCTTC A

## (2) INFORMATION FOR SEQ ID NO: 61:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 20 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 61:

CCAGGTGAAG TCCTCTGACA

## (2) INFORMATION FOR SEQ ID NO: 62:

950530 52520/230

21

22

21

20

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1417 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: double  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (ix) FEATURE:

- (A) NAME/KEY: CDS  
 (B) LOCATION: 249..884

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:

GAGTTTATA CCTCAATAGA CTCTTACTAG TTTCTCTTTT TCAGGTTGTG AACTCAACC 60  
 TTCAAAGACA CTCTGTTCCA TTTCTGTGGA CTAATAGGAT CATCTTTAGC ATCTGCCGGG 120  
 TGGATGCCAT CCAGGCTTCT TTTTCTACAT CTCTGTTTCT CGATTTTGTG GAGCCTAGGA 180  
 GGTGCCTAAG CTCCATTGGC TCTAGATTCC TGGCTTTCCC CATCATGTTC TCAAAGCAT 240  
 CTGAAGCT ATG GCT TGC AAT TGT CAG TTG ATG CAG GAT ACA CCA CTC CTC 290  
 Met Ala Cys Asn Cys Gln Leu Met Gln Asp Thr Pro Leu Leu  
 1 5 10  
 AAG TTT CCA TGT CCA AGG CTC AAT CTT CTC TTT GTG CTG CTG ATT CGT 338  
 Lys Phe Pro Cys Pro Arg Leu Asn Leu Leu Phe Val Leu Leu Ile Arg  
 15 20 25 30  
 CTT TCA CAA GTG TCT TCA GAT GTT GAT GAA CAA CTG TCC AAG TCA GTG 386  
 Leu Ser Gln Val Ser Ser Asp Val Asp Glu Gln Leu Ser Lys Ser Val  
 35 35 40 45  
 AAA GAT AAG GTA TTG CTG CCT TGC CGT TAC AAC TCT CCT CAT GAA GAT 434  
 Lys Asp Lys Val Leu Leu Pro Cys Arg Tyr Asn Ser Pro His Glu Asp  
 50 50 55 60  
 GAG TCT GAA GAC CGA ATC TAC TGG CAA AAA CAT GAC AAA GTG GTG CTG 482  
 Glu Ser Glu Asp Arg Ile Tyr Trp Gln Lys His Asp Lys Val Val Leu  
 65 70 75  
 TCT GTC ATT GCT GGG AAA CTA AAA GTG TGG CCC GAG TAT AAG AAC CGG 530  
 Ser Val Ile Ala Gly Lys Leu Lys Val Trp Pro Glu Tyr Lys Asn Arg  
 80 85 90  
 ACT TTA TAT GAC AAC ACT ACC TAC TCT CTT ATC ATC CTG GGC CTG GTC 578  
 Thr Leu Tyr Asp Asn Thr Thr Tyr Ser Leu Ile Ile Leu Gly Leu Val  
 95 100 105 110  
 CTT TCA GAC CGG GGC ACA TAC AGC TGT GTC GTT CAA AAG AAG GAA AGA 626  
 Leu Ser Asp Arg Gly Thr Tyr Ser Cys Val Val Gln Lys Lys Glu Arg  
 115 120 125  
 GGA ACG TAT GAA GTT AAA CAC TTG GCT TTA GTA AAG TTG TCC ATC AAA 674  
 Gly Thr Tyr Glu Val Lys His Leu Ala Leu Val Lys Leu Ser Ile Lys  
 130 135 140

960630 52520/280

CCC CCA GAA GAC CCT CCT GAT AGC AAG AAC ACA CTT GTG CTC TTT GGG 722  
 Pro Pro Glu Asp Pro Pro Asp Ser Lys Asn Thr Leu Val Leu Phe Gly  
 145 150 155  
 5  
 GCA GGA TTC GGC GCA GTA ATA ACA GTC GTC GTC ATC GTT GTC ATC ATC 770  
 Ala Gly Phe Gly Ala Val Ile Thr Val Val Val Ile Val Val Ile Ile  
 160 165 170  
 10  
 AAA TGC TTC TGT AAG CAC AGA AGC TGT TTC AGA AGA AAT GAG GCA AGC 818  
 Lys Cys Phe Cys Lys His Arg Ser Cys Phe Arg Arg Asn Glu Ala Ser  
 175 180 185 190  
 15  
 AGA GAA ACA AAC AAC AGC CTT ACC TTC GGG CCT GAA GAA GCA TTA GCT 866  
 Arg Glu Thr Asn Asn Ser Leu Thr Phe Gly Pro Glu Glu Ala Leu Ala  
 195 200 205  
 20  
 GAA CAG ACC GTC TTC CTT TAGTTCTTCT CTGTCCATGT GGGATACATG GTATTATGTG 924  
 Glu Gln Thr Val Phe Leu  
 210  
 25  
 GCTCATGAGG TACAATCTTT CTTTCAGCAC CGTGCTAGCT GATCTTTCGG ACAACTTGAC 984  
 ACAAGATAGA GTTAACTGGG AAGAGAAAGC CTTGAATGAG GATTTCTTTC CATCAGGAAG 1044  
 CTACGGGCAA GTTTGCTGGG CCTTTGATTG CTTGATGACT GAAGTGGA AAA GGCTGAGCCC 1104  
 ACTGTGGGTG GTGCTAGCCC TGGGCAGGGG CAGGTGACCC TGGGTGGTAT AAGAAAAAGA 1164  
 30  
 GCTGTCACTA AAAGGAGAGG TGCCTAGTCT TACTGCAACT TGATATGTCA TGTTTGTTG 1224  
 GTGTCTGTGG GAGGCCTGCC CTTTTCTGAA GAGAAGTGGT GGGAGAGTGG ATGGGGTGGG 1284  
 GGCAGAGGAA AAGTGGGGGA GAGGGCCTGG GAGGAGAGGA GGGAGGGGGA CGGGGTGGGG 1344  
 35  
 GTGGGGAAAA CTATGGTTGG GATGTAAAAA CGGATAATAA TATAAATATT AAATAAAAAG 1404  
 AGAGTATTGA GCA 1417

(2) INFORMATION FOR SEQ ID NO:63:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 212 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:

Met Ala Cys Asn Cys Gln Leu Met Gln Asp Thr Pro Leu Leu Lys Phe  
 1 5 10 15  
 55  
 Pro Cys Pro Arg Leu Ile Leu Leu Phe Val Leu Leu Ile Arg Leu Ser  
 20 25 30  
 Gln Val Ser Ser Asp Val Asp Glu Gln Leu Ser Lys Ser Val Lys Asp  
 35 40 45

Lys Val Leu Leu Pro Cys Arg Tyr Asn Ser Pro His Glu Asp Glu Ser  
 50 55 60  
 5 Glu Asp Arg Ile Tyr Trp Gln Lys His Asp Lys Val Val Leu Ser Val  
 65 70 75 80  
 Ile Ala Gly Lys Leu Lys Val Trp Pro Glu Tyr Lys Asn Arg Thr Leu  
 85 90 95  
 10 Tyr Asp Asn Thr Thr Tyr Ser Leu Ile Ile Leu Gly Leu Val Leu Ser  
 100 105 110  
 15 Asp Arg Gly Thr Tyr Ser Cys Val Val Gln Lys Lys Glu Arg Gly Thr  
 115 120 125  
 Tyr Glu Val Lys His Leu Ala Leu Val Lys Leu Ser Ile Lys Pro Pro  
 130 135 140  
 20 Glu Asp Pro Pro Asp Ser Lys Asn Thr Leu Val Leu Phe Gly Ala Gly  
 145 150 155 160  
 Phe Gly Ala Val Ile Thr Val Val Val Ile Val Val Ile Ile Lys Cys  
 165 170 175  
 25 Phe Cys Lys His Arg Ser Cys Phe Arg Arg Asn Glu Ala Ser Arg Glu  
 180 185 190  
 30 Thr Asn Asn Ser Leu Thr Phe Gly Pro Glu Glu Ala Leu Ala Glu Gln  
 195 200 205  
 Thr Val Phe Leu  
 210

(2) INFORMATION FOR SEQ ID NO:64:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1606 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: double  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS  
 (B) LOCATION: 249..926

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:

GAGTTTATA CCTCAATAGA CTCTTACTAG TTTCTCTTTT TCAGGTTGTG AAACCTCAACC 60  
 55 TTCAAAGACA CTCTGTTCCA TTTCTGTGGA CTAATAGGAT CATCTTTAGC ATCTGCCGGG 120  
 TGGATGCCAT CCAGGCTTCT TTTTCTACAT CTCTGTTTCT CGATTTTGTG GAGCCTAGGA 180  
 GGTGCCTAAG CTCCATTGGC TCTAGATTCC TGGCTTTCCC CATCATGTTC TCCAAAGCAT 240

960E80 55520/80

|    |          |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|----|----------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
|    | CTGAAGCT | ATG | GCT | TGC | AAT | TGT | CAG | TTG | ATG | CAG | GAT | ACA | CCA | CTC | CTC | 290 |     |
|    | Met      | Ala | Cys | Asn | Cys | Gln | Leu | Met | Gln | Asp | Thr | Pro | Leu | Leu |     |     |     |
|    | 1        |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     |     |     |     |
| 5  | AAG      | TTT | CCA | TGT | CCA | AGG | CTC | AAT | CTT | CTC | TTT | GTG | CTG | CTG | ATT | CGT | 338 |
|    | Lys      | Phe | Pro | Cys | Pro | Arg | Leu | Asn | Leu | Leu | Phe | Val | Leu | Leu | Ile | Arg |     |
|    | 15       |     |     |     | 20  |     |     |     |     | 25  |     |     |     |     |     | 30  |     |
| 10 | CTT      | TCA | CAA | GTG | TCT | TCA | GAT | GTT | GAT | GAA | CAA | CTG | TCC | AAG | TCA | GTG | 386 |
|    | Leu      | Ser | Gln | Val | Ser | Ser | Asp | Val | Asp | Glu | Gln | Leu | Ser | Lys | Ser | Val |     |
|    |          |     |     | 35  |     |     |     |     |     | 40  |     |     |     |     | 45  |     |     |
| 15 | AAA      | GAT | AAG | GTA | TTG | CTG | CCT | TGC | CGT | TAC | AAC | TCT | CCT | CAT | GAA | GAT | 434 |
|    | Lys      | Asp | Lys | Val | Leu | Leu | Pro | Cys | Arg | Tyr | Asn | Ser | Pro | His | Glu | Asp |     |
|    |          |     | 50  |     |     |     |     | 55  |     |     |     |     |     | 60  |     |     |     |
| 20 | GAG      | TCT | GAA | GAC | CGA | ATC | TAC | TGG | CAA | AAA | CAT | GAC | AAA | GTG | GTG | CTG | 482 |
|    | Glu      | Ser | Glu | Asp | Arg | Ile | Tyr | Trp | Gln | Lys | His | Asp | Lys | Val | Val | Leu |     |
|    |          |     | 65  |     |     |     |     | 70  |     |     |     |     | 75  |     |     |     |     |
| 25 | TCT      | GTC | ATT | GCT | GGG | AAA | CTA | AAA | GTG | TGG | CCC | GAG | TAT | AAG | AAC | CGG | 530 |
|    | Ser      | Val | Ile | Ala | Gly | Lys | Leu | Lys | Val | Trp | Pro | Glu | Tyr | Lys | Asn | Arg |     |
|    |          | 80  |     |     |     |     | 85  |     |     |     |     | 90  |     |     |     |     |     |
| 30 | ACT      | TTA | TAT | GAC | AAC | ACT | ACC | TAC | TCT | CTT | ATC | ATC | CTG | GGC | CTG | GTC | 578 |
|    | Thr      | Leu | Tyr | Asp | Asn | Thr | Thr | Tyr | Ser | Leu | Ile | Ile | Leu | Gly | Leu | Val |     |
|    |          | 95  |     |     |     | 100 |     |     |     |     | 105 |     |     |     |     | 110 |     |
| 35 | CTT      | TCA | GAC | CGG | GGC | ACA | TAC | AGC | TGT | GTC | GTT | CAA | AAG | AAG | GAA | AGA | 626 |
|    | Leu      | Ser | Asp | Arg | Gly | Thr | Tyr | Ser | Cys | Val | Val | Gln | Lys | Lys | Glu | Arg |     |
|    |          |     |     | 115 |     |     |     |     | 120 |     |     |     |     |     | 125 |     |     |
| 40 | GGA      | ACG | TAT | GAA | GTT | AAA | CAC | TTG | GCT | TTA | GTA | AAG | TTG | TCC | ATC | AAA | 674 |
|    | Gly      | Thr | Tyr | Glu | Val | Lys | His | Leu | Ala | Leu | Val | Lys | Leu | Ser | Ile | Lys |     |
|    |          |     |     | 130 |     |     |     | 135 |     |     |     |     |     | 140 |     |     |     |
| 45 | CCC      | CCA | GAA | GAC | CCT | CCT | GAT | AGC | AAG | AAC | ACA | CTT | GTG | CTC | TTT | GGG | 722 |
|    | Pro      | Pro | Glu | Asp | Pro | Pro | Asp | Ser | Lys | Asn | Thr | Leu | Val | Leu | Phe | Gly |     |
|    |          |     | 145 |     |     |     |     | 150 |     |     |     |     | 155 |     |     |     |     |
| 50 | GCA      | GGA | TTC | GGC | GCA | GTA | ATA | ACA | GTC | GTC | GTC | ATC | GTT | GTC | ATC | ATC | 770 |
|    | Ala      | Gly | Phe | Gly | Ala | Val | Ile | Thr | Val | Val | Val | Ile | Val | Val | Ile | Ile |     |
|    |          | 160 |     |     |     |     | 165 |     |     |     |     | 170 |     |     |     |     |     |
| 55 | AAA      | TGC | TTC | TGT | AAG | CAC | GGT | CTC | ATC | TAC | CAT | TTG | CAA | CTG | ACC | TCT | 818 |
|    | Lys      | Cys | Phe | Cys | Lys | His | Gly | Leu | Ile | Tyr | His | Leu | Gln | Leu | Thr | Ser |     |
|    |          | 175 |     |     |     | 180 |     |     |     | 185 |     |     |     |     |     | 190 |     |
| 50 | TCT      | GCA | AAG | GAC | TTC | AGA | AAC | CTA | GCA | CTA | CCC | TGG | CTC | TGC | AAA | CAC | 866 |
|    | Ser      | Ala | Lys | Asp | Phe | Arg | Asn | Leu | Ala | Leu | Pro | Trp | Leu | Cys | Lys | His |     |
|    |          |     |     | 195 |     |     |     | 200 |     |     |     |     |     |     | 205 |     |     |
| 55 | GGT      | TCT | CTA | GGT | GAA | GCC | TCT | GCA | GTG | ATT | TGC | AGA | AGT | ACT | CAG | ACG | 914 |
|    | Gly      | Ser | Leu | Gly | Glu | Ala | Ser | Ala | Val | Ile | Cys | Arg | Ser | Thr | Gln | Thr |     |
|    |          |     |     | 210 |     |     |     | 215 |     |     |     |     |     |     | 220 |     |     |

0870355 52520280



AAT GAA CCA CAG TAGTTCTGCT GTTCTGAGG ACGTAGTTTA GAGACTGAAT 966  
Asn Glu Pro Gln  
225

|    |            |            |             |            |            |            |      |
|----|------------|------------|-------------|------------|------------|------------|------|
| 5  | TCTTTGGAAA | GGACATAGGG | ACAGTTTGCA  | CATTTGCTTG | CACATCACAC | ACACACACAC | 1026 |
|    | ACACACACAC | ACACACACAC | ACACACACAC  | ACACACACAC | ACACACACAC | TCTCTCTCTC | 1086 |
| 10 | TCTCTCTCTC | GATACCTTAG | GATAGGGTTC  | TACCCTGTTG | CTCAGTGACA | AAGAATCACT | 1146 |
|    | CTGTGGCGGA | GGCAGGCTTC | AAGCTTGCAG  | CAATCCTCCT | GCACCAGTTT | CCTGAGTGCC | 1206 |
|    | AGACTTCCAG | GTGTAAGCTA | TGGCACCTTAG | CAGAACACTA | GCTGAATCAA | TGAAGACACT | 1266 |
| 15 | GAGGTTCCAA | GAGGGAACTT | GAATTATGAA  | GGTGAGTCAG | AATCCAGATT | TCCTGGCTCT | 1326 |
|    | ACCACTCTTA | ACCTGTATCT | GTTAGACCCC  | AAGCTCTGAG | CTCATAGACA | AGCTAATTTA | 1386 |
| 20 | AAATGCTTTT | TAATAAGCAG | AAGGCTCAGT  | TAGTACGGGG | TTCAGGATAC | TGCTTACTGG | 1446 |
|    | CAATATTTGA | CTAGCCTCTA | TTTTGTTTGT  | TTTTTAAAGG | CCTACTGACT | GTAGTGTAAT | 1506 |
|    | TTGTAGGAAA | CATGTTGCTA | TGTATACCCA  | TTTGAGGGTA | ATAAAAATGT | TGGTAATTTT | 1566 |
| 25 | CAGCCAGCAC | TTTCCAGGTA | TTTCCCTTTT  | TATCCTTCAT |            |            | 1606 |

(2) INFORMATION FOR SEQ ID NO:65:

30 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 226 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

35 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:

|    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| 40 | Met | Ala | Cys | Asn | Cys | Gln | Leu | Met | Gln | Asp | Thr | Pro | Leu | Leu | Lys | Phe |
|    | 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |
|    | Pro | Cys | Pro | Arg | Leu | Ile | Leu | Leu | Phe | Val | Leu | Leu | Ile | Arg | Leu | Ser |
|    |     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |     |     |
| 45 | Gln | Val | Ser | Ser | Asp | Val | Asp | Glu | Gln | Leu | Ser | Lys | Ser | Val | Lys | Asp |
|    |     |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |     |     |     |
|    | Lys | Val | Leu | Leu | Pro | Cys | Arg | Tyr | Asn | Ser | Pro | His | Glu | Asp | Glu | Ser |
|    | 50  |     |     |     |     |     | 55  |     |     |     |     | 60  |     |     |     |     |
| 50 | Glu | Asp | Arg | Ile | Tyr | Trp | Gln | Lys | His | Asp | Lys | Val | Val | Leu | Ser | Val |
|    | 65  |     |     |     |     | 70  |     |     |     |     | 75  |     |     |     |     | 80  |
|    | Ile | Ala | Gly | Lys | Leu | Lys | Val | Trp | Pro | Glu | Tyr | Lys | Asn | Arg | Thr | Leu |
|    |     |     |     |     | 85  |     |     |     |     | 90  |     |     |     |     | 95  |     |
| 55 | Tyr | Asp | Asn | Thr | Thr | Tyr | Ser | Leu | Ile | Ile | Leu | Gly | Leu | Val | Leu | Ser |
|    |     |     |     | 100 |     |     |     |     | 105 |     |     |     |     | 110 |     |     |

| 項目           | 単位         | 数値        | 単位           | 数値      |
|--------------|------------|-----------|--------------|---------|
| 1. 総人口       | 人          | 1,234,567 | 2. 男性人口      | 612,345 |
| 3. 女性人口      | 622,222    | 4. 出生率    | 12.5         |         |
| 5. 死亡率       | 8.7        | 6. 自然増減率  | 3.8          |         |
| 7. 人口密度      | 人/平方キロメートル | 150       | 8. 労働人口      | 876,543 |
| 9. 高齢化率      | %          | 22.1      | 10. 平均寿命     | 78.5    |
| 11. 識字率      | %          | 95.3      | 12. 進学率      | 88.9    |
| 13. 失業率      | %          | 4.2       | 14. 所得格差     | 1.5     |
| 15. 環境指数     | 点          | 75.0      | 16. 社会安定指数   | 82.0    |
| 17. 経済成長率    | %          | 5.1       | 18. 財政赤字率    | 2.3     |
| 19. 貿易収支     | 億ドル        | 120.0     | 20. 外債総額     | 500.0   |
| 21. 対GDP比率   | %          | 10.0      | 22. 国際競争力    | 85.0    |
| 23. 技術革新指数   | 点          | 90.0      | 24. 文化遺産数    | 100     |
| 25. 観光客数     | 万人         | 50.0      | 26. 観光収入     | 1000.0  |
| 27. 観光業GDP   | 億ドル        | 50.0      | 28. 観光業雇用    | 10000   |
| 29. 観光業労働力   | 万人         | 10.0      | 30. 観光業労働賃金  | 10000   |
| 31. 観光業労働生産性 | ドル/人       | 10000     | 32. 観光業労働時間  | 10000   |
| 33. 観光業労働時間  | 時間         | 10000     | 34. 観光業労働時間  | 10000   |
| 35. 観光業労働時間  | 時間         | 10000     | 36. 観光業労働時間  | 10000   |
| 37. 観光業労働時間  | 時間         | 10000     | 38. 観光業労働時間  | 10000   |
| 39. 観光業労働時間  | 時間         | 10000     | 40. 観光業労働時間  | 10000   |
| 41. 観光業労働時間  | 時間         | 10000     | 42. 観光業労働時間  | 10000   |
| 43. 観光業労働時間  | 時間         | 10000     | 44. 観光業労働時間  | 10000   |
| 45. 観光業労働時間  | 時間         | 10000     | 46. 観光業労働時間  | 10000   |
| 47. 観光業労働時間  | 時間         | 10000     | 48. 観光業労働時間  | 10000   |
| 49. 観光業労働時間  | 時間         | 10000     | 50. 観光業労働時間  | 10000   |
| 51. 観光業労働時間  | 時間         | 10000     | 52. 観光業労働時間  | 10000   |
| 53. 観光業労働時間  | 時間         | 10000     | 54. 観光業労働時間  | 10000   |
| 55. 観光業労働時間  | 時間         | 10000     | 56. 観光業労働時間  | 10000   |
| 57. 観光業労働時間  | 時間         | 10000     | 58. 観光業労働時間  | 10000   |
| 59. 観光業労働時間  | 時間         | 10000     | 60. 観光業労働時間  | 10000   |
| 61. 観光業労働時間  | 時間         | 10000     | 62. 観光業労働時間  | 10000   |
| 63. 観光業労働時間  | 時間         | 10000     | 64. 観光業労働時間  | 10000   |
| 65. 観光業労働時間  | 時間         | 10000     | 66. 観光業労働時間  | 10000   |
| 67. 観光業労働時間  | 時間         | 10000     | 68. 観光業労働時間  | 10000   |
| 69. 観光業労働時間  | 時間         | 10000     | 70. 観光業労働時間  | 10000   |
| 71. 観光業労働時間  | 時間         | 10000     | 72. 観光業労働時間  | 10000   |
| 73. 観光業労働時間  | 時間         | 10000     | 74. 観光業労働時間  | 10000   |
| 75. 観光業労働時間  | 時間         | 10000     | 76. 観光業労働時間  | 10000   |
| 77. 観光業労働時間  | 時間         | 10000     | 78. 観光業労働時間  | 10000   |
| 79. 観光業労働時間  | 時間         | 10000     | 80. 観光業労働時間  | 10000   |
| 81. 観光業労働時間  | 時間         | 10000     | 82. 観光業労働時間  | 10000   |
| 83. 観光業労働時間  | 時間         | 10000     | 84. 観光業労働時間  | 10000   |
| 85. 観光業労働時間  | 時間         | 10000     | 86. 観光業労働時間  | 10000   |
| 87. 観光業労働時間  | 時間         | 10000     | 88. 観光業労働時間  | 10000   |
| 89. 観光業労働時間  | 時間         | 10000     | 90. 観光業労働時間  | 10000   |
| 91. 観光業労働時間  | 時間         | 10000     | 92. 観光業労働時間  | 10000   |
| 93. 観光業労働時間  | 時間         | 10000     | 94. 観光業労働時間  | 10000   |
| 95. 観光業労働時間  | 時間         | 10000     | 96. 観光業労働時間  | 10000   |
| 97. 観光業労働時間  | 時間         | 10000     | 98. 観光業労働時間  | 10000   |
| 99. 観光業労働時間  | 時間         | 10000     | 100. 観光業労働時間 | 10000   |

Asp Arg Gly Thr Tyr Ser Cys Val Val Gln Lys Lys Glu Arg Gly Thr  
115 120 125

5 Tyr Glu Val Lys His Leu Ala Leu Val Lys Leu Ser Ile Lys Pro Pro  
130 135 140

Glu Asp Pro Pro Asp Ser Lys Asn Thr Leu Val Leu Phe Gly Ala Gly  
145 150 155 160

10 Phe Gly Ala Val Ile Thr Val Val Val Ile Val Val Ile Ile Lys Cys  
165 170 175

Phe Cys Lys His Gly Leu Ile Tyr His Leu Gln Leu Thr Ser Ser Ala  
180 185 190

15 Lys Asp Phe Arg Asn Leu Ala Leu Pro Trp Leu Cys Lys His Gly Ser  
195 200 205

20 Leu Gly Glu Ala Ser Ala Val Ile Cys Arg Ser Thr Gln Thr Asn Glu  
210 215 220

Pro Gln  
225

560E80 52520/80

CLAIMS

1. An isolated nucleic acid encoding a protein which binds CD28 or CTLA4 comprising a contiguous nucleotide sequence derived from at least one T cell costimulatory molecule gene, the nucleotide sequence represented by a formula A-B-C-D-E, wherein

A comprises a nucleotide sequence of at least one first exon of a T cell costimulatory molecule gene, wherein the at least one first exon encodes a signal peptide domain,

B comprises a nucleotide sequence of at least one second exon of a T cell costimulatory molecule gene, wherein the at least one second exon encodes an immunoglobulin variable region-like domain,

C comprises a nucleotide sequence of at least one third exon of a T cell costimulatory molecule gene, wherein the at least one third exon encodes an immunoglobulin constant region-like domain,

D comprises a nucleotide sequence of at least one fourth exon of a T cell costimulatory molecule gene, wherein the at least one fourth exon encodes a transmembrane domain, and

E comprises a nucleotide sequence of at least one fifth exon of a T cell costimulatory molecule gene, wherein the at least one fifth exon encodes a cytoplasmic domain,

with the proviso that E does not comprise a nucleotide sequence selected from a group consisting of SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29 and SEQ ID NO:31.

2. The isolated nucleic acid of claim 1 which is a cDNA.
3. The isolated nucleic acid of claim 2 which comprises a coding region of the cDNA.
4. The isolated nucleic acid of claim 1, wherein the nucleotide sequence is derived from a T cell costimulatory molecule gene encoding B7-1.
5. The isolated nucleic acid of claim 4, wherein B7-1 is murine.
6. The isolated nucleic acid of claim 4, wherein B7-1 is human.
7. The isolated nucleic acid of claim 5, wherein E comprises a nucleotide sequence shown in SEQ ID NO:4.

8. The isolated nucleic acid of claim 5, wherein E comprises a nucleotide sequence encoding an amino acid sequence shown in SEQ ID NO:5.

9. An isolated nucleic acid encoding a protein which binds CD28 or CTLA4 and is encoded by a T cell costimulatory molecule gene having

at least one first exon encoding a first cytoplasmic domain comprising a nucleotide sequence selected from the group consisting of a nucleotide sequence of SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29 and SEQ ID NO:31, and

at least one second exon encoding a second cytoplasmic domain,  
wherein the isolated nucleic acid comprises a nucleotide sequence encoding the second  
cytoplasmic domain.

10. The isolated nucleic acid of claim 9 which comprises a coding region of a cDNA.

11. The isolated nucleic acid of claim 9 which does not comprise a nucleotide sequence encoding the first cytoplasmic domain.

12. The isolated nucleic acid of claim 9 wherein the T cell costimulatory molecule gene is B7-1.

13. The isolated nucleic acid of claim 12 wherein B7-1 is murine.

14. The isolated nucleic acid of claim 12 wherein B7-1 is human.

15. An isolated nucleic acid encoding a protein which binds CD28 or CTLA4 comprising a nucleotide sequence shown in SEQ ID NO:1.

16. An isolated nucleic acid encoding a protein which binds CD28 or CTLA4 comprising a nucleotide sequence shown in SEQ ID NO:3.

17. An isolated nucleic acid encoding a cytoplasmic domain derived from a protein which binds CD28 or CTLA4, the nucleic acid comprising a nucleotide sequence shown in SEQ ID NO:4.

18. An isolated protein which binds to CD28 or CTLA4 having an amino acid sequence derived from amino acid sequences encoded by at least one T cell costimulatory molecule gene, the protein comprising a contiguous amino acid sequence represented by a formula A-B-C-D-E, wherein

A, which may or may not be present, comprises an amino acid sequence of a signal peptide domain encoded by at least one exon of a T cell costimulatory molecule gene,

B comprises an amino acid sequence of an immunoglobulin variable region-like domain encoded by at least one exon of a T cell costimulatory molecule gene,

C comprises an amino acid sequence of an immunoglobulin constant region-like domain encoded by at least one exon of a T cell costimulatory molecule gene,

D comprises an amino acid sequence of a transmembrane domain encoded by at least one exon of a T cell costimulatory molecule gene, and

E comprises an amino acid sequence of a cytoplasmic domain encoded by at least one exon of a T cell costimulatory molecule gene,

with the proviso that E not comprise an amino acid sequence selected from the group consisting of SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30 and SEQ ID NO:32.

19. The isolated protein of claim 18 which is B7-1.

20. The isolated protein of claim 19 which is murine.

21. The isolated protein of claim 19 which is human.

22. The isolated protein of claim 20, wherein E comprises an amino acid sequence shown in SEQ ID NO:5.

23. An isolated protein which binds CD28 or CTLA4 and is encoded by a T cell costimulatory molecule gene having  
at least one first exon encoding a first cytoplasmic domain comprising an amino acid sequence selected from the group consisting of an amino acid sequence of SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, and SEQ ID NO:32, and

at least one second exon encoding a second cytoplasmic domain,  
wherein the T cell costimulatory molecule comprises the second cytoplasmic domain.

24. The isolated protein of claim 23 which does not comprise the first cytoplasmic domain.

25. The isolated protein of claim 23 which is B7-1.

26. The isolated protein of claim 25 which is murine.

27. The isolated protein of claim 25 which is human.

28. An isolated protein which binds CD28 or CTLA4 comprising an amino acid sequence shown in SEQ ID NO:2.

29. An isolated cytoplasmic domain polypeptide derived from a protein which binds CD28 or CTLA4, the polypeptide comprising an amino acid sequence shown in SEQ ID NO:5.

30. A recombinant expression vector comprising the nucleic acid molecule of claim 15.

31. A host cell which contains the recombinant expression vector of claim 30.

32. An antibody which binds to the murine B7-1 cytoplasmic domain polypeptide of claim 29.

33. An isolated nucleic acid encoding a protein which binds CD28 or CTLA4 comprising a contiguous nucleotide sequence derived from at least one T cell costimulatory molecule gene, the nucleotide sequence represented by a formula A-B-C-D-E, wherein

A comprises a nucleotide sequence of at least one first exon of a T cell costimulatory molecule gene, wherein the at least one first exon encodes a signal peptide domain,

B comprises a nucleotide sequence of at least one second exon of a T cell costimulatory molecule gene, wherein the at least one second exon encodes an immunoglobulin variable region-like domain,

C comprises a nucleotide sequence of at least one third exon of a T cell costimulatory molecule gene, wherein the at least one third exon encodes an immunoglobulin constant region-like domain,

D, which may or may not be present, comprises a nucleotide sequence of at least one fourth exon of a T cell costimulatory molecule gene, wherein the at least one fourth exon encodes a transmembrane domain, and

E, which may or may not be present, comprises a nucleotide sequence of at least one fifth exon of a T cell costimulatory molecule gene, wherein the at least one fifth exon encodes a cytoplasmic domain,

5 with the proviso that A does not comprise a nucleotide sequence selected from a group consisting of SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39 and SEQ ID NO:41.

10 34. The isolated nucleic acid of claim 33 which is a cDNA.

35. The isolated nucleic acid of claim 34 which comprises a coding region of the cDNA.

15 36. The isolated nucleic acid of claim 33, wherein the nucleotide sequence is derived from a T cell costimulatory molecule gene encoding B7-2.

37. The isolated nucleic acid of claim 36, wherein B7-2 is murine.

20 38. The isolated nucleic acid of claim 36, wherein B7-2 is human.

39. The isolated nucleic acid of claim 37, wherein A comprises a nucleotide sequence shown in SEQ ID NO:14.

25 40. An isolated nucleic acid encoding a protein which binds CD28 or CTLA4 and is encoded by a T cell costimulatory molecule gene having  
at least one first exon encoding a first signal peptide domain comprising a nucleotide sequence selected from the group consisting of a nucleotide sequence of SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37 SEQ ID NO:39 and SEQ ID NO:41, and  
at least one second exon encoding a second signal peptide domain,  
30 wherein the isolated nucleic acid comprises a nucleotide sequence encoding the second signal peptide domain.

35 41. The isolated nucleic acid of claim 40 which comprises a coding region of a cDNA.

42. The isolated nucleic acid of claim 40 which does not comprise a nucleotide sequence encoding the first signal peptide domain.

43. The isolated nucleic acid of claim 40 wherein the T cell costimulatory molecule gene is B7-2.

44. The isolated nucleic acid of claim 43 wherein B7-2 is murine.

45. The isolated nucleic acid of claim 43 wherein B7-2 is human.

46. An isolated nucleic acid encoding a protein which binds CD28 or CTLA4 comprising a nucleotide sequence shown in SEQ ID NO:12.

47. An isolated nucleic acid encoding a signal peptide domain derived from a protein which binds CD28 or CTLA4, the nucleic acid comprising a nucleotide sequence shown in SEQ ID NO:14.

48. An isolated protein which binds CD28 or CTLA4 having an amino acid sequence derived from amino acid sequences encoded by at least one T cell costimulatory molecule gene, the protein comprising a contiguous amino acid sequence represented by a formula A-B-C-D-E, wherein

A comprises an amino acid sequence of a signal peptide domain encoded by at least one exon of a T cell costimulatory molecule gene,

B comprises an amino acid sequence of an immunoglobulin variable region-like domain encoded by at least one exon of a T cell costimulatory molecule gene,

C comprises an amino acid sequence of an immunoglobulin constant region-like domain encoded by at least one exon of a T cell costimulatory molecule gene,

D, which may or may not be present, comprises an amino acid sequence of a transmembrane domain encoded by at least one exon of a T cell costimulatory molecule gene, and

E, which may or may not be present, comprises an amino acid sequence of a cytoplasmic domain encoded by at least one exon of a T cell costimulatory molecule gene,

with the proviso that A not comprise an amino acid sequence selected from the group consisting of SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40 and SEQ ID NO: 42.

49. The isolated protein of claim 48 which is B7-2.

50. The isolated protein of claim 49 which is murine.

51. The isolated protein of claim 49 which is human.

52. The isolated protein of claim 50, wherein A comprises an amino acid sequence  
5 shown in SEQ ID NO: 15.

53. An isolated protein which binds CD28 or CTLA4 and is encoded by a T cell  
costimulatory molecule gene having

at least one first exon encoding a first signal peptide domain comprising an amino  
10 acid sequence selected from the group consisting of an amino acid sequence of SEQ ID  
NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40 and SEQ ID NO:42, and

at least one second exon encoding a second signal peptide domain,  
wherein the T cell costimulatory molecule comprises the second signal peptide domain.

54. The isolated protein of claim 53 which does not comprise the first signal  
15 peptide domain.

55. The isolated protein of claim 53 which is B7-2.

56. The isolated protein of claim 55 which is murine.

57. The isolated protein of claim 55 which is human.

58. An isolated protein which binds CD28 or CTLA4 comprising an amino acid  
25 sequence shown in SEQ ID NO:13.

59. An isolated signal peptide domain polypeptide derived from a protein which  
binds CD28 or CTLA4, the polypeptide comprising an amino acid sequence shown in SEQ  
ID NO:15.

60. A recombinant expression vector comprising the nucleic acid molecule of  
claim 46.

61. A host cell which contains the recombinant expression vector of claim 60.

62. An antibody which binds to the polypeptide of claim 59.

63. An isolated nucleic acid encoding a protein comprising a contiguous nucleotide sequence derived from at least one T cell costimulatory molecule gene, the nucleotide sequence represented by a formula A-B-C-D, wherein

5 A comprises a nucleotide sequence of at least one first exon of a T cell costimulatory molecule gene, wherein the at least one first exon encodes a signal peptide domain,

10 B comprises a nucleotide sequence of at least one second exon of a T cell costimulatory molecule gene, wherein the at least one second exon encodes an immunoglobulin constant region-like domain,

C comprises a nucleotide sequence of at least one third exon of a T cell costimulatory molecule gene, wherein the at least one third exon encodes a transmembrane domain, and

15 D comprises a nucleotide sequence of at least one fourth exon of a T cell costimulatory molecule gene, wherein the at least one fourth exon encodes a cytoplasmic domain.

20 64. The isolated nucleic acid of claim 63 comprising a nucleotide sequence shown in SEQ ID NO:8.

25 65. The isolated nucleic acid of claim 63 comprising a nucleotide sequence shown in SEQ ID NO:10.

30 66. An isolated protein having an amino acid sequence derived from amino acid sequences encoded by at least one T cell costimulatory molecule gene, the protein comprising a contiguous amino acid sequence represented by a formula A-B-C-D, wherein

35 A, which may or may not be present, comprises an amino acid sequence of a signal peptide domain encoded by at least one exon of a T cell costimulatory molecule gene,

B comprises an amino acid sequence of an immunoglobulin constant region-like domain encoded by at least one exon of a T cell costimulatory molecule gene, and

C comprises an amino acid sequence of a transmembrane domain encoded by at least one exon of a T cell costimulatory molecule gene, and

40 D comprises an amino acid sequence of a cytoplasmic domain encoded by at least one exon of a T cell costimulatory molecule gene.

67. The isolated protein of claim 66 comprising an amino acid sequence shown in SEQ ID NO:9.

68. The isolated protein of claim 66 comprising an amino acid sequence shown in SEQ ID NO:11.

5 69. An isolated nucleic acid encoding a protein comprising a contiguous nucleotide sequence derived from at least one T cell costimulatory molecule gene, the nucleotide sequence represented by a formula A-B-C-D, wherein

10 A comprises a nucleotide sequence of at least one first exon of a T cell costimulatory molecule gene, wherein the at least one first exon encodes a signal peptide domain,

B comprises a nucleotide sequence of at least one second exon of a T cell costimulatory molecule gene, wherein the at least one second exon encodes an immunoglobulin variable region-like domain,

15 C comprises a nucleotide sequence of at least one third exon of a T cell costimulatory molecule gene, wherein the at least one third exon encodes a transmembrane domain, and

20 D comprises a nucleotide sequence of at least one fourth exon of a T cell costimulatory molecule gene, wherein the at least one fourth exon encodes a cytoplasmic domain.

70. The isolated nucleic acid of claim 69 comprising a nucleotide sequence shown in SEQ ID NO:62.

25 71. The isolated nucleic acid of claim 69 comprising a nucleotide sequence shown in SEQ ID NO:64.

30 72. An isolated protein having an amino acid sequence derived from amino acid sequences encoded by at least one T cell costimulatory molecule gene, the protein comprising a contiguous amino acid sequence represented by a formula A-B-C-D, wherein

A, which may or may not be present, comprises an amino acid sequence of a signal peptide domain encoded by at least one exon of a T cell costimulatory molecule gene,

35 B comprises an amino acid sequence of an immunoglobulin variable region-like domain encoded by at least one exon of a T cell costimulatory molecule gene, and

C comprises an amino acid sequence of a transmembrane domain encoded by at least one exon of a T cell costimulatory molecule gene, and

D comprises an amino acid sequence of a cytoplasmic domain encoded by at least one exon of a T cell costimulatory molecule gene.

73. The isolated protein of claim 72 comprising an amino acid sequence shown in  
5 SEQ ID NO:63.

74. The isolated protein of claim 72 comprising an amino acid sequence shown in  
SEQ ID NO:65.

10 75. A recombinant expression vector comprising the nucleic acid molecule of  
claim 69.

76. A host cell which contains the recombinant expression vector of claim 75.

08702525-083096  
960320 52520/80



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|                                                                                                     |           |                                                           |                                                                         |
|-----------------------------------------------------------------------------------------------------|-----------|-----------------------------------------------------------|-------------------------------------------------------------------------|
| (51) International Patent Classification 6:<br><b>C12N 15/12, C11N 5/10, C07K 14/705,<br/>16/28</b> | <b>A2</b> | (11) International Publication Number: <b>WO 95/23859</b> | (43) International Publication Date: <b>8 September 1995 (08.09.95)</b> |
|-----------------------------------------------------------------------------------------------------|-----------|-----------------------------------------------------------|-------------------------------------------------------------------------|

(21) International Application Number: **PCT/US95/02576**(22) International Filing Date: **2 March 1995 (02.03.95)**(30) Priority Data:  
**08/205,697** **2 March 1994 (02.03.94)** **US**

(60) Parent Application or Grant

(63) Related by Continuation

**US** **08/205,697 (CIP)**  
**Filed on** **2 March 1994 (02.03.94)**(71) Applicants (for all designated States except US): **BRIGHAM AND WOMEN'S HOSPITAL [US/US]; 75 Francis Street, Boston, MA 02115 (US). DANA-FARBER CANCER INSTITUTE [US/US]; 44 Binney Street, Boston, MA 02115 (US).**

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SHARPE, Arlene, H. [US/US]; 305 Walnut Street, Brookline, MA 02146 (US). BORRIELLO, Francescopaolo [US/US]; Apartment #3, 20 Perry Street, Brookline, MA 02146 (US). FREEMAN, Gordon, J. [US/US]; 305 Walnut Street, Brookline, MA****02146 (US). NADLER, Lee, M. [US/US]; 36 Cross Hill Road, Newton, MA 02159 (US).**(74) Agents: **MANDRAGOURAS, Amy, E. et al.; Lahive & Cockfield, 60 State Street, Boston, MA 02109 (US).**(81) Designated States: **AU, CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).****Published***Without international search report and to be republished upon receipt of that report.*(54) Title: **NOVEL FORMS OF T CELLS COSTIMULATORY MOLECULES AND USES THEREFOR**

## (57) Abstract

Novel structural forms of T cell costimulatory molecules are described. These structural forms comprise a novel structural domain or have a structural domain deleted or added. The structural forms correspond to naturally-occurring alternatively spliced forms of T cell costimulatory molecules or variants thereof which can be produced by standard recombinant DNA techniques. In one embodiment, the T cell costimulatory molecule of the invention contains a novel cytoplasmic domain. In another embodiment, the T cell costimulatory molecule of the invention contains a novel signal peptide domain or has an immunoglobulin variable region-like domain deleted. The novel structural forms of T cell costimulatory molecules can be used to identify agents which stimulate the expression of alternative forms of costimulatory molecules and to identify components of the signal transduction pathway which results in costimulation of T cells.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |                                       |    |                          |
|----|--------------------------|----|---------------------------------------|----|--------------------------|
| AT | Austria                  | GB | United Kingdom                        | MR | Mauritania               |
| AU | Australia                | GE | Georgia                               | MW | Malawi                   |
| BB | Barbados                 | GN | Guinea                                | NE | Niger                    |
| BE | Belgium                  | GR | Greece                                | NL | Netherlands              |
| BF | Burkina Faso             | HU | Hungary                               | NO | Norway                   |
| BG | Bulgaria                 | IE | Ireland                               | NZ | New Zealand              |
| BJ | Benin                    | IT | Italy                                 | PL | Poland                   |
| BR | Brazil                   | JP | Japan                                 | PT | Portugal                 |
| BY | Belarus                  | KE | Kenya                                 | RO | Romania                  |
| CA | Canada                   | KG | Kyrgyzstan                            | RU | Russian Federation       |
| CF | Central African Republic | KP | Democratic People's Republic of Korea | SD | Sudan                    |
| CG | Congo                    | KR | Republic of Korea                     | SE | Sweden                   |
| CH | Switzerland              | KZ | Kazakhstan                            | SI | Slovenia                 |
| CI | Côte d'Ivoire            | LI | Liechtenstein                         | SK | Slovakia                 |
| CM | Cameroon                 | LK | Sri Lanka                             | SN | Senegal                  |
| CN | China                    | LU | Luxembourg                            | TD | Chad                     |
| CS | Czechoslovakia           | LV | Latvia                                | TG | Togo                     |
| CZ | Czech Republic           | MC | Monaco                                | TJ | Tajikistan               |
| DE | Germany                  | MD | Republic of Moldova                   | TT | Trinidad and Tobago      |
| DK | Denmark                  | MG | Madagascar                            | UA | Ukraine                  |
| ES | Spain                    | ML | Mali                                  | US | United States of America |
| FI | Finland                  | MN | Mongolia                              | UZ | Uzbekistan               |
| FR | France                   |    |                                       | VN | Viet Nam                 |
| GA | Gabon                    |    |                                       |    |                          |

Attorney's  
Docket  
Number BWI-120CPUS

Declaration, Petition and Power of Attorney  
for Continuation-in-Part Patent Application

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

NOVEL FORMS OF T CELL COSTIMULATORY MOLECULES AND USES  
THEREFOR

the specification of which  
(check one)

   is attached hereto.

X was filed on 30 August 1996 as U.S. National Application Serial No. 08/702,525  
(U.S. National filing of PCT/US95/02576)

and was amended on N/A  
(if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

This application in part discloses and claims subject matter disclosed in my earlier filed pending application,

Serial No. 08/205,697, filed March 2, 1994,

and I hereby claim the benefit of said United States prior application under Title 35, United States Code, §120.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

08/055 08309  
960830 52520/80

# AS TO PARENT APPLICATION:

As to the subject matter of this application which is common to said earlier application, I do not know and do not believe that the same was ever known or used in the United States of America before my or our invention thereof or patented or described in any printed publication in any country before my or our invention thereof, or more than one year prior to said earlier application, or in public use or on sale in the United States of America more than one year prior to said earlier application; that the common subject matter has not been patented or made the subject of an inventor's certificate issued before the date of said earlier application in any country foreign to the United States of America on an application filed by me or my legal representatives or assigns more than twelve months prior to said earlier application; and

As to applications for patents or inventor's certificate or PCT international application(s) designating at least one country other than the United States of America, on the common subject matter, filed in or designating any country foreign to the United States of America, prior to said earlier application by me or my legal representatives or assigns,

Check one:

☒ no such applications have been filed.

☐ such applications have been filed as follows

EARLIEST FOREIGN APPLICATION(S), IF ANY, FILED WITHIN 12 MONTHS  
(6 MONTHS FOR DESIGN) PRIOR TO SAID EARLIER U.S. APPLICATION

| Country | Application Number | Date of Filing<br>(month,day,year) | Priority Claimed<br>Under 35 USC 119                     |
|---------|--------------------|------------------------------------|----------------------------------------------------------|
|         |                    |                                    | <input type="checkbox"/> Yes <input type="checkbox"/> No |
|         |                    |                                    | <input type="checkbox"/> Yes <input type="checkbox"/> No |
|         |                    |                                    | <input type="checkbox"/> Yes <input type="checkbox"/> No |
|         |                    |                                    | <input type="checkbox"/> Yes <input type="checkbox"/> No |

ALL FOREIGN APPLICATION(S), IF ANY, FILED MORE THAN 12 MONTHS  
(6 MONTHS FOR DESIGN) PRIOR TO SAID EARLIER U.S. APPLICATION

|  |
|--|
|  |
|  |
|  |

AS TO THIS APPLICATION:

As to the subject matter of this application which is not common to said earlier application, I do not know and do not believe that the same was ever known or used in the United States of America before my or our invention thereof or patented or described in any printed publication in any country before my or our invention thereof, or more than one year prior to this application, or in public use or on sale in the United States of America more than one year prior to this application; that said non-common subject matter has not been patented or made the subject of an inventor's certificate issued before the date of this application in any country foreign to the United States of America on an application filed by me or my legal representatives or assigns more than twelve months prior to this application; and

As to applications for patents or inventor's certificate or PCT international application(s) designating at least one country other than the United States of America, on said non-common subject matter, filed in or designating any country foreign to the United States of America, prior to this application by me or my legal representatives or assigns,

Check one:

☐ no such applications have been filed.

☒ such applications have been filed as follows

EARLIEST FOREIGN APPLICATION(S), IF ANY, FILED WITHIN 12 MONTHS  
(6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION

| Country | Application Number | Date of Filing<br>(month,day,year) | Priority Claimed<br>Under 35 USC 119                     |
|---------|--------------------|------------------------------------|----------------------------------------------------------|
|         |                    |                                    | <input type="checkbox"/> Yes <input type="checkbox"/> No |
|         |                    |                                    | <input type="checkbox"/> Yes <input type="checkbox"/> No |
|         |                    |                                    | <input type="checkbox"/> Yes <input type="checkbox"/> No |
|         |                    |                                    | <input type="checkbox"/> Yes <input type="checkbox"/> No |
|         |                    |                                    | <input type="checkbox"/> Yes <input type="checkbox"/> No |
|         |                    |                                    | <input type="checkbox"/> Yes <input type="checkbox"/> No |

ALL FOREIGN APPLICATION(S), IF ANY, FILED MORE THAN 12 MONTHS  
(6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION

|                                     |
|-------------------------------------|
| PCT/US95/02576 Filed: March 2, 1995 |
|                                     |
|                                     |

960E80 52520/230

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorneys and/or agents to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

|                        |                        |                       |                        |
|------------------------|------------------------|-----------------------|------------------------|
| John A. Lahive, Jr.    | Reg. No. <u>19,788</u> | Jeremiah Lynch        | Reg. No. <u>17,425</u> |
| W. Hugo Liepmann       | Reg. No. <u>20,407</u> | Amy E. Mandragouras   | Reg. No. <u>36,207</u> |
| James E. Cockfield     | Reg. No. <u>19,162</u> | Elizabeth A. Hanley   | Reg. No. <u>33,505</u> |
| Thomas V. Smurzynski   | Reg. No. <u>24,798</u> | Anthony A. Laurentano | Reg. No. <u>38,220</u> |
| Ralph A. Loren         | Reg. No. <u>29,325</u> | Jane E. Remillard     | Reg. No. <u>38,872</u> |
| Thomas J. Engellenner  | Reg. No. <u>28,711</u> | Mark A. Kurisko       | Reg. No. <u>38,944</u> |
| Giulio A. DeConti, Jr. | Reg. No. <u>31,503</u> | Beth E. Arnold        | Reg. No. <u>35,430</u> |
| Ann Lamport Hammitte   | Reg. No. <u>34,858</u> | Jean M. Silveri       | Reg. No. <u>39,030</u> |
| Paul Louis Myers       | Reg. No. <u>35,965</u> | Matthew P. Vincent    | Reg. No. <u>36,709</u> |
| Michael I. Falkoff     | Reg. No. <u>30,833</u> | Lawrence E. Monks     | Reg. No. <u>34,224</u> |
| John V. Bianco         | Reg. No. <u>36,748</u> |                       |                        |

Send Correspondence to:

Amy E. Mandragouras, Lahive & Cockfield, 60 State Street, Boston, MA 02109

Direct Telephone Calls to: (name and telephone number)

Amy E. Mandragouras, (617) 227-7400

Wherefore I petition that letters patent be granted to me for the invention or discovery described and claimed in the attached specification and claims, and hereby subscribe my name to said specification and claims and to the foregoing declaration, power of attorney, and this petition.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

|                                                                                                            |                         |
|------------------------------------------------------------------------------------------------------------|-------------------------|
| Full name of sole or first inventor<br><u>Arlene H. SHARPE</u>                                             |                         |
| Inventor's signature<br><u>Arlene H. Sharpe</u>                                                            | Date<br><u>11/15/96</u> |
| Residence<br>305 Walnut Street, <u>Brookline</u> , Massachusetts <u>MA</u> 02146, United States of America |                         |
| Citizenship<br>United States of America                                                                    |                         |
| Post Office Address (if different)<br>same as above                                                        |                         |

200

|                                                                                                                        |                         |
|------------------------------------------------------------------------------------------------------------------------|-------------------------|
| Full name of second inventor, if any<br><u>Francesco Paolo BORRIELLO</u>                                               |                         |
| Inventor's signature<br><u>Francesco Paolo Borriello</u>                                                               | Date<br><u>11/14/96</u> |
| Residence<br>20 Perry Street, Apartment #3, <u>MA</u> <u>Brookline</u> , Massachusetts 02146, United States of America |                         |
| Citizenship<br>United States of America                                                                                |                         |
| Post Office Address (if different)<br>same as above                                                                    |                         |

300

|                                                                                                               |      |
|---------------------------------------------------------------------------------------------------------------|------|
| Full name of third inventor, if any<br><u>Gordon J. FREEMAN</u>                                               |      |
| Inventor's signature                                                                                          | Date |
| Residence<br><u>MA</u><br>305 Walnut Street, <u>Brookline</u> , Massachusetts 02146, United States of America |      |
| Citizenship<br>United States of America                                                                       |      |
| Post Office Address (if different)<br>same as above                                                           |      |

500

|                                                                                                             |      |
|-------------------------------------------------------------------------------------------------------------|------|
| Full name of fourth inventor, if any<br><u>Lee M. NADLER</u>                                                |      |
| Inventor's signature                                                                                        | Date |
| Residence<br><u>MA</u><br>36 Cross Hill Road, <u>Newton</u> , Massachusetts 02159, United States of America |      |
| Citizenship<br>United States of America                                                                     |      |
| Post Office Address (if different)<br>same as above                                                         |      |




FIGURE 1




FIGURE 2

8,702,520




FIGURE 3

Attorney's  
Docket  
Number BWI-120CPUS

Declaration, Petition and Power of Attorney  
for Continuation-in-Part Patent Application

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

NOVEL FORMS OF T CELL COSTIMULATORY MOLECULES AND USES  
THEREFOR

---

the specification of which  
(check one)

   is attached hereto.

X was filed on 30 August 1996 as U.S. National Application Serial No. 08/702,525  
(U.S. National filing of PCT/US95/02576)

and was amended on N/A  
(if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

This application in part discloses and claims subject matter disclosed in my earlier filed pending application,

Serial No. 08/205,697, filed March 2, 1994

and I hereby claim the benefit of said United States prior application under Title 35, United States Code, §120.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

950820 5252576

# AS TO PARENT APPLICATION:

As to the subject matter of this application which is common to said earlier application, I do not know and do not believe that the same was ever known or used in the United States of America before my or our invention thereof or patented or described in any printed publication in any country before my or our invention thereof, or more than one year prior to said earlier application, or in public use or on sale in the United States of America more than one year prior to said earlier application; that the common subject matter has not been patented or made the subject of an inventor's certificate issued before the date of said earlier application in any country foreign to the United States of America on an application filed by me or my legal representatives or assigns more than twelve months prior to said earlier application; and

As to applications for patents or inventor's certificate or PCT international application(s) designating at least one country other than the United States of America, on the common subject matter, filed in or designating any country foreign to the United States of America, prior to said earlier application by me or my legal representatives or assigns,

Check one:

☒ no such applications have been filed.

☐ such applications have been filed as follows

EARLIEST FOREIGN APPLICATION(S), IF ANY, FILED WITHIN 12 MONTHS  
(6 MONTHS FOR DESIGN) PRIOR TO SAID EARLIER U.S. APPLICATION

| Country | Application Number | Date of Filing<br>(month,day,year) | Priority Claimed<br>Under 35 USC 119                     |
|---------|--------------------|------------------------------------|----------------------------------------------------------|
|         |                    |                                    | <input type="checkbox"/> Yes <input type="checkbox"/> No |
|         |                    |                                    | <input type="checkbox"/> Yes <input type="checkbox"/> No |
|         |                    |                                    | <input type="checkbox"/> Yes <input type="checkbox"/> No |
|         |                    |                                    | <input type="checkbox"/> Yes <input type="checkbox"/> No |

ALL FOREIGN APPLICATION(S), IF ANY, FILED MORE THAN 12 MONTHS  
(6 MONTHS FOR DESIGN) PRIOR TO SAID EARLIER U.S. APPLICATION

|  |
|--|
|  |
|  |
|  |

AS TO THIS APPLICATION:

As to the subject matter of this application which is not common to said earlier application, I do not know and do not believe that the same was ever known or used in the United States of America before my or our invention thereof or patented or described in any printed publication in any country before my or our invention thereof, or more than one year prior to this application, or in public use or on sale in the United States of America more than one year prior to this application; that said non-common subject matter has not been patented or made the subject of an inventor's certificate issued before the date of this application in any country foreign to the United States of America on an application filed by me or my legal representatives or assigns more than twelve months prior to this application; and

As to applications for patents or inventor's certificate or PCT international application(s) designating at least one country other than the United States of America, on said non-common subject matter, filed in or designating any country foreign to the United States of America, prior to this application by me or my legal representatives or assigns,

Check one:

☐ no such applications have been filed.

☒ such applications have been filed as follows

EARLIEST FOREIGN APPLICATION(S), IF ANY, FILED WITHIN 12 MONTHS  
(6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION

| Country | Application Number | Date of Filing<br>(month,day,year) | Priority Claimed<br>Under 35 USC 119                     |
|---------|--------------------|------------------------------------|----------------------------------------------------------|
|         |                    |                                    | <input type="checkbox"/> Yes <input type="checkbox"/> No |
|         |                    |                                    | <input type="checkbox"/> Yes <input type="checkbox"/> No |
|         |                    |                                    | <input type="checkbox"/> Yes <input type="checkbox"/> No |
|         |                    |                                    | <input type="checkbox"/> Yes <input type="checkbox"/> No |
|         |                    |                                    | <input type="checkbox"/> Yes <input type="checkbox"/> No |
|         |                    |                                    | <input type="checkbox"/> Yes <input type="checkbox"/> No |

ALL FOREIGN APPLICATION(S), IF ANY, FILED MORE THAN 12 MONTHS  
(6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION

|                                     |
|-------------------------------------|
| PCT/US95/02576 Filed: March 2, 1995 |
|                                     |
|                                     |

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorneys and/or agents to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

|                        |                 |                       |                 |
|------------------------|-----------------|-----------------------|-----------------|
| John A. Lahive, Jr.    | Reg. No. 19,788 | Jeremiah Lynch        | Reg. No. 17,425 |
| W. Hugo Liepmann       | Reg. No. 20,407 | Amy E. Mandragouras   | Reg. No. 36,207 |
| James E. Cockfield     | Reg. No. 19,162 | Elizabeth A. Hanley   | Reg. No. 33,505 |
| Thomas V. Smurzynski   | Reg. No. 24,798 | Anthony A. Laurentano | Reg. No. 38,220 |
| Ralph A. Loren         | Reg. No. 29,325 | Jane E. Remillard     | Reg. No. 38,872 |
| Thomas J. Engellenner  | Reg. No. 28,711 | Mark A. Kurisko       | Reg. No. 38,944 |
| Giulio A. DeConti, Jr. | Reg. No. 31,503 | Beth E. Arnold        | Reg. No. 35,430 |
| Ann Lamport Hammitte   | Reg. No. 34,858 | Jean M. Silveri       | Reg. No. 39,030 |
| Paul Louis Myers       | Reg. No. 35,965 | Matthew P. Vincent    | Reg. No. 36,709 |
| Michael I. Falkoff     | Reg. No. 30,833 | Lawrence E. Monks     | Reg. No. 34,224 |
| John V. Bianco         | Reg. No. 36,748 |                       |                 |

Send Correspondence to:

Amy E. Mandragouras, Lahive & Cockfield, 60 State Street, Boston, MA 02109

Direct Telephone Calls to: (name and telephone number)

Amy E. Mandragouras, (617) 227-7400

Wherefore I petition that letters patent be granted to me for the invention or discovery described and claimed in the attached specification and claims, and hereby subscribe my name to said specification and claims and to the foregoing declaration, power of attorney, and this petition.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

|                                                                                          |      |
|------------------------------------------------------------------------------------------|------|
| Full name of sole or first inventor<br>Arlene H. SHARPE                                  |      |
| Inventor's signature                                                                     | Date |
| Residence<br>305 Walnut Street, Brookline, Massachusetts 02146, United States of America |      |
| Citizenship<br>United States of America                                                  |      |
| Post Office Address (if different)<br>same as above                                      |      |

|                                                                                                      |      |
|------------------------------------------------------------------------------------------------------|------|
| Full name of second inventor, if any<br>Francescopaolo BORRIELLO                                     |      |
| Inventor's signature                                                                                 | Date |
| Residence<br>20 Perry Street, Apartment #3, Brookline, Massachusetts 02146, United States of America |      |
| Citizenship<br>United States of America                                                              |      |
| Post Office Address (if different)<br>same as above                                                  |      |

|                                                                                          |                  |
|------------------------------------------------------------------------------------------|------------------|
| Full name of third inventor, if any<br>Gordon J. FREEMAN                                 |                  |
| Inventor's signature<br><i>Gordon J. Freeman</i>                                         | Date<br>11-21-96 |
| Residence<br>305 Walnut Street, Brookline, Massachusetts 02146, United States of America |                  |
| Citizenship<br>United States of America                                                  |                  |
| Post Office Address (if different)<br>same as above                                      |                  |

|                                                                                        |                  |
|----------------------------------------------------------------------------------------|------------------|
| Full name of fourth inventor, if any<br>Lee M. NADLER                                  |                  |
| Inventor's signature<br><i>Lee M. Nadler</i>                                           | Date<br>12/23/96 |
| Residence<br>36 Cross Hill Road, Newton, Massachusetts 02159, United States of America |                  |
| Citizenship<br>United States of America                                                |                  |
| Post Office Address (if different)<br>same as above                                    |                  |

960230-52520280